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Abstract 
A number of approaches have been taken towards the development of a vaccine 
protective against serogroup B meningococcal disease but, as yet, none have been 
successful. The commensal bacterium, Neisseria lactamica, shares many surface 
structures with N. meningitidis and N. lactarnica may therefore provide an alternative 
approach to vaccinating against serogroup B disease. Immunological evidence 
suggests that carriage of N. lactamica is involved in natural protection against disease 
caused by N. meningitidis. 
This study presents the important observation that N. lactarnica vaccines protect mice 
against meningococcal challenge. To identify the components responsible for 
protection, the outer membrane proteins of N. lactamica, extracted from whole cells, 
were separated by preparative electrophoresis and pooled into low «43 kOa), medium 
(43-65 kOa) and high (>67 kOa) molecular weight protein groups. The low molecular 
weight group provided the best protection of these groups, and further separation of this 
group indicated that proteins of 25-43 kOa provided the observed protection. Serum 
raised against N. lactamica proteins was cross-reactive with meningococci of different 
serogroups, serotypes and serosubtypes. N. lactarnica antisera raised in mice were not 
bactericidal and although sera raised in rabbits showed some bactericidal activity, titres 
did not correlate with protection. 
Meningococcal proteins cross-reactive with N. lactarnica antisera were identified using 
surface enhance laser-desorption ionisation time-of-flight mass spectroscopy. The 
cross-reactive proteins had molecular masses of approximately 11.2 kOa, 13.7 kOa, 
26.8 kOa, 17.4 kOa, 28.1 kOa, 33.1 kOa, 53.2 kOa and 66.6 kOa. Several 
meningococcal proteins of unknown function and others that have previously been 
considered as vaccine antigens (PorB and TbpB) were putatively identified. Proteins 
with epitopes homologous to these proteins are likely to be present in N. lactamica and 
may be involved in protection against meningococcal challenge. The identity of the 66.6 
2 
kDa protein as TbpB was confirmed by comparing the cross-reactivity of N. meningitidis 
OMPs from wild-type and TbpB knockout strains with N. lactamica antisera. 
Using a N. lactamica genomic expression library, the DNA sequences of recombinant N. 
lactamica proteins cross-reactive with N. lactamica antiserum were obtained. 
Meningococcal proteins with homology to the N. lactamica sequences were identified by 
comparison with the complete genome sequences of N. meningitidis serogroups A and 
B. Fifteen cross-reactive sequences coded, either partially or completely, for 23 different 
proteins. 
This study demonstrates that N. lactamica provides an effective vaccine in mice against 
lethal meningococcal challenge and that N. lactamica may provide an alternative 
approach to vaccination against serogroup B meningococcal disease. Putative 
identifications of the proteins involved in this protection have been made. 
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1.1. Neisseria meningitidis. 
Neisseria meningitidis is a Gram negative diplococcus that commonly colonises the 
human nasopharynx (Figure 1.1). Occasionally it invades the host causing 
meningococcal disease. Invasive N. meningitidis are normally encapsulated. The 
neisseriae grow under aerobic conditions and meningococci grow best on media 
containing blood, haemin and animal proteins in an atmosphere containing 5% carbon 
dioxide. With the advent of the Haemophilus influenzae type b vaccine, N. meningitidis 
has become the most common cause of bacterial meningitis in the western world. 
1.2. The History of Meningococcal Disease. 
The symptoms of meningitis have been described as long ago as the time of Hypocrites. 
In 1805 Vieusseux noted the symptoms of meningitis from an outbreak in Geneva. He 
described headaches, vomiting, stiffness and rashes on the skin. Matthey, a pathologist 
at the time, described congestion of the meningeal vessels and blood on the surface of 
the brain of the dead. N. meningitidis was first isolated in the late nineteenth century and 
soon afterwards meningococci were first isolated from cerebrospinal fluid by lumbar 
puncture (Cartwright, 1995). In addition to causing meningitis, N. meningitidis can be the 
cause of life-threatening septicaemia. The bacteria grow rapidly in the blood and if 
untreated, this leads to a cascade of inflammatory responses, circulatory failure and 
death. 
1.3. Pathogenesis by Neisseria meningitidis. 
The primary stage in infection by N. meningitidis is colonisation of the nasopharynx, this 
involves adherence of the organism to nasopharyngeal cells. Pili on the surface of the 
meningococcus are involved in primary adhesion to the epithelium. Haemagglutinating 
strains of N. meningitidis (those with pili) adhere better to cells of the nasopharynx than 
strains that do not haemagglutinate (Salit et al., 1981). Pili bind to receptors on the 
surface of epithelial cells. Kallstrom et al., (1997) showed that these receptors are CD46 
receptors which are found on almost every human cell. Antibodies directed towards 
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Figure 1.1 Electron micrograph of a meningococcus showing shedding of outer 
membrane blebs and pili. 
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CD46 blocked attachment of N. meningitidis to Cho cells transfected with human CD46 
cDNA in vitro. They suggested that bacterial contact between CD46 and pili causes 
signal transduction which induces internalisation of the bacteria. 
The opacity proteins Opa, especially OpaB, OpaD, and the Opc proteins are also 
involved in colonisation of the host by increasing bacterial ability to interact with the host 
(Virji et al., 1993). The Opa proteins establish a more intimate association with the 
epithelial cells than pili alone. Interactions between Opa and the epithelium lead to 
opsonin-independent uptake of the bacterium. A single strain of meningococcus may 
express three or four variants of the Opa protein. There may be several methods of 
uptake of the meningococcus by the host once this association has been established. In 
Chang cells Opa50, an Opa protein specific for the heparan sulphate proteoglycan, may 
interact with cell surface associated heparan sulphate, resulting in activation of 
phosphatidylcholine-dependent phospholipase C resulting in formation of diacylglycerol. 
This in turn activates sphingomyelinase generating ceramide which is thought to be 
involved in cytoskeletal reorganisation of the host cell. Bacterial uptake is by a method 
resembling phagocytosis (Dehio et al., 1998). An alternative opacity protein, Opa52, may 
initiate internalisation of the meningococcus by interactions with CD66 receptors on the 
epithelial cell. This results in activation of the src-family of non-receptor protein tyrosine 
kinases, Hck and Fgr causing increased cellular protein tyrosine phosphorylation and 
activation of Rac1 (a G-protein) which results in cytoskeletal rearrangements and 
phagocytosis. (Dehio et al., 1998). 
Dunn et al., (1995) showed that meningococci are toxic to the epithelium of the 
nasopharynx and that the level of toxicty corresponded to the adherance of the 
bacterium to the human epithelial cells. Using polymixin B, a biological inhibitor of LPS 
they showed that LPS was the cause of the observed toxicity. They suggested that the 
interaction might aid in breaching the epithelium of the respiratory tract required for 
meningococcal disease. 
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Once the meningococcus has adhered to the epithelial cells, IgA protease is produced 
which reduces local mucosal immune responses by cleaving IgAl (Mulks et al., 1978). 
The production of cilia by the epithelial cells is down-regulated by meningococci 
producing ciliostatic substances. Non-ciliated epithelial cells engulf meningococci by 
endocytosis, transporting encapsulated strains to the sub-epithelial layer of cells 
(Ala'Aldeen, 1995). 
Some encapsulated cells are able to resist local immune responses and enter the 
circulation causing bacteraemia. The meningococcus is protected in the blood stream by 
its polysaccharide capsule, which includes sialic acid in its composition. Jarvis et al., 
(1987) showed that in the absence of natural antibody, C3 deposition onto the bacterial 
surface was increased by enzymic removal of sialic acid from the capsule. This implied 
that sialic acid was involved in the down-regulation of complement-mediated attack. N. 
meningitidis also sheds blebs of lipopolysaccharide (LPS), pili and other outer 
membrane components and capsular polysaccharide including sialic acid, to which 
circulating antibodies are directed. Blebs play an important role in the pathogenesis of 
meningococcal disease inducing endotoxic shock (Cartwright, 1995). Dunn et al., (1995) 
showed that viable meningococcal cells and outer membrane vesicles (OMV) had a 
toxic effect on endothelial cells. Hyperadherant and piliated strains exhibited increased 
toxicity when compared with non-piliated strains, implying that the level of damage to 
the endothelium correlated to the ability to bind to the epithelial layer. It is suggested 
that the synergistic effect of LPS, pili and OMVs cause the haemorrhagic lesions in the 
skin of an infected person. 
Perrin et al., (1999) identified regions of the chromosome of N. meningitidis and N. 
gonoffhoeae which are common to pathogenic but not commensal neisseriae. The 
regions from N. lactamica present in the meningococcal and gonococcal genomes were 
subtracted and both pathogens had sequences in common that were absent from N. 
lactamica. In addition to pilin, IgA protease genes, porA and a number of other genes 
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were present only in pathogenic neisseriae. They suggested that this group of genes 
were probably involved in common aspects of their life cycle such as colonisation and 
survival at the port of entry. 
1.4. Classification of N. meningitidis. 
The classification system of N. meningitidis is based on antigenic differences in key 
structures on the surface of the cells such as the capsular polysaccharide (CPS), Class 
2/3 outer membrane proteins (PorB), Class 1 outer membrane proteins (PorA) and the 
lipooligosaccharide (LOS) (Figure 1.2). These structures determine the serogroup, 
serotype, serosubtype and immunotype, respectively, of different strains. Table 1.1 
describes the function and classification of the components of the outer membrane of 
the meningococcus. 
Thirteen serogroups of N. meningitidis have been identified due to slight antigenic 
variations of the CPS (Ala'Aldeen, 1995). Only five serogroups are able to survive in the 
blood stream, A, B, C, Y and W135. The remainder are killed on entry into the 
bloodstream. Groups A, Band C are the most common, accounting for approximately 
ninety percent of cases world-wide. The CPS of some strains, including serogroups B 
and C, contain sialic acid which prevents complete the assembly of the complement 
membrane attack complex (Jarvis, 1987). Serogroup B CPS is poorly immunogenic as it 
resembles a host molecule on host neuronal cell adhesion molecules. Many strains of 
N. meningitidis, particularly those isolated from carriers, do not possess a capsule and 
these strains are known as non-groupable. 
Five classes of outer membrane proteins are expressed constitutively at high levels and 
classes 1 to 3 are porins which permit the passage of ions across the membrane. Either 
class 2 or class 3 OMPs, coded for by the porB gene, are possessed by all 
meningococci and, due to the great antigenic heterogeneity of both of these proteins, 
over twenty serotypes have been identified through the use of monoclonal antibodies 
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Pilius 
Figure 1.2 Surface structure of the meningococcus. Based on Cartwright et a/., 1995. 
(lp = lipoprotein) 
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Outer Membrane Component 
Polysaccharide capsule 
Lipopoly-/Lipooligo-saccharide 
Pili 
Opa 
Opc 
PorA 
PorB 
Reduction Modifiable Protein (Rmp) 
Transferrin Binding Protein A (TbpA) 
Transferrin Binding Protein B (TbpB) 
Ferric Binding Protein (FbpA) 
Neisserial Surface Protein (NspA) 
Molecular 
Weight 
26-30kDa 
25kDa 
44-47kDa 
37-42kDa 
37-42kDa 
98kDa 
65-90kDa 
37kDa 
18-22kDa 
Function 
Contains sialic acid which protects the bacterium against the 
complement membrane attack complex 
Responsible for the toxicity of the meningococcus 
Involved in primary binding of the meningococcus to the 
epithelium of the nasopharynx 
Establish intimate associations with the epithelium of the 
nasopharynx. Enable opsonin-independent uptake of the 
meningococcus 
Establish intimate associations with the epithelium of the 
nasopharynx 
Permit passage of cations across the membrane 
Permit passage of anions across the membrane 
Unknown 
Binds host transferrin enabling survival of the meningococcus 
in the blood 
Binds host transferrin enabling survival of the meningococcus 
in the blood 
Binds Iron in the periplasm 
Unknown 
Classification 
Serogrouping antigen: 13 
serogroups exist 
Immunotyping antigen: 12 
immunotypes exist 
Class 5 protein 
Class 5 protein 
Serosubtyping antigen. Class 1 
protein 
Serotyping antigen: over 20 
serotypes exist. Class 2/3 protein 
Class 4 protein 
Table 1.1 The Outer Membrane Components of Neisseria meningitidis; Function, molecular weight and classification. Adapted from Pollard et al., 
(2001) and Rosenstein et al., (2001) 
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(Frasch et al., 1985). Heterogeneity is due to surface-exposed variable regions of the 
proteins. The monoclonal antibodies do not recognise class 2 or 3 proteins possessed 
by all strains and these are known as non-typeable. Antigenic variations in the class 1 
proteins, coded for by the porA gene, are used to determine the serosubtype of 
meningococcal strains (McGuinness et al., 1993). Antigenic diversity results from 
substitution, deletion and genetic exchange between the surface exposed variable 
regions VR1 and VR2. 
Antigenic heterogeneity of the lipooligosaccharide (lOS), an outer membrane bound 
glycolipid, between different strains is used to further classify meningococcal cells into 
immunotypes (Griffiss et al., 1987). Twelve immunotypes exist and individual strains can 
express more than one immunotype (e.g. l3,7,9). LOS is responsible for many of the 
toxic effects found in meningococcal disease. 
Molecular typing methods are also used for further characterisation of N. meningitidis. 
Multilocus enzyme electrophoresis (MlEE) has been used to divide meningococci into 
electrophoretic types (ET) based on the electrophoretic mobility of cytoplasmic 
enzymes. Differences in mobilities of these enzymes are caused by charge differences 
due to amino acid substitutions in the enzyme peptide sequence (Yakubu et al., 1999). 
ET5 and ET37 are known as hyperinvasive clones. ET5 causes elevated levels of 
infection and ET37 is particularly likely to cause localised outbreaks of disease. In 
Europe, serogroup B disease has been caused mainly by ET5 meningococci and 
serogroup C disease by ET37 meningococci (Achtman, 1995). Recently N. meningitidis, 
strain W135, ET37, was associated with a disease outbreak (Maclennan et al., 2000). 
More recently, multilocus sequence typing (MLST) has been described as a method for 
characterisation of meningococci (Maiden et al., 1998). This involves comparing the 
DNA sequences of six housekeeping genes, aroE, pgm, adk, abcZ, pdhC and gdh, 
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rather than comparing the electrophoretic mobilities of the enzymes they encode. This 
has been used to define a range of sequence types. 
1.5. Epidemiology of Meningococcal Disease. 
Meningococcal disease is endemic in all countries, most notably in children less than 
five years of age. Approximately 10% of the UK population are carriers of N. 
meningitidis at any particular time but annually there are 3-5 disease cases per 100,000 
of the population and 10% of these cases are fatal (Cartwright et al., 1995). Between 
25% and 40% of young adults are carriers of N. meningitidis and most are never 
affected by the disease. In 1994, Jones et al., (1995) found that 70% of meningococcal 
disease cases in England and Wales were caused by serogroup B strains and the 
majority of the remaining cases by serogroup C strains. In the developed world 
serogroup B meningococcal disease is most common. In the UK, between the years 
1996 and 2000, serogroup B disease accounted for 59% of all disease cases, 
serogroup C for 36% and serogroup W135 for 5% (www.phls.org.uk). Figure 1.3 shows 
the prevalence of meningococcal disease caused by the various serogroups between 
1989 and 2001. The epidemiology of meningococcal disease has changed over the last 
few years (Memish et al., 2002). Serogroups A, Band C account for 90% of disease 
cases worldwide. In Europe serogroup C is increasing, serogroup Y is increasing in the 
USA and Sweden and W135 in Saudi Arabia. 
In the 'meningitis belt' of Africa, a region extending the width of Africa from Gambia to 
Ethiopia, epidemics of serogroup A disease have a regular cyclical pattern of 8 to 14 
years (Moore, 1992). Serogroup A disease is rarely associated with developed countries 
and in Africa, children susceptible to meningococcal disease are older (5-10 years) than 
in industrialised nations. During a recent epidemic, the percentage of cases of 
meningitis caused by meningococci approximately doubled and as well as serogroup A 
disease, W135 disease has emerged in Cameroon, Burkina Faso and Niger (Taha et 
al., 2002, Fonkoua et al., 2002). 
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Figure 1.3 Incidence of meningococcal disease in England and Wales between 1989 
and 2001. From 1996 data includes peR confirmed cases in addition to culture 
confirmed cases. (Data obtained from PHLS Meningococcal Reference Unit) 
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Pinner et al., (1986) studied the epidemiology of meningococcal disease in the United 
States. Forty-seven percent of cases of meningococcal disease occurred in those aged 
less than two years and the incidence of meningococcal disease was higher in the black 
and hispanic populations. Approximately 48% of disease cases were attributed to 
serogroup B, 46% to serogroup C, 3% to serogroup W135 and 1% to serogroup Y. An 
increase is serogroup C disease was observed in 1986 when the study was carried out. 
However, between 1992 and 1996 cases of meningococcal disease were much more 
likely to be caused by serogroup Y compared with previous years and to occur among 
older age groups (Rosenstein et al., 1999). The proportion of disease cases caused by 
serogoup Y increased from 10.6% in 1992 to 32.6% in 1996. Patients with serogroup Y 
disease had higher incidence of pneumonia than patients with disease caused by other 
serogroups. 
1.5.1. Seasonality. 
Epidemics of meningococcal disease are seasonal. In the African meningitis belt, the 
incidence of meningitis increases towards the end of the dry, dusty season. However, in 
temperate climates, cases of meningitis rise over the winter months. A study of monthly 
meningococcal disease incidence from 1993 to 1994 in England and Wales indicated 
that cases followed the pattern observed for temperate climates (Jones et 8/., 1995). It is 
unknown why seasonality occurs, but it is thought that in the African meningitiS belt, dust 
interferes with mucosal immune responses in the nasopharynx; in areas with temperate 
climates the observed increase over winter is due to closer personal contact and the 
increase in catarrhal infections (Cartwright, 1995). 
1.5.2. Age Related Incidence. 
Meningococcal disease is most prevalent in young children, peaking at about six 
months of age (Goldschneider et al., 1969). Jones et al., (1994) showed that 54% of 
isolates in England and Wales were from children aged between 0 and 4 years. 
Immunity to meningococcal disease is associated with the presence of circulating 
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bactericidal antibodies, which develop after carriage of different strains of N. 
meningitidis. Young children are unlikely to have been exposed to a large variety of 
strains and therefore do not possess bactericidal antibodies. A slight peak in the 
disease occurs in young adults aged between 17 and 18 years (Goldschneider, 1969), 
corresponding to the high carriage rate observed in this age group (Stuart et aJ., 1989) 
1.6. Host Susceptibility. 
Many factors affect the host's susceptibility to the disease. Davies et a/., (1996) found 
that social class, being female and having had rhinorrhoea in the previous month as well 
as personal and parental smoking had statistically significant associations with carriage 
of N. meningitidis and thus incidence of disease. 
Smoking is associated with increased susceptibility, having a damaging effect on the 
mucosal epithelium of the nasopharynx. In a survey of staff and students at a school in 
Scotland, 46% of smokers were found to be carriers of N. meningitidis compared with 
25% of non-smokers. There was found to be no association between passive smoking 
and carriage (Blackwell et a/., 1990). However, Kremastinou et a/., (1994) found that 
children in Greece who were in close contact with smokers had a higher carriage rate of 
N. meningitidis (7.5%) than children whose contacts were non-smokers (3.5%). Riordan 
et a/., (1998) found that although there was a strong association between carriage of N. 
meningitidis and smoking, this was not so for acquiSition of meningitis. They suggested 
that smoking may increase the duration of meningococcal carriage rather than increase 
the rate of acquisition. EI Ahmer et a/., (1999) investigated the effects of cigarette 
smoking on binding of a number of respiratory pathogens, including N. meningitidis, to 
buccal epithelial cells. Greater adherance of each isolate tested was observed for cells 
from smokers than non-smokers. After treatment of cells from non-smokers with 1/10 
dilution of water soluble Cigarette smoke extract, binding of the respiratory pathogens 
increased (however, binding decreased when the cells were treated with neat Cigarette 
smoke extract). They found that the increased binding of the isolates was not due to 
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enhanced expression of receptors on the host cells but suggested that coating of the 
mucosal surfaces with components of the cigarette smoke may alter the epithelial cell 
surface, enhancing binding of bacteria. 
Overcrowding, for example of military recruits, also leads to increased susceptibility to 
meningococcal disease (Riordan et al., 1998). However, Davies et a/., (1996) found that 
overcrowding did not have an effect on carriage in school children in Wales in 1995; 
there was no difference in overcrowding between meningococcal carriers and non-
carriers. Neal et al., (2000) studied the changing carriage rate of meningococci amongst 
university students over the first term of the year. This was particularly obvious for 
students living in halls of residence. Carriage rates increased from 6.9% to 23.1 % over 
the first four days. The average carrier rate was 13.9% in October and this increased to 
34.2% by December. 
People with an impaired immune system are at a greater risk of contracting the disease 
due to decreased bactericidal antibodies. However, immune impaired people receiving 
chemotherapy for leukaemia do not have an increased risk of meningitis probably 
because they possess prior immunity (Cartwright, 1995). Individuals who are deficient 
in terminal complement component are also more likely to suffer from multiple attacks of 
meningococcal disease than a healthy individual. Merino et al., (1983) found that 30% of 
patients who suffered from multiple attacks of meningococcal disease had deficiencies 
in complement components. Complement deficiency has been found to predispose 
sufferers to meningitis due to non-groupable meningococci, those strains that are 
normally vulnerable to bactericidal activity (Fijen et al., 1993). 
Respiratory syncitial virus (RSV) has also been suggested to predispose sufferers to 
meningitis. RSV infection changes the nature of the mucosal surfaces. It was found to 
enhance expression of CD14, CD15 and CD18, which increases attachment of non-
pilate strains (Raza et al., 1999). 
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Carriage of N. meningitidis or N. lactamica reduces the risk of developing meningitis due 
to the development of mucosal immunity and bactericidal antibodies (Gold et aI., 1978, 
Pollard et a/., 2001). Assessment of pre- and post- outbreak sera from an outbreak of 
meningococcal disease at Southampton University in 1997 provided further evidence to 
support this. Serum from 90% of students (n=76) showed no bactericidal activity 
towards the disease-causing strain prior to the outbreak. There was low prevalence of 
N. lactamica carriage resulting in a high incidence of invasive disease in those acquiring 
the outbreak strain (Jones et a/., 2000). 
1.7. Diagnosis of Meningococcal Disease. 
Meningitis is a complication of infection by N. meningitidis. The symptoms that are most 
common include fever, headaches, vomiting, photophobia and sleep verging on a coma. 
Neurological signs such as seizures are also observed. Initial diagnosis of meningitis 
requires suspicion that an individual is suffering from the disease, when the appropriate 
signs are presented. Lumbar puncture is the main method used for confirmation of 
diagnOSis when patients present with some or all of the symptoms described. Cerebro-
spinal fluid (CSF) is examined for the presence of polymorphonuclear cells in hundreds 
to thousands per millilitre, low glucose levels and high levels of protein. Once 
centrifuged, Gram's stain of the sediment of the CSF and subsequent culturing reveals 
the presence of the bacterium in approximately 90% of patients (Bohr et a/., 1983). 
Recently PCR-based techniques have been used to detect meningococci and other 
bacteria causing meningitis, primarily to decrease the length of time before a diagnosis 
can be made (24-48 hours). PCR reduces the requirement for culture-based techniques 
and negates problems with false negative cultures. These are common in developing 
countries where serogroup A meningococci are the major cause of disease epidemics 
and where pre-admission antibiotics have been administered. A number of methods for 
PCR diagnosis have been assessed, for example using primers designed to specifically 
amplify a fragment of the gene coding for an enzyme involved in the synthesis of the 
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serogroup A capsular polysaccharide, serogroup A infection can be directly identified 
(Orvelid et a/., 1999). However, these primers do not allow the identification of other 
meningococcal serogroups. Using primers that amplify a fragment of the N. meningitidis 
porA gene, meningococcal disease can be efficiently diagnosed. Use of an automated 
DNA analysis system such as DARAS (Tepnel Life Sciences, Manchester, UK) provides 
accurate detection of peR products eliminating interpretational problems with 
conventional agarose gel analysis (Seward and Towner, 2000a). Multiplex peR has 
also been investigated which involves simultaneous detection of the sequence coding 
for bacterial 16s rRNA and the porA gene. After completion of peR, an immunoassay 
detects positive peR products. A specific diagnosis of meningococcal disease can be 
completed within four hours of receipt of the specimen (Seward and Towner, 2000b). 
However, a TaqMan peR machine (Applied Biosystems), which enables amplification 
and detection of amplified DNA to be carried out at the same time (real-time peR) has 
been shown by Guiver et a/., (2000) to provide sensitive and specific detection of N. 
meningitidis by amplification of the capsular transport gene (ctrA). Further investigations 
have led to the development of multiplex real-time peR with the TaqMan for the 
detection of meningitis causing bacteria; Neisseria meningitidis, Haemophilus influenzae 
and Streptococcus pneumoniae (Corless et al., 2001). This involves simultaneous 
amplification of the ctrA gene from N. meningitidis, the capsulation gene from H. 
influenzae (bexA), and the pneumolysin gene from S. pneumoniae (ply) for detection of 
the three main causes of bacterial meningitis. Fluorescently labelled probes are 
incorporated into the reaction mixture and the TaqMan takes readings of the 
fluorescence. The primers are highly specific, not amplifying DNA from other bacteria or 
viral DNA and not reacting with human genomic DNA, but amplifying the DNA from a 
diverse range of the target bacteria. In the case of N. meningitidis, the ctrA primers were 
used to amplify parts of the gene that are highly conserved and common to all 
meningococci. This technique is used for diagnosis by the Meningococcal Reference 
Unit, Manchester PHL. 
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Most patients suffering from meningococcal disease show signs of septicaemia, 
diagnosed by the presence of a skin rash and blood cultures that are positive for N. 
meningitidis. Three patterns of rash are observed: maculopapular, petechial and 
necrotic. Maculopapular rash lesions are pink and blanch under pressure. They are 
usually distributed over the torso. Petechial rash lesions are small and do not blanch 
under pressure. They are found on the torso and lower limbs and may become 
confluent and develop into necrotic rash. Frequently patients with septicaemia go into 
shock due to the circulating endotoxin (Cartwright, 1995). 
If acute meningococcal disease is left untreated it is fatal. Initial treatment involves 
administration of intravenous antibiotics such as penicillin G or for individuals who are 
allergic, cefotaxime or ceftriaxone. 
1.8. Meningococcal Vaccines. 
Many approaches have been taken towards developing a vaccine which protects 
against meningococcal disease. Vaccines have been produced which are protective 
against serogroup A and C strains but none have yet been shown to protect completely 
against serogroup B disease due to its poorly immunogenic CPS (see section 1.4). The 
ideal vaccine is one that provides protection and induces cross-reactive antibodies 
against the five virulent serogroups of meningococcus and the surface proteins of 
hyperinvasive families, induces T-cell dependent immunity, reducing age dependence 
and provides good booster responses. 
1.8.1. Whole Cell Vaccines. 
Whole cell preparations were the first type of vaccine to be developed for 
meningococcal disease. These were found to have variable efficacy and reactogenicity, 
so their use was discontinued (Cartwright, 1995). 
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1.8.2. CPS Vaccines. 
CPS has been the main focus for the development of vaccines against meningococcal 
disease due to the role it plays in protecting N. meningitidis from the immune response. 
Also CPS vaccines have been prepared from S. pneumoniae against pneumococcal 
disease and used for many years (Austran, 1977, Mufson, 2000) 
The persistence of serum antibodies to a serogroup A meningococcal CPS vaccine in 
children vaccinated between the ages of 10 weeks and 19 years were studied in Finland 
over the period 1975-1979 (Kayhty et al., 1980). Antibodies could be detected for one 
year post vaccination in children younger than 12 months only after a booster 
vaccination was given. Antibodies persisted for two years in children aged 12-17 months 
after a booster vaccination. Children between 18 and 23 months did not receive a 
booster vaccination and their antibody response declined within one year. A booster 
vaccination of the serogroup A CPS vaccine was required to maintain antibody titres for 
more than one year. 
Gotshlich et al., (1969) produced the first safe and effective meningococcal vaccine from 
serogroups A and C CPS. Immunisation with these vaccines induced the production of 
both haemagglutinating and bactericidal antibodies. During an epidemic of serogroup C 
disease it was shown that vaccination with the serogroup C CPS significantly reduced 
acquisition of serogroup C meningococci compared with unvaccinated individuals. The 
efficacy of a serogroup C CPS vaccine was also assessed in a large trial where 
approximately 20% of a susceptible population were vaccinated with a 50 Ilg dose of the 
vaccine and the efficacy of the vaccine, assessed as acquisition of serogroup C 
meningococci, was 87% (Artenstein et al., 1970). 
The current CPS vaccine, widely used around the world, is a tetravalent vaccine 
consisting of the CPS of serogroups A, C, W135 and Y. In 1994, vaccination of recruits 
to the Israel Defence Force with the tetravalent polysaccharide vaccine became routine. 
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Previously between 1984 and 1994 there were twenty-one cases of meningococcal 
disease caused by a variety of different serogroups. However, after routine 
immunisation was introduced, only four cases occurred. Two were due to serogroup C 
meningococci but occurred in unvaccinated soldiers enlisted before 1994 and the 
remainder were due to serogroup B, which does not form part of the tetravalent vaccine. 
The immunogenicity of the tetravalent vaccine was also studied by Cadoz et al., (1985) 
who found it induced significantly increased levels in bactericidal antibodies directed 
towards all serogroups encompassed by the vaccine. The tetravalent vaccine does not 
provide protection against serogroup B disease. Another limitation is age dependant 
protection; the tetravalent vaccine is not effective in juveniles, the age group at greatest 
risk. Age dependency was also demonstrated for the serogroup A and C polysaccharide 
vaccine, used until recently in the UK. Serogroup C specific IgG, tested for by ELISA, 
and bactericidal antibody titres were significantly lower in vaccinated children less than 
two years of age than older children (Borrow et a/., 2000). 
CPS, like other polysaccharides, is a T-cell independent antigen and the immune 
system of a young child is not developed sufficiently to respond to an antigen of this 
nature. The protection afforded by this vaccine is also relatively short-lived and a 
booster response is not normally seen. The vaccine is mainly used to control outbreaks 
of meningitis that are caused by the serogroups covered by the vaccine. 
1.8.3. Conjugated CPS Vaccines. 
By conjugation of the CPS to a carrier protein some of the problems encountered by the 
tetravalent vaccine can be overcome. Conjugation to diphtheria and tetanus toxins has 
successfully converted the polysaccharide from a T-cell independent antigen to a T-cell 
dependent antigen (Goldblatt, 1998). Responses in the very young and the length of the 
immunity are also improved by conjugation to a carrier protein. 
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Jennings et al., (1981) showed that conjugation of serogroups A and C CPS to tetanus 
toxoid (IT) converted the antigens into T-cell dependent antigens. The immunogenicity 
of the two polysaccharides was increased when examined in mice and rabbits 
compared with the native polysaccharide. Trials involving conjugated serogroup B CPS 
have been unsuccessful. Conjugation of serogroup B CPS to TI did not increase the 
immunogenicity of the CPS and no bactericidal activity to the homologous strain was 
detected in mice or rabbits (Jennings et a/., 1981). 
Several groups have carried out trials involving a modified serogroup B CPS conjugate. 
Jennings et a/., (1985) originally modified the structure of the serogroup B CPS and 
conjugated it to tetanus toxoid. Antigenicity of the serogroup B CPS was preserved by 
maintaining carboxylate and N-carbonyl groups intact; these are required for 
preservation of CPS conformation. The most successful modification involved the 
substitution of N-acetylated groups with N-propionylated groups. When conjugated to 
TI, the modified CPS was found to induce high levels of cross-reactive IgG antibodies 
specific for serogroup B CPS. The immune response was demonstrated to be T-cell 
dependent due to the booster response observed. Further work demonstrated that as 
well as inducing antibodies in mice that were cross-reactive for serogroup B CPS, this 
conjugate also induced antibodies that were bactericidal for serogroup B N. meningitidis 
(Jennings et a/., 1987). Although trials of this vaccine were promising in laboratory 
animals, there are concerns that use of an immunogenic serogroup B CPS vaccine may 
induce autoimmune responses in humans due to the resemblance of serogroup B CPS 
to human antigens. Fusco et a/., (1996) produced a conjugate vaccine consisting of the 
modified serogroup B CPS and a recombinant PorB protein. This vaccine generated 
elevated bactericidal immune responses over the serogroup B CPS conjugated to TT 
vaccine against a broad spectrum of serogroup B serotypes and no adverse effects 
were noted in tests on non-human primates. It was found that the IT conjugate was 
unable to induce bactericidal activity but the recombinant PorB conjugate generated 
high levels of bactericidal antibodies after booster vaccinations. 
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MacDonald et al., (1998) investigated the induction of immunological memory by 
serogroup C polysaccharide conjugated to CRM197 when compared with the plain C 
polysaccharide vaccine in toddlers aged between 15 and 23 months. CRM197 is a non-
toxic mutant of diphtheria toxin. Toddlers were given two doses of vaccine, two months 
apart and, twelve months after the second dose, a follow up dose of plain serogroup C 
polysaccharide was administered to assess immunological memory. After two doses of 
the conjugate vaccine, antibody titres were ten-fold greater than for the polysaccharide 
vaccine and 90% of toddlers produced bactericidal antibody titres of more than 1/8 (the 
antibody dilution required to kill 50% of bacteria) compared with 32% of those 
vaccinated with plain polysaccharide. Evidence of induction of a memory response was 
observed in children administered the conjugate vaccine after twelve months. 
Hyporesponsiveness was observed with the plain polysaccharide vaccine whilst two fold 
lower antibody titres were observed following the one year follow-up injection than the 
control vaccine, a licensed hepatitis B vaccine. After the booster vaccination, 
bactericidal antibody titres increased dramatically in children given the conjugate 
vaccine compared to children given the plain polysaccharide vaccine whose bactericidal 
titre remained the same both before and after the follow-up polysaccharide vaccination. 
Three manufacturers competed to produce a meningococcal serogroup C conjugate 
vaccine. Two of the vaccines are composed of polysaccharide conjugated to CRM197 
and the third to tetanus toxoid. A CRM197 vaccine was assessed by Richmond et al., 
(1999) and was found to be well tolerated and immunogenic in infants of 2, 3 and 4 
months. Bactericidal titres were much higher than those generated by meningococcal 
polysaccharide vaccines. Richmond et al., (2000) assessed the safety and 
immunogenicity of the tetanus toxoid conjugate vaccine. The vaccine was well tolerated, 
the majority of reactions being mild. A greater than 300-fold mean increase in IgG titre 
was observed in vaccinees when compared to the specific IgG titre prior to vaccination. 
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The vaccines were made available in the UK in autumn of 1999 and a vaccination 
program was developed by the Department of Health to introduce the serogroup C 
vaccine (Donaldson et al., 1999). Table 1.2 shows the schedule for the introduction of 
this vaccine. The efficacy of the vaccine was monitored in teenagers and toddlers over 
the first nine months of implementation of the vaccination program (Ramsay et al., 
2001). There were 24 laboratory confirmed cases of meningococcal disease in 
teenagers between 15 and 17 years of age compared to 101 cases during the 
corresponding period of 1999; a reduction of 76%. Of the 24 cases of meningococcal 
disease, one occurred ten days post vaccination and the remainder were not 
vaccinated. In children aged between one and two years, there was a 34% reduction in 
the disease during the same period. In the unvaccinated group and in people aged 
between 20 and 44 years, cases of serogroup C disease increased. Four fold increases 
in serum bactericidal antibody titre were seen in 94% of toddlers (12-14 months) 
compared to their pre-vaccination titres. Miller et al., (2002) further described the 
success of the vaccination program on the incidence of meningococcal serogroup C 
disease. They stated that the total reduction in disease in the vaccinated groups over 
the period between July 2000 and April 2001 is 81% compared to the same period of 
1998/1999. 
Concerns have been raised over the possibility of capsule switching by serogroup C 
meningococci to serogroup B meningococci (Maiden et al., 1999). Selection pressure 
caused by the serogroup C conjugate vaccine may result in an increase in serogroup B 
disease against which no vaccine is available. Capsule switching is the result of 
substitution of the serogroup B siaD polysialyltransferase, a capsular biosynthetic gene, 
with the serogroup C siaE polysialyltransferase (Swartley et al., 1997). However, 
although cases of serogroup B disease increased after the introduction of the serogroup 
C conjugate vaccine, Ramsay et al., (2001) suggested that as yet there is no evidence 
of capsule switching occurring. 
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Phase 
1 
(autumn 1999) 
Target Group 
Babies: 2, 3 and 4 months 
Babies: 4 and 12 months 
Children: 13 months 
School Children: 15 to 17 years 
Adults: 18 to 19 years on entry to 
higher education 
Dose 
3 
2 
1 
1 
1* 
2 Children: 14 months to 5 years 1 
(January 2000) Children: 5 to 14 years 1 
Adults: 18 to 20 years 1 * 
·Vaccination with plain polysaccharide vaccine 
Chapter 1 
Coincident vaccines 
DTP, Hib, Polio 
MMR 
Table 1.2 Introduction of the serogroup C conjugate vaccine; the vaccination schedule 
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1.8.4. Outer Membrane Protein Vaccines. 
A vaccine strategy to overcome infection caused by serogroup B strains has been the 
development of outer membrane vesicle (OMV) vaccines. However these are generally 
only protective to the homologous strain from which the OMV originated. Studies 
involving OMV vaccines in Chile, Cuba and Norway have shown that antibodies 
produced against OMV vaccines are protective against serogroup B strains. The 
efficacy of an OMV vaccine against serogroup B disease was studied in Norway in a 
trial involving 171,800 students aged between 13 and 21 years. The vaccine only 
conferred 57% protection in secondary school children after 29 months and this was 
insufficient to justify a public vaccination programme (Bjune et al., 1991). More recently 
phase " trials in two to three year old children of a monovalent serogroup B OMV 
vaccine in Holland have been described (de Kleijn et al., 2001). The vaccine was 
administered with either aluminium phosphate or aluminium hydroxide as adjuvants and 
two vaccination schedules for each vaccine were assessed. The vaccines were either 
administered three times with three to six weeks between each injection or twice with six 
to ten weeks between each injection respectively and a booster vaccination was given 
20 to 40 weeks after the final vaccination. The vaccines were well tolerated and both 
vaccines induced bactericidal antibodies but titres were higher when there were three 
vaccinations before the booster. Vermont et al., (2002) assessed the immune responses 
of sera from these toddlers. They found that the avidity of antibodies for the homologous 
OMVs were high after boosting and that there was a strong correlation between 
bactericidal activity and ELISA titres. IgG1 was the predominant isotype of the 
antibodies. Cross-reacting IgG3 was also detected but no IgG2 or IgG4 were found. 
An OMV vaccine consisting of OMPs from serogroup B meningococci enriched with high 
molecular weight proteins and blended with serogroup C CPS, called VA-MENGOC-BC, 
was used to vaccinate secondary school children in Cuba. It was shown to have an 
efficacy of over 80% and the ability to induce long lasting bactericidal antibodies (Sierra 
et al., 1990). Based on these results, in 1989 the Cuban Ministry of Public Health carried 
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out mass vaccination of the population aged less than twenty years and the vaccine was 
included in the national immunisation programme for all infants. Between the pre-
vaccination period (1988) and 1994 the total incidence of meningococcal disease had 
decreased from 922 cases to 88 cases per 100,000 of the population (Rodriguez et al., 
1999). The most marked decrease was in children under three years old. The Cuban 
vaccine based on OMV from the Cuban epidemic serogroup B meningococcal strain 
was given to approximately 2.4 million children aged from 3 months to 6 years in 1989 
and 1990 in Sao Paulo, Brazil. The vaccine efficacy was estimated as 74% in children 
aged more than 48 months, 47% in children aged between 24 and 47 months and 37% 
in children less than 24 months old. Age-dependent differences were observed in the 
immune responses of the children (de Moraes, 1992). Of 120 children aged between 3 
and 23 months, only 25% had a greater than two-fold increase in serum bactericidal 
titre. Of 80 children aged between 24 and 83 months, 48% had a greater than two-fold 
increase in bactericidal antibody titre. The rates of serogroup B disease in the children 
remained approximately equivalent before and after vaccination. It was suggested that 
the vaccine would be more useful in adults than Children if administered routinely in 
Brazil. 
The immunogenicity of the Norwegian and Cuban vaccines were assessed among 
secondary school children aged 15-20 years in Iceland with the aims of comparing 
bactericidal activity and antibody titres elicited by the vaccines and the control vaccine 
(serogroup AlC CPS vaCCine); to compare the immune response elicited by two and 
three doses of the vaccines; and to determine bactericidal activity elicited by the 
vaccines against heterologous strains. The Cuban vaccine did not produce a significant 
increase in bactericidal antibody or ELISA titre when compared with the control 12 
months after two doses of the vaccine. After vaccination with the Norwegian vaccine, 
47% of students had elevated IgG titres. Twelve months after vaccination a third dose of 
either vaccine provided a significant increase in bactericidal antibody or IgG titre in 
comparison to the two-dose vaccination schedule. After 20 months however, there was 
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no significant difference between two and three doses. The vaccines were ineffective 
against non-vaccine strains and the efficacy of the vaccines in young children was not 
assessed. 
The efficacy of both the Norwegian OMV vaccine and the Cuban OMV vaccine were 
also compared during an epidemic of serogroup B disease in Chile (Tappero et al., 
1999). The vaccines were administered to infants less than one year of age, children 
aged 2-4 years and adults aged 17-30 years and were administered intramuscularly in a 
three dose regime, each given two months apart. The control vaccine in two of the 
groups was the H. influenzae type B vaccine and in the adult group the control was 
aluminium hydroxide adjuvant. No response was observed in infants to heterologous 
meningococcal strains and only 31-35% of children and 37-60% of adults vaccinated 
with either vaccine showed an increase in bactericidal antibody titre to homologous 
strains. It was suggested that neither serogroup B OMV vaccine would provide 
protection during a heterologous epidemic. OMV vaccines provide best protection in the 
countries of origin, as they are homologous to the epidemic strain of that country. 
During an outbreak in Iquique, Chile, the efficacy of a serogroup B OMP vaccine, 
purified from the case strain isolated from the outbreak, was assessed in 40,811 
volunteers aged 1-21 years. The vaccine strain was genetically similar to the outbreak 
strain in Norway, Brazil and Cuba and the vaccine consisted of OMPs complexed with 
serogroup C CPS. During the surveillance period of 20 months post vaccination, there 
were 18 cases of serogroup B disease and protection was observed only in volunteers 
aged between 5 and 21 years; the vaccine efficacy for this age group was 70%. 
However, the overall efficacy of the vaccine was 51 %. Although IgG titres were highest 
amongst the youngest children, the IgG titre declined between 8 weeks and 6 months 
post vaccination. Bactericidal antibody responses were greatest amongst the older 
children and an increase in titre was observed over the surveillance period. It was 
suggested that this increase in bactericidal titre was a result of meningococcal carriage. 
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The efficacy of the vaccine was high enough for it to be useful in older children and 
adults during an outbreak. (Boslego et a/., 1995) 
Research is being carried out into the use of the major OMPs for vaccines and, as most 
strains of N. meningitidis possess class 1 and either class 2 or class 3 OMPs, these 
have been the main focus of attention. However, due to the considerable heterogeneity 
between strains of these proteins, vaccines consisting of these proteins are 
serotype/subtype specific. For example seventy-three different PorA types were found 
from 281 strains associated with sporadic incidence of meningococcal disease in USA 
(Sacchi et al., 2000). To overcome the specificity of OMP vaccines, a multivalent 
vaccine was constructed by insertion of additional parA genes into the chromosome of 
H44/76, deficient in PorB (Van der Ley et a/., 1992). Immunisation of mice with OMPs 
isolated from this strain produced high bactericidal titres for strains with the homologous 
PorA. Christodoulides et a/., (1998) have shown that immunogenicity of PorA is 
increased when incorporated into liposomes. 
A hexavalent PorA vaccine has recently been used to vaccinate infants aged between 
eight and twelve weeks in clinical trials (Cartwright et a/., 1999). OMVs from two 
isogenic strains each expressing three variant PorA OMPs were prepared and 
formulated into a vaccine. Four doses were found to induce good immune responses to 
the homologous six strains from which the PorA originated. Passive protection in rats by 
monoclonal antibodies raised against class 1, 2 and 3 OMPs of different strains of N. 
meningitidis was assessed (Saukkonen et a/., 1989). It was found that monoclonal 
antibodies to the PorB proteins were not protective but monoclonal antibodies to the 
PorA proteins were highly protective and bactericidal. Although PorA vaccines are highly 
immunogenic, disease causing isolates have been obtained which are PorA negative 
(Van der Ende et a/., 1999) thus limiting the potential utility of PorA-mediated immunity 
in vaccine design. Furthermore, Newcombe et a/., (1998) described a serogroup C 
isolate containing the insertion sequence IS1301 within the VR1 region of parA. 
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Native OMV vaccines have been suggested as an alternative to the OMV vaccines used 
in Cuba and Norway (Saunders et al., 1999). These consist of high levels of LOS so 
could not be used as a parenteral vaccine beause of the toxic effect of LOS, but could 
be administered intranasally. This vaccine was found to produce large bactericidal 
antibody titres in mice and the advantage of the native vaccine is that the components 
remain in their native configuration; antigenic epitopes are not disrupted by detergent. 
Other authors have also suggested administration of OMV vaccines intranasally due to 
the induction of both mucosal and serum antibodies (Dalseg et al., 1999). 
Administration of OMV vaccines intranasally as opposed to subcutaneously has been 
investigated (Bakke et al., 2001). Significant IgA responses were observed after four 
weekly doses of the vaccine in mice. Concentrations of IgA were augmented by a 
further four doses administered one week apart two months later. Intranasal boosting 
after subcutaneous priming had the same effect as subcutaneous boosting. Serum from 
mice primed with the OMV vaccine either subcutaneously or intranasally produced the 
same bactericidal activity. Increased serum bactericidal activity was only observed after 
boosting subcutaneously. They suggested that priming intranasally and secondary 
subcutaneous immunisations may not induce immunological tolerance, as antibody 
resposes were stronger than after priming and boosting subcutaneously. Katial et al., 
(2002) assessed the safety and immunogenicity of intranasal administration of a native 
serogroup B OMV vaccine in adults. They showed that the vaccine was well tolerated 
even though, being native, it contained up to 25% LOS relative to protein. It did not 
cause nasal inflammatory responses and levels of secretory IgA and IgG were 
significant, though levels of total serum antibodies were poor. However, in all cases, 
independent of the route of administration, protection by OMV vaccines is short lived, 
age-dependent and inconsistent between the different trials (Katial et al., 2002). It is 
possible that this is due to the variability of OMVs. 
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Conjugation of N. meningitidis serogroup C polysaccharide to serogroup 8 OMVs has 
also been suggested as an alternative OMV vaccine providing protection to both 
serogroup Band C disease (Fukasawa et al., 1999). Using this approach anti-serogroup 
C polysaccharide IgG titres and serum bactericidal antibody titres against serogroup C 
meningococci in mouse sera increase eight and 32 fold, respectively, 7 weeks post-
primary vaccination compared to vaccination with plain serogroup C polysaccharide. 
Anti-OMV IgG titres and serum bactericidal antibody titres against serogroup B 
meningococci in mouse sera showed no significant difference when compared with 
vaccination with OMV alone and protection experiments were not described. 
1.8.5. Live Attenuated Vaccines. 
The use of a live attenuated vaccine to protect against serogroup 8 disease is an 
approach that has been suggested by Tang et al., (1999). They propose that serogroup 
8 strains attenuated by recombinant DNA techniques and intranasal administration 
could work well as vaccines against serogroup 8 disease. A live attenuated vaccine 
could be multivalent. consisting of several different strains; the strains would retain their 
native configuration and if administered mucosally would potentially elicit mucosal 
immune responses. However, there is a concern that the attenuated strains may revert 
to a pathogenic form causing disease in recipients of the vaccine following gene transfer 
from other Neisseria species present in the nasopharynx. 
1.8.6. Other Vaccine Candidates. 
Other vaccine candidates being investigated include LOS, transferrin binding proteins 
(Tbp), neisserial surface protein A (NspA) and proteins identified from the complete 
genome sequence of N. meningitidis strain MC58 (Pizza et al., 2000). LOS has been 
conjugated to a variety of carrier proteins and its immunogenicity assessed. L2 and 
L3,7,9 LOS conjugated to IT and aMPs were found to induce IgG1 antibody responses 
(Verheul et al., 1993). Administration with adjuvants also induced IgG2a and IgG2b 
responses in mice but the antibodies induced were not bactericidal for serogroup 8 
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meningococci. Poolman et a/., (1991) suggested the use of LOS in vaccine formulations 
due to its limited heterogeneity. However, induction of bactericidal antibodies by LOS is 
poor. Furthermore, LOS is highly toxic and the cause of septic shock in meningococcal 
disease patients, thus limiting its use as a vaccine component. 
Tbps are involved in the acquisition of iron from the host and vaccination with these 
proteins may prevent iron uptake by the bacterium. TbpA and TbpB are immunogenic 
during disease (Gorringe et a/., 1995) and antibodies that recognised the TbpA+B 
complex have been shown to have opsonic activity (Lehmann et a/., 1999). Danve et a/., 
(1993) evaluated the purified TbpA+B complex from N. meningitidis strain B16B6, as a 
protective antigen in mice and the bactericidal activity of sera raised against these 
antigens. TbpA+B were shown to protect mice assessed by both passive and active 
immunisation. Anti-TbpA+B serum was shown to be bactericidal toward 5 of 10 
heterologous strains tested including serogroup A, C and Y strains. 
To assess the activity of the Tbps independently, Lissolo et aI., (1995) purified TbpA 
and TbpB and evaluated their capacity to induce antibodies that mediate bactericidal 
killing of N. meningitidis; that inhibit transferrin binding to the proteins; and that inhibit 
bacterial growth. They demonstrated that anti-TbpB serum exhibited bactericidal activity 
but anti-TbpA serum did not. Mice immunised with TbpB were protected against 
meningococcal challenge to a similar extent to mice immunised with the TbpA+B 
complex. However, the protective efficacy of TbpA was not assessed. TbpA and TbpB-
specific antiserum inhibited binding of human transferrin (hTt) to the TbpA+B complex 
receptor and inhibited growth of the bacterium. West et a/., (2001) evaluated 
recombinant TbpA and TbpB, both isolated in a functional form, individually and in 
combination for vaccine potential. It was found that recombinant TbpA afforded greater 
protection than recombinant TbpB to the homologous strain and to 2 heterologous 
strains tested. However, this protection was observed in mice in the absence of 
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bactericidal antibodies. In rabbits, however, bactericidal titres were observed but titres 
were much higher for antiserum raised against Tbp8 than TbpA. 
NspA is conserved among neisseriae. Cadieux et al., (1999) showed sequence 
comparison of nspA from three strains, and NspA antiserum was bactericidal and 
protective against 14 serologically distinct meningococcal strains. They also showed 
that 71 meningococcal strains posess the nspA gene by DNA hybridisation. However, 
the value of NspA as a protective antigen against meningococcal disease is disputed. 
Moe et al., (2001) found that sera raised against NspA from a variety of meningococcal 
strains show variable passive protection, bactericidal activity and surface binding among 
a range of strains. It was also shown that NspA is not critical for virulence as a NspA 
knockout strain is highly virulent in infant rats. 
A number of proteins were identified by Pizza et al., (2000) as potential meningococcal 
vaccine antigens. Five hundred and seventy open reading frames that potentially 
encoded novel surface exposed or exported proteins were identified from the genome 
sequence of N. meningitidis, strain MCS8. Three hundred and fifty genes were 
successfully cloned into E. coli and expressed as either His-tagged or GST fusion 
proteins. Sera were raised in mice against these proteins and tested by ELISA, 
bactericidal activity and to assess cell surface exposure of the proteins. Seven proteins 
were found to be surface expressed, bactericidal and to elicit high IgG titres; two of 
which induced bactericidal titres similar to that induced by OMV vaccines. Genes 
homologous to the seven proteins were found in 31 representative strains of N. 
meningitidis suggesting that these proteins could induce immunity against a variety of 
meningococcal strains. 
1.9. Neisseria lactamica. 
N. lactamica is a commensal Gram negative diplococcus (Figure 1.4). It is very similar to 
N. meningitidis except for its ability to ferment lactose, it is unencapsulated and it is 
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Figure 1.4 Electron micrograph of N. lactamica showing shedding of outer membrane 
blebs. 
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unable to produce IgA protease, both of which render it non-pathogenic (Muller et al., 
1983) thoug h rare cases of encapsulated N. lactamica have been reported (Martin et al., 
1986). It is able to grow in the media used to select for N. meningitidis from clinical 
isolates. N. lactamica does not possess a class 1 OMP (Perrin et al., 1999) but it 
possesses a porin that is homologous to the PorS of N. meningitidis. 
1.10. Carriage of N. lactamica. 
Carriage of N. lactamica is thought to be involved in natural immunity to meningococcal 
disease by the development of bactericidal antibodies. Gold et al., (1978) showed that 
colonisation by N. lactamica led to a fourfold or greater rise in IgG titre to N. meningitidis 
compared to control children who were not colonised. 
Nasopharyngeal carriage of N. meningitidis and N. lactamica was analysed during a 
survey carried out in Stonehouse, Gloucestershire (Cartwright et al., 1987, Stuart et a/. , 
1989). Carriage of N. lactamica was far greater than carriage of N. meningitidis in 
children under the age of five years and there was an inverse relationship between 
carriage of the two neisserial species (Figure 1.5). This confirmed results found by Gold 
et al., (1978) in a study of children in Connecticut over the period between 1971 and 
1975. Interestingly, male children under the age of fifteen years had a greater carriage 
rate of N. lactamica than their female peers, but the reverse was seen in people over 
fifteen years of age. 
A survey of a community in the Faroe Islands showed that the carriage rate of N. 
meningitidis by N. lactamica carriers was approximately a quarter of the rate of non-
carriers (Olsen et al., 1991). During a study of meningococcal and N. lactamica carriage 
in Nigeria, carriage rates of N. lactamica were higher than carriage rates of N. 
meningitidis (Blakebrough et al., 1982). No sex difference in carriage was observed and 
the duration of carriage was similar to N. meninigitidis. They found that N. lactamica 
carriage declined less rapidly amongst the population when compared to carriage 
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Figure 1.5 Age specific carriage of N. lactamica and N. meningitidis. Based on 
Cartwright et al., (1987). The total number of subjects was 5006. Although 
meningococcal disease is most prevalent in the 0-4 year age group, carriage of N. 
meningitidis is low. Carriage of N. lactamica however, is most common in this age 
group. 
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studies in the USA. No correlation was observed between meningococcal carriage and 
N. lactamica carriage, however correlation between meningococcal disease and 
carriage of N. lactamica was not examined. Carriage of N. lactamica during an epidemic 
of meningococcal disease in Auckland, New Zealand was investigated by Simmons et 
a/., (2000). Overall carriage rates of N. lactamica were 10.5% and a peak carriage rate 
of 61.5% was observed in two-year-old children. They found a high rate of carriage of N. 
lactamica amongst contacts of people with invasive meningococcal disease and that at 
the population level there is not an inverse relationship between meningococcal disease 
and carriage of N. lactamica. But at the level of the individual, carriers of N. lactamica 
show low carriage of N. meningitidis. The two organisms infrequently co-exist in the 
nasopharynx, which is suggestive of the role of N. lactamica in prevention of N. 
meningitidis carriage. Andrade et al., (1986) showed that carriage of N. lactamica 
inhibited the attachment of meningococci to epithelial cells reinforcing the role of N. 
lactamica in prevention of meningococcal carriage. 
Factors predictive of N. lactamica carriage included running nose, cough, passive but 
not personal smoking, age and overcrowding. They suggest that host resistance among 
individuals not carrying N. lactamica has an influence on development of meningococcal 
disease (Simmons et al., 2000). Kremastinou et al., (1999) found that passive smoking 
was associated with isolation of N. lactamica. They also found that there was a low level 
of carriage amongst adult males and suggested that the source of N. lactamica among 
children is probably mothers and younger siblings. Using mathematical modelling, Coen 
et al., (2000) suggest that acquisition of meningococci is inhibited by N. lactamica. They 
state that protection by N. lactamica carriage lasts for an average of 4.7 years. 
1.11. N. lactamica Meningitis and Septicaemia. 
In rare cases N. lactamica has been found to cause meningitis and septicaemia. A 
number of authors describe N. lactamica infections with symptoms similar to those for 
meningococcal meningitis; lethargy, fever, irritability, stiffness of the neck and 
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photophobia (Lauer et al., 1976, Greenberg, 1978, Hansman, 1978, Denning et al., 
1991). Septicaemia (Brown et al., 1987, Schifman et al., 1983, Wilson et al., 1976) and 
acute otitis media (Orden, 1991) have also been reported. A number of these cases 
were in immunocompromised or debilitated patients. For example one patient had 
previously suffered skull trauma (Denning et al., 1991) and another was 
immunosuppressed from chemotherapy following treatment for leukaemia (Schifman et 
al., 1983). Greenberg (1978) suggested that otitis media might be the initial source of 
septicaemia or meningitis caused by N. lactamica. 
Disease caused by other non-meningococcal, non-goncoccal Neisseriae has also been 
reported including N. mucosa, N. subflava and N. sicca (Feder and Garibaldi, 1984). 
They also found that over a ten-year span only 0.1 % of the 8000 cases of neisserial 
infection was caused by non-meningococcal, non-gonococcal Neisseriae. 
1.12. Genetic Diversity of N./actamica. 
The genetic diversity of N. meningitidis has been defined by MLST (Maiden et al., 1998). 
Studies of the genetic diversity of 26 strains of N. lactamica isolated from school 
children from three different towns were carried out by Alber et al., (2001). The 
genotypes of these strains were determined using four loci not under immune selection 
pressure in an analogous fashion to MLST. The four genes; argF, recA, rho and the 
16S ribosomal gene, were sequenced. Sequencing of these genes indicated a high 
degree of variability. There were 10 alleles of the 16S ribosomal gene, five alleles of 
argF, nine alleles of rho and eight alleles of recA among the 26 strains. When taken 
together a high degree of genetic diversity could be shown for N. lactamica by use of 
the four genes. However, among the 26 strains analysed 17 genotypes were defined. 
Alber et aI., (2001) also showed that recombination occurred frequently amongst N. 
lactamica isolates. It was also unusual to find identical isolates among epidemiologically 
unrelated hosts. Linz et al., (2000) showed genetic exchange between N. lactamica 
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(and other neisserial commensals) and N. meningitidis, indicating that genetic exchange 
is not species restricted. 
1.13. Cross-Reacting N. lactamica and N. meningitidis Antigens. 
Many authors have discussed the presence of cross-reactive antigens between N. 
lactamica and N. meningitidis. N. lactamica epitopes do not cross-react with N. 
meningitidis serogrouping antibodies and Kim et al., (1989) deduced that cross-reacting 
antibodies were directed towards the non-capsular antigens. One of 35 N. lactamica 
strains reacted with the serogrouping antigens and this reaction was very weak when 
assessed by a dot blot assay and this may reflect the lack of specificity of the reagent. 
However, they found that N. lactamica rarely shared epitopes antigenically similar to the 
PorA or PorB meningococcal OMPs; no cross-reactivity was observed with serotyping or 
sero-subtyping antibodies. They showed that most N. lactamica strains bound the 
monoclonal antibodies 06B4 or 3F11 which are directed towards L9 LOS. As a result 
they suggested that LOS epitopes were similar for both N. lactamica and N. 
meningitidis. 
Cann and Rogers (1989) identified three antigens; proteins of 70, 65 and 15-20kDa 
common to N. meningitidis, N. lactamica and N. polysaccharea to which cross-reacting 
antibodies from children's convalescent sera were directed. Bands of 55kDa and 35kDa 
were specific to N. meningitidis and a band of 43kDa was specific to N. lactamica. A 
similar pattern of cross-reactivity was observed for adult convalescent sera. Bactericidal 
sera were more cross-reactive than non-bactericidal sera. They suggested that the 
human immune response conferring protection to N. meningitidis is to several antigens 
rather than a single one. 
Recently, mouse sera raised against OMVs from both a pathogenic strain of N. 
meningitidis and from N. lactamica along with human convalescent sera have been 
used to identify a number of antigens that are common to both commensal and 
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pathogenic strains of Neisseria (Troncoso et al., 2000). Mouse sera raised against the 
two types of OMVs showed a high degree of cross-reactivity with the homologous 
strains. Cross-reactivity profiles of the sera with a number of strains were similar for 
antigens between 30kDa and 70kDa. Antibodies against N. lactamica OMVs were 
directed towards antigens of 65, 55, 37 and 32kDa from all strains and serum against N. 
meningitidis OMVs were directed towards antigens of 83,55,37,32 and 15kDa. Human 
convalescent sera reacted with three antigens common to all strains of 65, 55 and 
32kDa. Only the 55 and a 32kDa protein were present in all strains of N. meningitidis 
and N. lactamica tested. Sanchez et a/., (2001) showed that serum raised against the N. 
lactamica OMVs were not bactericidal, but those generated against N. meningitidis OMV 
sera were. 
1.14. Study Aims. 
It has been suggested that N. lactamica is involved in the formation of natural immunity 
against N. meningitidis (Gold et al., 1978, Pollard et a/., 2001). The aim of this work was 
to confirm experimentally that vaccines based on N. lactamica can provide protection 
and to find the components of N. lactamica responsible for this protection. To address 
this aim a number of approaches were taken. Preparative electrophoresis was used to 
fractionate detergent extracted OMPs from N. lactamica. Protection in a mouse i.p. 
challenge model of meningococcal disease provided by small groups of these protein 
was assessed and compared with N. lactamica OMVs and killed whole cells (KWC) of 
N. lactamica. Two approaches were then taken to identify proteins that react with sera 
raised against N. lactamica. Surface enhanced laser desorption ionisation (SELDI) was 
used to identify N. meningitidis OMPs that cross-react with a variety of N. lactamica 
sera. A phage display genomic library prepared from N. lactamica genomic DNA was 
screened with N. lactamica rabbit vaccine antiserum. Inserts from cross-reacting phage 
were sequenced, their homology with N. meningitidis proteins assessed and putative 
identification of these proteins made. The introduction and methods used will be 
expanded upon in chapters 3-5 where relevant. 
60 
Chapter 2 
Chapter 2 
Materials and Methods 
61 
Chapter 2 
2.1. N. meningitidis and N. lactamica Strains. 
Meningococcal and N. lactamica strains used in this study are listed on Table 2.1. 
2.2. Routine Growth and Storage of N. meningitidis, N. lactamica and E. coli. 
N. meningitidis and N. lactamica strains were frozen in Mueller-Hinton broth (MHB) 
containing 30% (v/v) glycerol, at -70°C, on beads. Strains were recovered by overnight 
growth on blood agar at 37°C in 5% carbon dioxide (C02), The bacterial lawn was 
resuspended in 5 ml MHB containing 30% glycerol (v/v) and aliquoted into 10 x 500 ~I 
and stored at -70°C. Procedures involving N. meningitidis were carried out in a Class III 
safety cabinet according to local codes of practice. 
Bead stocks of E. coli were frozen in New Zealand broth (NZY) containing 30% (v/v) 
glycerol and recovered by overnight growth on either Luria-Bertani (LB) agar or LB 
supplemented with 12.5 ~g/ml tetracycline at 37°C. The bacterial lawn was resuspended 
in 5 ml NZY containing 30% (v/v) glycerol and aliquoted into 10 x 500 ~I and stored at -
70°C. 
2.3. Growth of N. meningitidis and N. lactamica under Iron-Limited Conditions. 
One hundred millilitres MHB depleted of iron by the addition of ethylenediamine di (0-
hydroxy-phenylacetic acid) (EDDHA) (5-10 ~g/ml) was inoculated with a 10 ~lloopful of 
agar grown cells and incubated with shaking at 37°C for 18 h. The EDDHA solution was 
freshly prepared by the addition of EDDHA to 0.36 M NaOH, the pH adjusted to 7.0 with 
6 M HCI and the solution filter sterilised (0.2 ~m filter). 
For the growth of 500 ml culture volumes, a starter culture was prepared by inoculation 
of 100 ml MHB with a loopful of plate grown cells followed by incubation with shaking at 
37°C for 6 h. Five hundred millilitres of MHB depleted of iron with EDDHA was 
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Strain 
Y92-1009 
K454 
L91 113 
L2412 
L91 543 
L93658 
L91 705 
L94-4931 
M99242020 
M99 242180 
C11 
JB 
LV 
AR 
GN 
SO 
Z3524 
Z4673 
Z4662 
Z8948 
B16B6 
B16B6 N96 
B16B6 N91 
MC58 cap-
MC58 sad C-
H44/76 
394/98 
Details 
Neisseria lactamica 
B15P1,7.16 
B2bP1.10 
Ant 
C 2a P1.2R 
X nt 
B nt P1.6 
A 4 P1.9R 
B 2b P1.2, 1.5 
B2bP1.10 
C 
B nt 
C nt 
A 4 P1.9 
C nt 
B15P1.16 
A 
B nt 
B 
C 
B 2a P1.2 
B 2a P1.2 
B 2a P1.2 
B15P1,7.16 
B15P1,7.16 
B 15 P1.7, 16 
B 4 P1.4 
Source 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
R. Borrow, MRU 
Chapter 2 
R. Wall, Clinical Research Centre 
R. Wall, Clinical Research Centre 
R. Wall, Clinical Research Centre 
R. Wall, Clinical Research Centre 
R. Wall, Clinical Research Centre 
M. Achtman, Max-Planck Institute 
M. Achtman, Max-Planck Institute 
M. Achtman, Max-Planck Institute 
M. Achtman, Max-Planck Institute 
A. Schryvers, University of Calgary 
A. Schryvers, University of Calgary 
A. Schryvers, University of Calgary 
S. Kroll, ICSM 
S. Kroll, ICSM 
J. Holst, Oslo 
Chiron 
Table 2.1 N. lactamica and Meningococcal strains used in this study. All strains listed 
are meningococci except for Y92-1009 which is a N. lactamica strain. 
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inoculated with a 10 ml starter culture, 00650 1.0, and incubated with shaking at 37°C for 
18 h. 
2.4. Gel Electrophoresis. 
2.4.1. Polyacrylamide Gels. 
Samples were analysed on polyacrylamide gels using the method described by Laemmli 
(1970). 
2.4.1.1. Denaturing Gels. 
To prepare denaturing resolving gels, Protogel (30% acrylamide/0.8% bisacrylamide 
(w/v) , National Diagnostics) was mixed with resolving gel buffer (Appendix A 1) in the 
appropriate proportions to produce 10, 12 and 15% gels. To 40 ml of the acrylamide 
mixture, 300 J..l.1 of freshly prepared 10% (w/v) ammonium persulphate solutiuon (APS, 
Sigma-Aldrich) and 30 J..l.1 N,N,N',N'-Tetramethylethylenediamine (Temed, Sigma-
Aldrich) were added. To prepare the stacking gel, Protogel was mixed with stacking gel 
buffer (Appendix A1) in the appropriate proportions to produce a 1% gel. To 10 ml, 100 
J..l.1 APS and 10 J..l.1 Temed were added. 
2.4.1.2. Non-Denaturing Gels. 
Non denaturing gels were prepared in the same way as described for denaturing gels 
except for the use of different resolving gel buffer and stacking gel buffer (Appendix A 1 ) 
2.4.2. 50S-PAGE of Proteins. 
Gels were run in a Mighty Small II system (SE250, Hoeffer Scientific 
instruments). The running tank was filled running buffer (Appendix A 1) and the 
current set at 40 mA per gel. 
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2.4.3. Preparation of Protein Samples for Electrophoresis. 
Protein samples were mixed in the ratio of 1:5 for denaturing gels or 1: 1 for non 
denaturing gels with sample buffer (Appendix A 1). Samples mixed with denaturing 
sample buffer were boiled for 10 min before being loaded onto the gel. Approximately 
1 0 Jlg/well of protein was loaded onto the gel. 
2.4.4. Determination of Molecular Weight on SDS·PAGE. 
To determine the molecular weight of protein samples, low range molecular weight 
standards (Amersham Pharmacia Biotech) were electrophoresed. 
2.4.5. Coomassie Staining. 
Gels were stained with 0.1 % (w/v) Coomassie Brilliant Blue R-250 (BioRad) in 50% (v/v) 
methanol and 10% (v/v) acetic acid for a minimum of 1 h. Destaining was with 40% (v/v) 
methanol solution. 
2.4.6. Agarose Gels. 
To prepare agarose gels, 0.8% (w/v) agarose was added to desired quantity of TAE 
(0.04 M tris-acetate, 0.001 M ethylenediamine tetra-acetic acid (EDTA) and heated 
until the agarose had dissolved. Ethidium bromide was added from a 10 mg/ml stock 
solution to a final concentration of 0.5 Jlg/ml once the agarose solution had cooled to 
50c C. 
2.4.7. Electrophoresis of DNA. 
Gels were run at 80-120 V until the dye front had reached the required position. 
2.4.8. Preparation of DNA Samples for Electrophoresis. 
100-500 ng DNA was mixed in the ratio of 1:6 with sample buffer (0.25% (w/v) 
bromophenol blue, 0.25% (w/v) xylene cyanol FF and 30% (v/v) glycerol). 
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2.4.9. Size Determination of DNA. 
To determine the size of the DNA samples, 1 kb DNA ladder (GibcoBRL) was run along 
side the samples as a standard. 
2.4.10. Paragon Serum Protein Electrophoresis. 
Electrophoresis of purified serum proteins was carried out using Paragon serum protein 
electrophoresis system (Beckman-Coulter) as described in the manufacturer's 
instructions. 
2.5. Protein Purification. 
2.5.1. Preparation of Detergent Extracted OMPs. 
A 500 ml broth culture of N. lactamica or N. meningitidis was centrifuged at 4000 g for 
60 min in an RC3B centifuge with rotor H6000 (Sorval). The supernatant was discarded 
and the pellet washed with 100 ml phosphate buffered saline (PBS) by centrifugation at 
4000 g for 30 min. The supernatant was again discarded and 2 ml PBS containing 0.3% 
(v/v) Elugent detergent was added for each gram of pellet. The pellet was homogenised 
using an Ultra-turrax T25 homogeniser (Janice and Kunkel, Germany) and incubated at 
37°C with shaking for 20 min. The solution was centrifuged at 14,000 rpm for 10 min 
and the pellet discarded. To the supernatant 10 mM (w/v) EDTA, 0.5% (w/v) N-Iauryl-
sarcosine (Sigma-Aldrich) and 0.1% (v/v) of a 10% (w/v) phenyl methyl sulphonyl 
fluoride (PMSF) solution was added. The supernatant containing extracted OMPs was 
stored at -20°C. 
2.5.2. Separation of Detergent Extract by Preparative Electrophoresis. 
Preparative electrophoresis was carried out using the model 419 Prep-Cell (BioRad) as 
described in the protocol supplied. The gels used were non-denaturing consisting of 
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either 7% or 12% (v/v) Protogel for separation of OMPs of <100 kDa and <43kDa 
respectively. 
2.5.3. Purification of IgG from Serum. 
A Protein G Sepharose Fast Flow gel column (Amersham-Pharmacia) was packed as 
described by the manufacturer. The serum sample was diluted 1:4 in 20 mM sodium 
phosphate buffer, pH 7.0 (buffer A) and the column equilibrated with the same buffer. 
The diluted sample was loaded onto the column and washed through the column with 
buffer A at a rate of 1 ml/min. The eluate was collected as 5 ml fractions. After 48 ml 
had washed through the column the buffer was changed for 0.1 M glycine, pH 2.8 
(buffer B). This was eluted through the column at 1 ml/min, stripping the column of 
bound IgG. Twenty-two millilitres of buffer B was washed through the column and the 
sample was collected in 2 ml fractions into 0.5 ml 1 M Tris, pH 9.0 to neutralise the pH. 
2.5.4. Protein Quantification. 
Proteins were quantified using the bicinchonic acid (BCA) assay (Sigma) according to 
the manufacturer's instructions. 
2.6. Limulus Amoebocyte Lysate (LAL) Assay. 
LAL assay was carried out by the immunoassay group (CAMR) as described by 
Hochstein (1985). 
2.7. Protection Experiments in Mice. 
2.7.1. Killed Whole Cell Vaccine. 
A 100 ml broth culture was prepared, centrifuged at 10,000 rpm for 30 min and the 
pellet resuspended in 60 ml PBS containing 600 j.ll of 40% (v/v) formaldehyde and 0.1 % 
(w/v) thiomersal. The cell suspension was incubated at 4°C for 18 hours. After 
67 
Chapter 2 
homogenising the suspension, it was collected by centrifugation at 3000 rpm for 20 min, 
the supernatant was discarded and the pellet resuspended to an 00650 of 0.1 with 
sterile PBS containing 25% (v/v) alhydrogel suspension (Superfos, Denmark). Mice 
were immunised sUb-cutaneously (s.c) with 200 1-11 of resuspended killed whole cell 
solution. 
2.7.2. Protein Vaccine. 
Mice were immunised s.c with 10 I-1g protein in 200 1-11 50% (v/v) Freund's complete 
adjuvant (FCA) for primary vaccinations or Freund's incomplete adjuvant (FIA) for 
booster vaccinations. 
2.7.3. Vaccination Schedule. 
Primary vaccinations were administered to groups of 5 female NIH mice (Harlan, UK) 
aged 6-8 weeks on day 1 of the experiment. The vaccinations were boosted on days 21 
and 28 and challenge was on day 35 of the experiment. A group of non-vaccinated mice 
was included in each protection experiment at each challenge dose. Deaths were 
monitored for 4 days post infection. 
2.7.4. Intraperitoneal (i.p) Infection of Mice. 
Mice were challenged Lp with a target dose of 5 x 106 or 1 x 108 CFU of N. meningitidis 
in 500 III MHB containing 10 mg human transferrin (hTf) as an exogenous iron source. 
To augment the infection, mice were injected with a further 10 mg hTf 24 h later. Actual 
doses were calculated by 104 , 10~ and 10-8 dilutions of the challenge doses and colony 
counts of 100 III of each dilution after over night growth at 37°C on blood agar. 
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2.7.5. Production of Sera. 
All protection experiments included groups of mice for raising sera. These were 
immunised with each vaccine but not challenged and sera was taken on day 35 of the 
experiment. 
Rabbit sera were raised following a vaccination schedule similar to that for mice. 
However each vaccine consisted of 60 Ilg protein in 2 ml of 25% (v/v) alhydrogel 
administered at four sites over their backs. 
2.7.6. Statistical Analysis of Protective Efficacy. 
The statistical significance between the protective efficacy provided by one vaccine to a 
group of mice and the protective efficacy of another vaccine to a second group of mice 
was assessed using 2 x 2 contingency tables. The general formula for this is shown on 
Appendix A2. Significance was assessed at the 95% and 99% confidence levels 
(Wardlaw, 1985). 
2.8. Immunological Techniques. 
2.8.1. Enzyme Linked Immunosorbent Assay (ELISA). 
The protocols used for ELISA were based on the method described by Abdillahi et aJ. 
(1987). For whole cell ELISA, microtitre plates (Nunc Maxisorb) were coated as follows. 
A 100 ml broth culture was prepared and the cells heat killed at 56°C for 30 min. The 
culture was centrifuged at 2000 g for 20 min and resuspended to an 00650 of 0.1 with 
PBS. A 100 III volume of the cell suspension was added to each well of a microtitre 
plate and left to dry for 18 h at 37°C. For protein ELISA, plates were coated with 2 1l9/ml 
protein in coating buffer (1.59 g sodium carbonate, 2.93 g sodium bicarbonate/L) and 
incubated at 4°C for 18 h. Coated plates were blocked by incubation at room 
temperature for 1 h with 300 III PBS per well with 0.1 % (v/v) polyoxyethylene-sorbitan 
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monolaurate (Tween-20, Sigma-Aldrich) (PBS-T) containing 10% (v/v) newborn calf 
serum. Plates were washed with 0.1 % (v/v) PBS-Tusing a Titertek plate washer 
(S8/12). Plates were incubated with primary antibody for 1 h, washed as before and 
incubated for a further hour with species-specific secondary antibody conjugated to 
horseradish peroxidase (HRP). After washing, the plates were developed with 100 III of 
3,3'5,5'-tetramethyl-benzidine (TMBlue, Intergen) per well for 10 min and the reaction 
was stopped by the addition of 50 III of 2 M sulphuric acid (H2S04), Absorbance at 450 
nm of each well was determined using the Titertek Multiscan MCC/340 plate reader. 
Titres were calculated by comparison with the 50% endpoint of a standard pool of all 
sera assayed. 
2.8.2. Western Blotting. 
Proteins were transferred to immobilon PVDF membrane (Millipore) by Western blotting 
using the 2117 Novablot Electrophoretic Transfer Unit (LKB) at a constant current 
equivalent to 0.8 mA x area of the gel (cm2) for 1 h. The transfer buffer consisted of 25 
mM Tris, 200 mM glycine and 20% (v/v) methanol (pH B.3). The membrane was blocked 
with 0.05% (v/v) PBS-T containing 1% (w/v) skimmed milk powder (Marvel) for 1 h. The 
membrane was washed for 5 min, 3-fold, with 0.05% (v/v) PBS-T, incubated for 1 h in 
primary antibody dilution, washed again as previously and incubated in species specific 
HRP conjugated secondary antibody dilution for a further hour. The membrane was 
finally washed for 5 min, 3-fold, in PBS and developed with 4-chloro-1-naphthol as 
follows; 400 III of 2% (w/v) 4-chloro-1-naphthol in methanol was added drop-wise to 40 
ml PBS containing 40 III hydrogen peroxide (H20 2) (Sigma-Aldrich). 
2.8.3. Serum Bactericidal Assay (SBA). 
SBA was performed by a standardised method (Centres for Disease Control, report of 
the second international workshop on meningococcal immunology and serology, 1992). 
Briefly blood agar plates were inoculated with 10 fresh, plate grown colonies and 
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incubated at 37°C for 2-3 h. Cells were resuspended in bactericidal buffer (BB) (20 
mg/ml bovine serum albumin and 0.5 U/ml heparin dissolved in Geys balanced salts 
solution (GibcoBRL», the 00650 adjusted to 0.1 and the suspension diluted by 1/1000 
with BB. Twenty microlitres BB was added to the wells of columns 1-11 of a 96 well U-
bottom microtitre plate and 10 I-li to column 12. Twenty microlitres of heat inactivated 
serum was diluted using doubling dilutions from column 1-9 and 10 I-li to column 12. Ten 
microlitres of serum containing active complement was then added to columns 1-10 and 
10 I-li heat inactivated complement to columns 11 and 12. Finally, 10 I-li of diluted N. 
meningitidis suspension in BB was added to each well and the plate incubated at 37°C 
for 1 h. Viable counts were then performed by transferring 10 I-li from each well onto 
brain heart infusion agar (BHI) followed by incubation at 37°C in 5% carbon dioxide 
(C02) overnight. The bactericidal titre is calculated by comparing the viable counts from 
columns 1-9 with column 11 and analysing for >50% killing. For assays involving 
serogroup B N. meningitidis as the target strain, human complement was used. For 
assays involving serogroup C N. meningitidis, baby rabbit complement was used and 
heparin was not included in the BB. 
2.9. Preparation of Genomic Library. 
2.9.1. Preparation of N./actamica Genomic DNA. 
100 ml MHB (Oxoid) was inoculated with a loopful of plate grown N. lactamica (strain 
Y92-1009) and incubated with shaking at 37°C for 18 h. The culture was centrifuged at 
4000 g and the pellet resuspended in 9.5 ml TE buffer (10 mM tris-[hydroxymethyl]-
aminomethane (Tris, Sigma-Aldrich), 1 mM ethylenediaminetetraacetic acid (EDTA) 
(Sigma-Aldrich), pH 8.0). To this 0.5 ml 10% (w/v) sodium dodecyl sulphate (SDS) 
(BioRad) and 50 J..l1 20 mg/ml proteinase K (Sigma-Aldrich) was added to the suspension 
and this was incubated for 1 h at 37°C. Following incubation 1.8 ml of CTAB buffer (5 M 
sodium chloride (NaCI) (Sigma-Aldrich) and 1.5 ml celyltrimethylamoniumbromide 
(CTAB) (Sigma-Aldrich) solution (10% (w/v) CTAB and 0.7 M NaCI)) was added and the 
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solution incubated at 65°C for 20 min. DNA was extracted form the lysed cells by the 
addition of an equal volume of chloroform:isoamyl alcohol (Sigma-Aldrich). The solution 
was centrifuged at 6000 g for 10 min and 0.6 of the total volume of isopropanol was 
added to the recovered aqueous phase to precipitate the DNA. Precipitated DNA was 
washed in 1 ml 70% (v/v) ethanol by centrifugation at 10,000 g for 5 min, the supernatant 
discarded and the pellet resuspended in 4ml TE buffer. Exactly 1.075 g/ml caesium 
chloride (CsCI) (Sigma-Aldrich) and 50 J.!I of 10 mg/ml ethidium bromide (Sigma) were 
added and the solution was centrifuged in quick-seal centrifuge tubes at 250,000 g at 
15°C for 18 h. The CsCI gradient was visualised under longwave UV and the band 
removed. Ethidium bromide was removed by sequential extractions with water-saturated 
butanol. CsCI was removed by preCipitation of the DNA with ethanol at 4°C for 15 min 
followed by centrifugation at 10,000 g for 15 min. The pellet was resuspended in TE 
buffer for long term storage. 
2.9.2. Preparation of Partially Digested Genomic DNA. 
Approximately 10 J.!g genomic DNA was digested as follows; 10 J.!g genomic DNA, 1 J.!g 
BSA, 10 J.!I NEBuffer 3 (New England Biolabs), 6 J.!I Mbol (New England Biolabs) and 63 
J.!I molecular biology grade water (Sigma-Aldrich) were incubated at 37°C for 2 h. The 
products were run on a 0.8% (w/v) low melting point agarose gel (Sigma-Aldrich). Bands 
of between 1 and 4 kb were located using longwave UV and cut from the gel. Digested 
DNA was removed from the gel using the QIAquick Gel Extraction Kit (Qiagen), 
following the protocol supplied. Extracted DNA was stored at -20°C in TE buffer. 
2.9.3. Ligation of DNA and Vector. 
To ligate partially digested DNA to the ZAP Express vector (Stratagene) a ligation 
reaction was set up as follows; 1 ).I.g vector, 0.4 J.!g digested DNA, 0.5 J.!I of 10x T4 DNA 
ligase buffer (New England Biolabs). 2.7 III molecular biology grade water and 10 units 
of T 4 DNA ligase (New England Biolabs) were incubated at 4°C for 18 h. 
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2.9.4. Packaging of Vector. 
The phage particles were packaged using the Gigapack III Gold packaging extract 
(Stratagene). Three microlitres ligation reaction was added to the packaging extract and 
mixed well. The mixture was centrifuged at 6000 g for 5 seconds and incubated at room 
temperature for 2 h. Five-hundred microlitres SM buffer (5.8 g NaCI, 2 g magnesium 
sulphate (MgS04 .7H20) (Sigma-Aldrich), 50 ml 1 M Tris (pH 7.5), 5 ml 2% (w/v) gelatine 
(Sigma-Aldrich) diluted to 1 L with H20) and 20 I.d chloroform were added to the mixture, 
the contents mixed centrifuged briefly and the supernatant stored at 4°C. 
2.9.5. Plating Packaged Ligation Product. 
E. coli, strain XL 1 Blue MRF', was grown overnight on LB agar plate at 37°C for 18 h. A 
10 ml LB broth supplemented with 10 mM MgS04 and 0.2% (w/v) maltose (Sigma) was 
inoculated with a single colony and incubated with shaking at 37°C for 6 h. The cells 
were centrifuged at 1000 g for 10 min, the supernatant removed and the pellet 
resuspended in 10 mM MgS04• The 00600 was adjusted to 0.5 and 2 III of the final 
packaged reaction was mixed with 200 III of XL 1 Blue MRF' and incubated with gentle 
shaking at 37°C for 15 min. Three millilitres NZY top agar at 48°C, 15 III 0.5 M isopropyl-
~-O-thiogalactopyranoside (IPTG) and 12.5 mg 5-bromo-4-chloro-3-indolyl-~-0-
galactopyranoside (X-gal) (Sigma) were added and the mixture poured immediately 
onto NZY agar plates and incubated at 30°C for 18 h. Twenty, 9 cm diameter petri 
dishes (Sterilin) were prepared to cover the entire N. lactamica genome. Bacteriophage 
were recovered by overlaying the plates with 8-10 ml SM buffer and incubating with 
gentle shaking at 4°C for 18 h. Five percent (v/v) chloroform was added to the 
bacteriophage suspension and the cell debris removed by centrifugation at 500 g for 10 
min. After addition of 0.3% (v/v) chloroform to the supernatant, the library was stored at 
4°C. 
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2.10. Analysis of Genomic Library. 
2.10.1. Plaque Lifts. 
Three microlitres of the bacteriophage library was plated as described above on to 
enough NZY agar plates to cover the genome. After incubation at 30°C for 18 h, IPTG 
soaked nitrocellulose membranes (Amersham Pharrnacia Biotech) were applied to the 
plates and incubated at 30°C for a further 18 h. The membranes were carefully removed 
and blocked, incubated with antibody and developed with 4-chloro-1-naphthol as 
described in section 2.8.2 to identify cross-reactive phage. 
2.10.2. Plaque Purification. 
A plug of agar containing the positive plaque was removed from the plates for each 
plaque identified. The plugs were placed in 1 ml SM buffer containing 0.5% (v/v) 
chloroform and incubated at 4°C for 18 h. Phage suspension (10 J.l1) was plated, lifted 
and positives identified as previously described. This was carried out for each positive 
and repeated until the suspensions were pure. Long term storage of phage was at 4°C 
in SM buffer. 
2.10.3. Polymerase Chain Reaction (PCR). 
Positive phage were plated as previously described. One plaque was picked for each 
positive, pipetted into 500 J.l1 molecular biology grade water, vortexed and incubated at 
4°C for 18 h to release phage particles from the agar. This was used as the template for 
PCR. The following reaction mixture was used to amplify N. lactamica inserts from 
positive phage; 1 J.l1 T3 primer (Life Technologies), 1 J.l1 T7 primer (Life Technologies), 1 
J.l1 template, 2.5 U Taq DNA polymerase (Roche) ,Sill 10 x PCR buffer (Roche), 1 III of 
10 mM dNTP (Roche) and 40.5 J.l1 were mixed on ice in a 200 J.l1 PCR tube (Anachem-
Scotlab) for each template. The reactions were heated to 94°C for 3 min. Thermal 
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cycling was repeated 35 times as follows; 94°C for 30 seconds, 52°C for 30 seconds, 
72°C for 2.5 min. The reactions were finally incubated at 72°C for 10 min. 
2.10.4. Phagemid Excision. 
Positive phage were plated as previously described. Individual phage stocks were 
prepared by transfer of one plaque to 500 III SM buffer containing 20 III chloroform, 
which was then vortexed and incubated at 4°C for 18 h. pBK-CMV phagemids were 
excised from the ZAP Express vector following the protocol supplied. In brief, 200 III 
XL 1 Blue MRF' diluted to an OD600 of 1.0 was combined with 250 III phage stock and 1 
III ExAssist helper phage (Stratagene) and incubated at 37°e for 15 min. 3 ml NZY 
broth was added to each mixture and these were further incubated with gentle shaking 
at 37°C for 2.5 h and finally heated to 700e for 20 min and centrifuged at 1000 g for 15 
min. The supernatant, consisting of excised pBK-CMV phagemid vector, was decanted 
and stored at 4°C. This was repeated for each phage stock. 
2.10.5. Plating Excised Phagemid. 
E. coli, strain XLOLR, was grown in 10 ml NZY broth at 30°C for 18 hours, centrifuged at 
1000g for 15 min and the pellet resuspended in 10 mM MgS04 to obtain OD600 of 1. 
One-hundred microlitres of the phagemid supernatant was mixed with 200 III 
resuspended cells and incubated at 37°C for 15 min. Three-hundred microlitres NZY 
broth was added and the mixture further incubated at 37°C for 45 min. The cell mixture 
(200 Ill) was ten plated on LB agar supplemented with 50 Ilg/ml kanamycin (Sigma) and 
incubated at 37°C for 18 h. 
2.10.6. Phagemid Purification. 
Phagemids were purified using Wizard Plus Minipreps (Promega) following the protocol 
supplied. 
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2.10.7. Sequencing. 
Thirty microlitres of approximately 100 pM/ill purified phagemid stocks were sequenced 
by Cytomyx (Cambridge) initially using T3 and T7 primers and subsequently by primer 
walking. New primers were designed from the sequences produced using PrimerSelect 
(DNAStar) and synthesised by Invitrogen. 
2.11. Surface Enhanced Laser-Desorption Ionisation (SELDI). 
2.11.1. Coating of Dynabeads with N. lactamica IgG and N. meningitidis Protein 
Pools. 
Two-hundred and fifty microlitres magnetic tosyl-activated dynabeads were placed into 
a 1.5 ml tube and the beads retained using a magnet. The solution was removed and 
the beads were resuspended with mixing for 2 min in 250 III 0.1 M borate buffer (pH 
9.5). This was repeated twice then the buffer was removed and the beads resuspended 
in 500 III borate buffer containing 30 Ilg IgG purified from mouse N. lactamica antisera. 
The beads were incubated for 18 h at 37°C with slow tilt rotation. The beads were 
blocked by resuspension in 500 III PBS containing 0.1 % (w/v) bovine serum albumin 
(BSA). The wash was repeated twice then the solution was removed and replaced with 
0.2 M Tris (pH 8.5) containing 0.1 % (w/v) BSA and incubated for 4 hours at 37°C with 
slow tilt rotation. The solution was removed and the beads resuspended in 500 III PBS 
containing 0.1% (w/v) BSA. The beads were washed in 500 III PBS containing 0.5% 
(v/v) Triton-X 1 00, resuspended in 500 III PBS containing 0.1% (w/v) BSA and finally 
resuspended in 100 III PBS containing 0.1% (w/v) BSA. Ten microlitres of the IgG 
coated bead solution was incubated with 50 Ilg of N. meningitidis OMP pool for 4 h with 
slow tilt rotation. The supernatant was removed and the beads washed with sterile water 
or PBS containing 0.5% (v/v) Triton X100 for 5 min in triplicate. Washed beads were 
resuspended in 10 III sterile water for analysis. Beads coated with normal rabbit IgG and 
incubated with N. meningitidis OMPs were used as controls. 
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2.11.2. Analysis of Beads. 
Two microlitres of bead solution were placed onto 1 JlI 50% (v/v) acetonitrile on each 
spot of H4 chips. These were left to dry and covered with 0.7 JlI of a 10 mg/ml solution 
of sinapinic acid in 0.25% (v/v) trifluoric acid and 50% (v/v) acetonitile. Proteins bound 
by the IgG were desorbed from the surface of the beads by the laser and analysed in a 
time-of-f1ight mass spectrometer. This produces an accurate mass for each protein 
species desorbed. 
2.11.3. Calibration of the Apparatus. 
Calibration was carried out as described in the Ciphergen handbook. 
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Separation of and Protection by Neisseria 
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3.1. Introduction. 
Vaccines based on outer membrane proteins are a promising approach to prevention of 
meningococcal disease. Bactericidal antibodies have been shown to be directed against 
the non-capsular components of the meningococcus (Kim et aI., 1989). Outer 
membrane vesicles, consisting largely of OMPs, are protective in humans, and high 
molecular weight OMPs (Sierra et al., 1990, Bjune et al., 1991) have been shown to 
induce bactericidal antibodies in humans. A number of authors have also described the 
vaccine potential of the OMP PorA (Van der Ley et aI., 1992, Cartwright et al., 1999, 
Saukkonen et al., 1989). Human convalescent sera is cross-reactive with outer 
membrane proteins from both N. meningitidis and N. lactamica (Cann and Rogers, 
1998, Troncoso et al., 2000). This indicates that the N. lactamica proteins may be able 
to induce protective antibodies against N. meningitidis. It has been suggested that N. 
lactamica may be involved in eliciting natural immunity to meningococcal disease. Gold 
et al., (1978) showed that carriers of N. lactamica had greater antibody titres to 
meningococci than non-carriers and Olsen et al., (1991) found that people colonised 
with N. lactamica had a quarter of the meningococcal carriage rate of non-carriers than 
N. lactamica. An inverse relationship between N. lactamica carriage and meningococcal 
disease has been suggested (Coen et al., 2000). Thus OMPs from N. lactamica may be 
an ideal choice for a meningococcal vaccine protecting against a variety of serogroups 
and serotypes. This chapter describes separation of N. lactamica OMPs by preparative 
electrophoresis and their immunogenicity and protective efficacy in mice against lethal 
challenge with N. meningitidis. 
3.1.1. Protein Separation Techniques. 
A number of techniques can be used for the separation of protein mixtures and the 
purification of proteins from complex mixtures. The majority of these involve some form 
of chromatography. Column chromatography involves either separation by size or 
adsorption of proteins to a solid matrix and the removal of the proteins with a change in 
buffer. Separation of the individual protein components occurs because of their differing 
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adsorption behaviour (Scopes, 1996). The least adsorbed proteins pass through the 
column quickly. However, this is not simple as often proteins either do not stick at all or 
they bind so tightly that they cannot be removed. Changes in buffer properties are often 
required throughout the course of the chromatography. 
Different sorts of chromatography include ion exchange chromatography, hydrophobic 
chromatography, affinity chromatography, immobilised metal affinity chromatography, 
and gel filtration. These exploit the properties of the proteins to be separated or purified. 
For ion exchange chromatography proteins are bound by and removed from the column 
due to changes in the buffer pH. Similarly changing salt concentrations in the buffers 
facilitate binding and removal of proteins from hydrophobic columns. Affinity 
chromatography and immobilised metal affinity chromatography involve binding of the 
protein to an immobilised ligand or metal ion on the matrix of the column. Gel filtration 
involves separation of proteins by size as the matrix slows the passage of proteins, the 
smaller proteins being retained for longer within the matrix. 
Equally, proteins can be separated on a size basis by preparative electrophoresis. 
However, unlike gel filtration, smaller proteins are eluted before the larger ones. 
3.1.2. Preparative Electrophoresis. 
Preparative electrophoresis involves the separation of mixtures of proteins by gel 
electrophoresis and collection of the proteins eluted from the gel. Any molecule that can 
be resolved in a conventional slab gel can be purified using continuous elution 
electrophoresis. The model 491 Prep Cell (BioRad) can be used to isolate proteins from 
crude extracts or from partially purified samples and liquid fractions are eluted. The Prep 
Cell uses conventional polyacrylamide gel electrophoresis (PAGE) and buffer systems 
to separate proteins. Depending on the gels and buffers used, proteins can be 
separated in either a native or denatured form. The advantage of using a native system 
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over a 50S-PAGE is that proteins are not only separated on a basis of molecular weight 
but also charge. 
The Prep Cell consists of many components (Figure 3.1). It has two buffer chambers; 
the lower buffer chamber holds the electrophoresis running buffer and the upper 
chamber elution buffer. Buffer runs through a cooling core which cools the gel during 
electrophoresis. This ensures that proteins migrate in compact parallel bands through 
the gel. The gel is cast in a gel tube and is in contact with an elution frit and dialysis 
membrane. The dialysis membrane reduces loss of protein from the gel during elution. 
Elution buffer continuously flows to the perimeter of the elution frit, is drawn to the centre 
of the frit and passes through an elution tube in the centre of the cooling core and 
pumped out to a fraction collector. Once bands of protein migrate from the gel they enter 
the centre of the frit. The flow of the elution buffer overcomes the downward force of 
electrophoresis the protein bands are eluted with the buffer. 
Three variables are considered when optimising the resolution of the protein bands. 
These are the gel pore size, the length of the gel and the diameter of the gel. The 
optimum pore size of the gel depends on the molecular weights of proteins of interest. If 
specific proteins are to be purified, the optimum pore size is that which results in a 
relative mobility (Rf) the protein of between 0.55 and 0.6. 
Rf = Distance that the protein of interest migrated on a slab gel 
Distance that the ion front migrated 
Generally however, the higher the molecular weight of the protein of interest the lower 
the percentage of polyacrylamide required in the gel. Gel length increases the resolution 
between proteins. Small differences in the molecular weights of proteins require longer 
gels to resolve the proteins, but a disadvantage of increasing the gel length is increased 
diffusion of the proteins from the gel. Two different sized gel tubes are available for 
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Figure 3.1 Schematic of the Model 491 Prep Cell. Proteins are electrophoresed 
through the cylindrical gel matrix where they separate into ring shaped bands. 
Individual bands migrate off the bottom of the gel and pass into an elution frit in the 
elution chamber. A dialysis membrane traps proteins in the elution frit. As individual 
bands exit the gel , they are drawn to the centre of the frit, out through the collection 
tube to a peristaltic pump, which drives separated molecules on to a fraction collector. 
(Taken from www.bio-rad.co.uk) 
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preparative electrophoresis and the larger of the two allows the maintenance of compact 
bands within the gel due to the increased surface area of the gel. 
A number of authors have described the use of the prep-cell for separating proteins. 
Anderson et a/., (BioRad Bulletin) used preparative electrophoresis to purify 
immunoglobulin heavy chain binding proteins from spinach leaf cells. They were able to 
partially purify the protein by affinity chromatography but the protein tended to form 
aggregates with other proteins when being separated by ion exchange chromatography 
or size exclusion chromatography. Using denaturing preparative electrophoresis they 
were able to achieve a high degree of purification. Non-denaturing gels have been used 
to successfully separate NADP-specific glutamate dehydrogenase from Chlorella 
sorokiniana, fusion proteins, nitrate reductase from Geobacter metallireducens and 
carboxylesterase A2 from mosquitoes where conventional chromatography techniques 
have not worked (Miller et a/., Vanderspek et al., Murillo et al., Ketterman et aJ., from 
BioRad US/EG Bulletins 1987, 1844, 1839 respectively, unpublished data). 
3.1.3. Animal Protection Models. 
A number of different animal models have been assessed for the study of 
meningococcal infection and protection of antigens against meningococcal disease. 
Animal species used in protection models include monkeys, rabbits, rats, mice, guinea 
pigs and chicken embryos. However, none of these provide the ideal infection model. 
Branham and Lillie (1932) produced clinical and pathological meningitis in rabbits but a 
large dose had to be administered, the clinical effects were variable and meningitis was 
only observed in 39% of rabbits. Branham et al., (1937) went on to repeat this work in 
guinea pigs and in this model infection generally remained localised but meningococci 
were rarely cultured from blood. A guinea pig subcutaneous implant model was 
described by Frasch et al (1978) and smaller inocula of N. meningitidis were required to 
establish localised infection. Passive protection by meningococcal antisera was 
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assessed in a chicken embryo model (Frasch et a/., 1976). The chicken embryo was 
chosen because, like man, meningococcal infection caused the development of lesions. 
However they do not posses an active complement system. Miller (1933) discussed the 
large doses of even the most virulent strains required before guinea pigs and mice 
succumb to intraperitoneal (i.p.) infection. He suggested that such heavy inoculations 
might in fact cause intoxication of the animal rather than meningococcal disease. 
However, supplementary mucin produced fatal infection in mice with very few organisms 
(Miller et a/., 1935). Mucin provides iron in an iron-depleted environment for the growth 
of N. meningitidis. Iron dextran (Holbein et a/., 1980) and human transferrin (hTf) 
(Schryvers et al., 1989) can be used instead of mucin with the same effect. Branham et 
al., (1940) used a similar model to show that passive protection could be achieved by 
Lp. administration of serum. Saukkonen et al .• (1987 and 1988) developed an infant rat 
model for testing the passive protection against meningococcal infection of anti-
meningococcal antibodies. They showed that monoclonal antibodies to PorA and to 
capsular polysaccharide were both protective against meningococcal infection. 
Observed mortality showed good correlation with bacterial load and a clear difference 
was observed between protection and no protection. The majority of these animal 
models utilise Lp. challenge with meningococci which does not mimic the natural route 
of infection in man. 
MacKinnon et a/.. (1992) investigated intranasal (Ln.) infection in a mouse 
meningococcal challenge model. They tested two inoculum volumes, 3.5 J.l1 or 10 J.l1, and 
found that lung colonisation was achieved with a larger inoculum and the fatality rate 
was greater in these mice. Unlike infection in man, bacteraemia was only observed after 
colonisation of the lungs. Also the model uses infant mice so cannot be used for 
protection following active immunisation. In all infection models an exogenous source of 
iron is required (Arko. 1989). Martin et a/ .• (1962) showed that iron enhanced infection 
by Klebsiella pneumoniae and Pseudomonas aeruginosa in rats and mice. Unsaturated 
transferrin, an iron binding protein in humans. inhibited the infection to a small extent. 
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MacKinnon et al., (1992) tested two iron sources, iron dextran and saturated hTf. These 
supported infection to the same extent but hTf was more effective, as a smaller amount 
of iron was required to support equivalent infection. 
Of the models described, Gorringe et al., (2001) suggests that the most versatile model 
for meningococcal infection, is the mouse i.p. model. Although the symptoms of 
meningococcal infection are not the same in mice, the mouse immune system functions 
in many respects like that of humans and protection following active immunisation can 
be assessed in this model. 
None of the models described provide the ideal meningococcal infection model. For the 
purposes of protection studies described in this chapter, the mouse Lp. infection model 
is considered the best available. Exogenous iron in the form of hTf is administered for 
infection to be maintained. Symptoms of meningitis are not observed but challenge with 
meningococci causes lethal bacteraemia. This model can be used to assess the 
protective efficacy of meningococcal vaccines and the immune responses to the 
vaccines can be investigated. 
3.2. Results 
3.2.1. Separation of N. iactamica Outer Membrane Proteins 
OMPs of N. lactamica strain Y92-1009 were extracted using 0.3% (v/v) Elugent. The 
extracted OMPs were separated by preparative electrophoresis using the Prep-Cell 
model 419 (BioRad). A 7% acrylamide native gel was found to provide good separation 
of the extracted OMPs (Figure 3.2). Fractions were pooled into three groups based on 
approximate molecular weight; less than 43 kOa (LMW), 43-65 kOa (MMW) and greater 
than 65 kOa (HMW) (Figure 3.3). The pooled proteins were concentrated by freeze-
drying and used to immunise mice and to assess protection following meningococcal 
challenge. 
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Figure 3.2 N. lactamica detergent extracted OMPs separated by preparative 
elecrophoresis. The molecular weight markers are shown in lane A. Increasing sized 
OMPs, separated by preparative electrophoresis, are shown in lanes 8-H. 
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Figure 3.3 N. lactamica OMPs separated by preparative electrophoresis were pooled 
into three groups of proteins. The molecular weight marker is shown on lane A. Lane B 
shows the LMW protein pool consisting of proteins of approximately <43 kDa. Lane C 
shows the MMW protein pool consisting of proteins of approximately 43-67 kDa. Lane 0 
shows the HMW protein pool consisting of proteins that are mostly >67 kDa. 
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The LMW proteins were further separated by preparative electrophoresis using a 12% 
acrylamide native gel. Once separated, the proteins were again pooled into three 
groups and concentrated by freeze-drying. The three pools consisted of proteins of 
approximately less than 25kDa (L 1), 25-35kDa (L2) and 35-43kDa (L3) (Figure 3.4). 
3.2.2. Protection by N. lactamica OMPs. 
Groups of five mice were immunised on days 0, 21 and 28 with either N. lactamica 
detergent extracted proteins (DE), KWC or LMW, MMW or HMW protein pools. A group 
of unvaccinated mice was used as a negative control. At day 35 the immunised mice 
were challenged with N. meningitidis strain K454 at doses of either 2 x 107 or 6 x 108 
CFU. Supplementary hTf was administered to provide an exogenous iron source to the 
mice at the same time as the mice were challenged. A second hTf dose was 
administered Lp. 24 h later to augment the infection. At both challenge doses all of the 
unvaccinated mice had died by the end of the second day post challenge (Figure 3.5). 
At the lower challenge dose, the HMW pool provided the least protection with only one 
mouse surviving challenge beyond the third and up to the fourth day post challenge. 
Both the MMW pool and the detergent extract provided good protection. In both cases, 
challenge was fatal to one mouse by the second day but 4 mice from each group had 
survived at the end of the experiment. The LMW protein pool provided the best 
protection with all mice surviving challenge by strain K454. At the lower challenge dose 
survival was significant, both at the point when there were no survivors in the 
unvaccinated group, and at the end of the experiment for mice vaccinated with the 
detergent extract, LMW and MMW (P=2.3%, 0.4% and 2.3% respectively). KWC and 
HMW provided no protection (P>5%). At the higher challenge dose only mice 
vaccinated with LMW proteins survived the duration of the experiment. Of this group of 
mice the survival rate was 60%. Only protection by LMW was significant at the point 
when there were no survivors in the unvaccinated group (P=2.3%). Protective efficacy of 
the LMW group was assessed in larger groups of mice (Figure 3.6). At the low challenge 
dose (5 x 106 CFU) protection was observed in 14/20 mice by the end of the 
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Figure 3.4 N. lactamica LMW OMPs separated by preparative electrophoresis were 
pooled into three groups of proteins. The molecular weight marker is shown on lane A. 
Lane B shows the L 1 protein pool consisting of proteins <25 kOa . Lane C shows the L2 
protein pool consisting of proteins 25-35 kOa . Lane 0 shows the L3 protein pool 
consisting of proteins 35-43 kOa. 
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Figure 3.5 Protection provided to groups of five mice by N. lactarnica vaccines 
prepared from killed whole cells , detergent extracted proteins or the LMW, MMW or 
HMW protein pools against meningococcal challenge doses of 2 x 107 CFU and 6 x 108 
CFU. The control group was unvaccinated. 
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Figure 3.6 Protection provided by LMW protein vaccine to 20 mice following lethal 
meningococcal challenge at 5 x 106 CFU and 1 x 108 CFU. The control group was 
unvaccinated. 
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experiment. There were no survivors in the unvaccinated group. Protection was highly 
significant at the low challenge dose at both time pOints (P<1%). At the higher challenge 
dose (1 x 108 CFU) there was little difference in protection provided by the vaccinated 
and unvaccinated groups at the end of the experiment (P>5%). No difference was 
observed between the protection provided by LMW to 20 mice or 5 mice at either 
challenge dose (P>5%). 
Following a similar protocol to the previous protection experiment, the L 1, L2 and L3 
protein pools were used to immunise groups of five mice. Groups of mice were also 
immunised with a mixture of the MMW and HMW proteins, N. lactamica strain Y92-1009 
KWC or detergent extract (Figure 3.7). The mice were challenged with N. meningitidis 
strain K454 at doses of 5 x 106 and 1 x 108 CFU. At both challenge doses unvaccinated 
mice did not survive the duration of the experiment. All vaccines provided good 
protection at the lower challenge dose. Protection by the ~C, detergent extract, L 1, L2 
and the mixture of HMW and MMW proteins, was 100% and only one mouse immunised 
with L3 OMPs did not survive challenge by K454 at this dose. At the points when there 
were no survivors in the unvaccinated group and at the end of the experiment, all 
vaccines provided significant protection in comparison to the unvaccinated group 
(P=O.4% for all vaccines except for L3 where P=2.3%). At the higher challenge dose L 1 
and MMW+HMW proteins provided poor protection. Three of the five mice from each of 
the groups immunised with either L2 or L3 pools survived lethal challenge. However 
protection by these vaccines was insignificant at the end of the experiment (P>5%). L3 
provided protection at the point when there were no survivors in the unvaccinated group 
(P=O.4%). 
3.2.3. Quantification of Endotoxin in the OMP Pools. 
A Limulus Amoebocyte Lysate (LAL) assay was carried out to quantify the amounts of 
endotoxin in each of the protein pools used in the protection experiments to determine 
whether LOS had a role to play in the protection observed by the LMW, L2 and L3 
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Figure 3.7 Protection provided to groups of five mice by N. lactamica vaccines 
prepared from killed whole cells, detergent extracted proteins or the L 1, L2, L3 or a 
mixture of MMW and HMW protein pools against two lethal meningococcal challenge 
doses of 5 x 106 CFU and 1 x 108 CFU. The control group was unvaccinated. 
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protein pools. Endotoxin was found in all of the protein groups tested but the greatest 
amount was found in the L 1 pool. The quantity of endotoxin in the LMW, L2 and L3 
pools was approximately one third of that in the L 1 pool (Table 3.1). The amount of 
endotoxin allowed in commercial vaccines for use in humans is 5 endotoxin units per 
dose per kg body weight. 200 endotoxin units of LOS is present in the Norwegian OMV 
vaccine for every milligram of protein. However, the LAL assay is not specific for 
neisserial LOS. 
3.2.4. Cross-Reactivity of Antisera Raised against N. lactamica Protein Fractions. 
Whole cell ELiSAs were used to determine the cross-reactivity of sera raised against the 
proteins used in the protection experiments. Maxisorp 96 well immuno-plates were 
coated with 2 N. lactamica and 14 N. meningitidis strains. Sera raised were cross 
reactive with a variety of strains. In most cases antibodies in sera raised against 
proteins larger than 43 kDa were the least cross-reactive, producing the lowest titres. 
For each anti-No lactamica serum, the percentage of neisseriae cross-reactive with 
serum was determined. The MMW+HMW serum cross-reacted with the least number of 
neisserial strains (Figure 3.8). The remaining sera recognised the majority of strains 
tested implying that these antigens elicit a more broadly cross-reactive response than 
MMW+HMW sera. 
3.2.5. Specificity of Antibody Responses. 
Maxisorp 96 well immuno-plates were coated with the protein pool at a concentration of 
2 J.lg mr1. Sera raised against the protein pools were found to be specific for the proteins 
against which they were raised. MMW serum only reacted with MMW OMPs. The 
remaining sera reacted with LMW, MMW and HMW OMPs (Figure 3.9a). However 
HMW serum was most specific for MMW OMPs. KWC, DE and LMW sera were most 
reactive with LMW proteins, suggesting that LMW OMPs are highly immunogenic. 
Cross-reactivity of the MMW+HMW serum was undetectable with L 1 and L2 OMPs. L 1 
sera did not react with L3 and MMW+HMW nor L3 serum with L 1 OMPs (Figure 3.9b). 
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Sample EU/ml EU/vaccine Iml 
L1 26580 5316 0.53 
L2 9149 1830 0.18 
L3 9348 1870 0.19 
LMW 8515 1703 0.17 
MMW 1523 305 0.03 
HMW 118 24 0.02 
DE 28190 5638 0.56 
Table 3.1 Endotoxin titres of N. lactamica vaccine formulations determined by LAL 
assay. EU = endotoxin units. Due to the low molecular weight of LOS the higher 
molecular weight vaccines (MMW and HMW) consist of the least endotoxin. 
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Figure 3.8 Percentage of neisserial strains, including a variety of serogroups, 
serotypes and serosubtypes, reacting with N. lactamica sera determined by whole cell 
ELISA with N. lactamica, strains Y92-1 009 and Y92 1011 and N. meningitidis, strains 
K454, GN, BM, L91-113, L2412, L91-543, L93-658, L91-705, JB, LV, L94-4931, AR, 
B16B6 and H44/76 . 
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Figure 3.9 Specificity of anti-No lactamica serum towards the homologous proteins. A 
Cross-reaction of KWC, DE, LMW, MMW or HMW sera with LMW, MMW and HMW 
proteins. B Cross-reaction of KWC, DE, L 1, L2, L3 or MMW+HMW, sera with L 1, L2, 
L3, MMW+HMW and DE proteins. 
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3.2.6. Antibody Isotype Responses. 
Plates were coated with N. lactamica Y92-1009 detergent-extracted OMPs. Antibody 
isotype ELiSAs were performed using sera raised against L 1, L2 and L3 proteins, N. 
lactamica KWC, detergent extracted OMPs and proteins of more than 43 kDa to detect 
the presence of IgA, IgG1, IgG2a, IgG2b, IgG3 and IgM. The antibody isotype was 
predominantly IgG1 and IgG2b. IgA, IgG2a, IgG3 and IgM were not detected in any of 
the sera tested (Table 3.2). 
3.2.7. Determination of Antibodies in Human Acute and Convalescent 
Meningococcal disease Sera that Cross-React with N.lactamica Antigens. 
Plates were coated with N. lactamica vaccine preparations. ELiSAs were carried out to 
detect IgG and IgM in 10 pairs of human acute and convalescent sera that react with the 
proteins used to coat the plates. Many of the pairs of sera contained IgG which cross-
reacted with the range of proteins tested (Figure 3.10a). However, the LMW pool was 
the least cross-reactive with the serum pairs. In general, convalescent sera showed 
higher titres against more of the antigens than acute sera except for with LMW OMPs. 
L 1 proteins were recognised by antibodies in the least number of sera. IgM was 
detected in very few of the pairs of sera tested (Figure 3.1 Ob). A similar result was 
observed with serum from immunised mice, where IgM was undetectable (section 
3.2.6). MMW proteins were recognised by antibodies in the greatest number of 
convalescent sera. 
3.2.8. Detection of cross-reactive proteins by Immuno-Blotting. 
Elugent extracts from a variety of N. meningitidis strains, including those expressing 
class 2 or class 3 PorB, were separated by SDS-PAGE and transferred to nitro-
cellulose. Blots were then incubated with sera raised against N. lactamica OMPs to 
identify the proteins recognised by antibodies (Figure 3.11). L 1 serum reacted with 
fewer proteins than sera raised against other protein groups. This was probably due to 
this serum containing antibodies directed mainly against LOS. The most obvious bands 
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Con'u ate 
Serum 
algA aigGM algG1 algG2a algG2b algG3 
KWC <100 <100 3382 <100 669 <100 
DE <100 <100 9190 <100 272 <100 
L1 <100 <100 2430 <100 <100 <100 
L2 <100 <100 2177 <100 <100 <100 
L3 <100 <100 679 <100 <100 <100 
MMW+HMW <100 <100 504 <100 <100 <100 
Table 3.2 Antibody isotype 50% endpoint titre of N. lactamica antiserum. Cross-
reactivity of the sera was assessed with N. lactamica, strain Y92-1009, detergent 
extract. 
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Figure 3.10 Percentage of human meningococcal disease acute and convalescent 
antiserum IgG (A) and IgM (8 ) containing antibodies that react with N. lactamica OMPs. 
Ten serum pairs were tested . 
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Figure 3.11 Western blots showing cross-reactivity of N. lactamica antisera with 
detergent extracts from 6 meningococcal strains; A K454, B GN, C L91 -705, 0 H44/76, 
E M99-242020, F M99-242180. The molecular weight markers are shown on lane A. 
Lanes 8-G are probed with L 1, L2, L3, KWC, DE and MMW+HMW antisera 
respectively. 
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had a molecular weights of approximately 30 kDa. Sera raised against proteins larger 
than 43 kDa, N. lactamica KWC or detergent extracted proteins highlighted a protein 
band of approximately 67 kDa. 
3.2.9. Serum Bactericidal Activity of Sera raised against N. lactamica Vaccines. 
The bactericidal activity of mouse and rabbit sera in the presence of human or rabbit 
complement was tested. Bactericidal titres of mouse sera against N. meningitidis strain 
K454 were inconsistent between assay replicates for all of the sera tested, so no 
conclusions could be drawn from this data (Table 3.3). Rabbit sera were bactericidal 
against serogroup B meningococci, however, the serum from unvaccinated rabbits was 
also bactericidal with a titre of 128. The titres obtained were standardised by subtracting 
the pre-immune titres from the post immune titres and the standardised serum 
bactericidal titres obtained with rabbit N. lactamica antiserum against serogroup B 
meningococci are shown (Table 3.4a). Assays were performed in duplicate (titre A and 
B) and results were considered acceptable if the titres were within one dilution of each 
other. Only KWC, DE, LMW and MMW rabbit sera were found to be bactericidal and 
their bactericidal activity was <8. The same rabbit sera were generally more bactericidal 
towards the serogroup C target strain once the titres were standardised. HMW and L3 
sera showed no bactericidal activity towards strain C11. The duplicate titres of LMW and 
MMW antisera were not within one dilution of each other after standardisation and the 
bactericidal activity of the remaining sera was <16 (Table 3.4b). 
3.3. Discussion 
This study has shown that N. lactamica OMPs protected mice against lethal 
meningococcal challenge. The immunogenicity of N. lactamica OMPs was also 
assessed. Antibodies were cross-reactive with a variety of meningococcal strains 
assessed by both ELISA and western blotting. Bactericidal studies with mouse sera 
were inconclusive but from the results shown in this chapter, N. lactamica proteins of 
<43kDa (LMW) were observed to be important in protection. 
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Serum SSA 1 SBA2 SBA3 
L1 128 4 4 
L1 8 8 4 
L2 64 4 4 
L2 32 32 8 
L3 128 8 4 
L3 32 4 8 
MMW+HMW 32 8 4 
MMW+HMW 16 8 4 
KWC 8 8 4 
KWC 16 8 4 
DE 4 8 4 
DE 4 8 4 
Table 3.3 Mouse Serum Bactericidal Assay Raw Data showing the serum dilution giving 
>50% killing. The assay was repeated in triplicate with K454 as the target strain and a 
human complement source. Bactericidal titres of the duplicates of both L 1 and L3 
anitsera were not within one dilution of each other initially (SBA 1). On repetition of the 
assay, SBA2 and SBA3, the titres were much lower than initially observed rendering all 
results inconclusive. 
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A 
Immuno en Titre A Titre B 
KWC 8 4 
DE 8 8 
LMW 4 8 
MMW 4 <4 
HMW <4 <4 
L1 <4 <4 
L2 <4 <4 
L3 <4 <4 
B 
Immuno en Titre A Titre B 
KWC 16 8 
DE 8 8 
LMW 32 8 
MMW 16 4 
HMW <4 <4 
L1 8 4 
L2 4 <4 
L3 <4 <4 
Table 3.4 Standardised serum bactericidal antibody titres obtained with rabbit N. 
lactamica antiserum against A, serogroup B, and B, serogroup C target strains. 
104 
Chapter 3 
3.3.1. Protection by N. lactamica OMPs. 
It has been suggested that carriage of N. lactamica by young children may be involved 
in natural protection against meningococcal disease due to the high carriage rates of N. 
lactamica in children under the age of five years in comparison to N. meningitidis 
carriage (Gold et al., 1978). Although the symptoms of meningitis are not observed in 
the mouse i.p. protection model, the model is useful in assessing the protective efficacy 
of vaccines as infection by N. meningitidis, augmented by hTf, is lethal to mice. 
Protection experiments involving sUb-cutaneous vaccination of mice with N. lactamica 
KWe have demonstrated a protective effect. 
Attention has been focussed on OMPs of N. meningitidis by a number of groups for the 
production of a vaccine protecting against meningococcal disease (Morley et al., 2002). 
However, heterogeneity of the major OMPs creates problems for a vaccine of this type, 
as a successful vaccine must contain the OMPs expressed by a variety of strains to 
provide broad protection. Poolman et al., (1991) reviewed the work of a number of 
authors who have found that OMPs which produced a cross-reactive antibody response 
to a variety N. meningitidis strains were not bactericidal, but OMPs which were variable 
among meningocccal serotypes and serosubtypes, such as class 1, 2 and 3 proteins, 
generated antibodies which were bactericidal. Despite their variablilty, they investigated 
the immunogenicity of a multivalent PorA OMV vaccine as a vaccine against serogroup 
B meningococci. Although this induced bactericidal antibodies, the bactericidal activity 
was directed only towards the homologous strains (Cartwright et al., 1999). An ideal 
meningococcal vaccine would provide protection that is serogroup, serotype and 
serosubtype independent. Due to the cross-reactive immunity provided by N. lactamica 
with a variety of meningococcal strains described in this chapter, N. lactamica OMPs 
may provide protection that is not strain specific. 
OMPs isolated from N. lactamica were shown to provide similar levels of protection to 
mice as N. lactamica killed whole cells. To identify the OMPs that provided protection, 
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the detergent extracted OMPs were separated by preparative electrophoresis and 
pooled into three groups of proteins. Protection was found to be greatest for LMW 
proteins «43 kDa). Of the protein pools, HMW proteins (proteins of more than 65 kOa) 
provided the least protection. However, Sierra et al., (1990) enriched an OMV vaccine 
with native high molecular weight proteins. These were shown to have the capacity to 
induce long lasting bactericidal antibodies. This vaccine was effective in preventing 
disease in children over 4 years of age in clinical trials. Wedege et al., (1986) showed 
that sera from humans vaccinated with N. meningitidis OMVs contained antibodies that 
reacted with N. meningitidis OMPs of 140, 86, 65, 43, 30 and 22 kOa. However, patterns 
of reactivity varied between individuals. This study has shown that N. lactamica LMW 
proteins provided protection to mice suggensting that the 43, 30 and 22 kDa proteins 
may be important in mounting a protective immune response against meningococcal 
disease. Wedege et al. (1986) identified the 43 kDa protein as the class 1 OMP (PorA) 
and the 30 kDa protein as the class 5 protein (Opa). 
LMW proteins were further separated into protein pools of less than 25 kDa (L 1), 25-35 
kDa (L2) and 35-43 kOa (L3). Good protective efficacy was provided by L2 and L3 
proteins at the 1 x 108 CFU challenge dose, better even than I<YVC and N. lactamica 
detergent extract. Although all mice were vaccinated with 10J..lg of protein, the 
concentration of the 25-35 kOa and 35-43 kOa proteins in the L2 and L3 vaccines, 
respectively, is greater than the concentration of these proteins in the killed whole cell 
and detergent extract vaccines. This may account for their improved protection. 
3.3.2. Involvement of LOS In Protection. 
Antibodies directed towards LOS are raised during meningococcal infection and LOS is 
important in the pathogenesis of meningococcal disease. Although a number of authors 
have suggested and tested the use of LOS in vaccine formulations, these have not been 
successful due to LOS heterogeneity (Verheul et al., 1993, Poolman et al., 1991). 
Vaccines for human use are required to contain a limited amount of LOS i.e. less than 5 
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endotoxin units per dose per kg body weight. Measurement of circulating endotoxin in 
patients with systemic meningococcal infection has shown that levels of endotoxin 
exceed 700 ng per litre (Schlichting et al., 1993). By comparison endotoxin is 
undetectable in the serum of patients with meningitis and the uninfected. 
The LAL assay was used to determine the role of LOS in the protection provided by 
LMW OMPs (section 3.2.3). The quantity of LOS in the LMW protein pool was between 
five and six times that found in the MMW and HMW protein pools. However, the quantity 
of LOS in the L 1 protein pool was approximately three times greater than in the L2 and 
L3 proteins. This group was less protective than L2 and L3, suggesting that LOS did not 
play a major role in the observed protection. However, these results cannot be relied 
upon as the LAL assay does not specifically detect LOS, but endotoxin as a whole. 
Generally, LAL assay results are difficult to interpret due to the presence of non-specific 
activators and inhibitors of LOS. Using the LAL assay, Schlichting et al., (1993) had 
trouble quantifying the LOS in different culture filtrates due to the variable Limulus-
activating potential of LOS from different meningococcal strains. Furthermore, the 
vaccine formulations may have been contaminated with endotoxin at some point during 
preparation or quantification, adding to the difficulties with this method for LOS 
quantification and comparison of the different vaccines. Tsai et al., (1989) used the LAL 
assay to measure LOS in vaccine preparations. They found that this assay was 
inaccurate for the measurement of LOS when it was in a mixture with proteins. Protein 
bound LOS was 20 to 40 fold less reactive than purified LOS by LAL assay. They also 
found that in a mixture with proteins, LOS was not as toxic to rabbits as purified LOS 
suggesting that protein vaccine formulations could be used even when the quantity of 
LOS is higher than would normally be allowable for purified LOS in human vaccines. 
3.3.3. Cross-Reactivity of N.lactamica Antiserum with N. meningitidis. 
ELISA and immuno-blotting techniques showed that all sera raised against N. lactamica 
in this study were cross-reactive for a wide range of meningococcal strains including 
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serogroups A, Band C. Sera raised against MMW+HMW proteins produced lowest 
titres towards N. meningitidis whole cells and were also the least cross-reactive, 
reacting with only 31 % of strains tested. L2 serum cross-reacted with the same 
percentage of strains as the detergent extract serum but the cross-reaction of L 1 and L3 
sera with the panel of neisserial strains was also good (>80% of strains). 
Immuno-blots also showed that N. lactamica antisera are cross-reactive with detergent 
extracts from a variety of N. meningitidis strains (section 2.4). Soth PorS class 2 or 3 
positive meningococcal strains were tested and the patterns of cross-reaction were 
similar for all strains, indicating that sera raised against all N. lactamica vaccines tested 
did not cross-react in a serotype-specific manner. A meningococcal protein of 
approximately 30 kOa was recognised by all sera tested and sera raised against N. 
lactamica OMPs of more than 43 kOa, killed whole cells or detergent extracted proteins 
cross-reacted with a protein of approximately 70 kOa. Two human convalescent immune 
sera from patients recovering from meningococcal disease and two mouse sera raised 
against N. lactamica strain P033 and N. meningitidis strain GLO have recently been 
shown by Troncoso et al., (2000) to recognise N. meningitidis proteins of 65, 55 and 32 
kDa. The 32 kDa protein was not regulated by iron levels and it was suggested that it 
could be a class 4 OMP. The cross-reactive protein of approximately 30 kDa could also 
be either PorS class 2 or 3 (37-42 kDa), Opa (26-30 kDa) or Opc (25 kOa). However, 
Kim et al., (1989) suggest that N. lactamica do not possess OMPs that are antigenically 
similar to meningococcal class 2 or 3 proteins. The 70k Oa protein could be FetA (70 
kDa) and probing N. meningitidis strains grown under iron limited and iron replete 
conditions may confirm this. 
Now that the genome sequence of N. meningitidis strain MC58 has been completed, it 
would be of interest to determine the proteins of N. lactamica that are cross reactive with 
immunogenic recombinant proteins described by Pizza et a/2000. 
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3.3.4. Isotype Response of N. lactamica Cross-Reacting Antiserum. 
Four subclasses of IgG are found in mouse serum; IgG1, IgG2a, IgG2b and IgG3. IgG1 
was found to be the predominant antibody isotype of sera raised against N. lactamica 
OMP fractions, KWe or detergent extract. Low IgG2b antibody titres were detected in 
sera raised against killed whole cells or Elugent extract. IgM was not detected in the 
sera but this was to be expected as the assay was detecting secondary antibody 
responses to the vaccinations. 
Previous investigations of predominant isotypes of the antibodies evoked by LOS 
conjugation to IT or OMP showed that the main antibody response was by IgG 1 
(Verheul et al., 1993). This is consistent with results found in this study (section 3.2.6); 
IgG 1 was also the predominant isotype in sera reacting with the meningococcal porins 
(Lehmann et al., 1999, Guttormsen et al., 1993). In humans IgG1 and IgG3 are the most 
effective of the IgG isotypes at triggering complement activation and binding to the Fc 
receptors. However, of the antibody subclasses present in mice, IgM, IgG2a, IgG2b and 
IgG3 are complement activators. IgG1 displays no activity and is even capable of 
inhibiting the lytic activity of complement activating subclasses (Ey et al., 1980). 
3.3.5. Human Antibody Responses. 
After vaccination, IgM and subsequently IgG antibodies are induced in humans. Serum 
IgA may also be formed. The route of administration and site of immunisation affect the 
subclass and isotype response of the antibodies. For example oral administration of a 
vaccine will produce a localised mucosal immune response. In man, protein antigens 
induce IgG1 antibodies and carbohydrates induce IgG2 (Hammarstrom et al., 1986). 
This study focused only on the antibody subclass response in humans and not the IgG 
isotype responses. 
Detection of IgG in human acute and convalescent sera cross-reactive with N. lactamica 
did not follow a particular pattern (section 3.2.7). IgG in sera was not directed 
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specifically towards a particular group of proteins. Nine of the ten convalescent sera 
tested contained antibodies that cross-reacted with MMW proteins but only three of the 
convalescent sera possessed antibodies that were cross-reactive for LMW proteins. 
Although LMW proteins were found to be the most protective group of N. lactamica 
OMPs, similar proteins of N. meningitidis may not be the most immunogenic proteins in 
humans. One serum pair reacted with all proteins tested with highest titres detected for 
cross-reaction with MMW and HMW proteins and N. lactamica detergent extract. The 
same serum was also found to consist of IgM cross-reactive for all protein groups 
tested, but highest titres were for the cross-reaction with MMW proteins. Paired sera 
from another patient did not recognise any of the protein groups. IgM that was cross-
reactive for N. lactamica OMPs was detected in very few of the human sera tested. 
Results involving cross-reactivity of human disease sera with N. lactamica OMPs are 
inconclusive. However, cross-reacting antibodies against N. meningitidis outer 
membrane complexes have been demonstrated in convalescent sera from patients with 
serogroup B disease (Guttormsen et al., 1992). 
Mandrell et al., (1989) quantified the OMP specific antibodies in human convalescent 
and post vaccination sera. As shown in section 3.2.7 they also found that there was 
considerable heterogeneity among individual human antibody responses. They 
assessed the reactivity of human sera with 3 different OMPs; class 1, 2 and 5. Some 
individuals had a high response to one protein but none to the others and other 
individuals had no measurable response to any of the proteins. They suggested that a 
difference in response may be due to the presence or absence of pre-existing antibody 
or to variable expression of antigens in meningococcal disease patients and vaccinees. 
Heterogeneity among antibody responses to N. meningitidis OMPs has also been 
shown by Wedege et a/., (1986) by Western blotting. IgG antibodies in some sera 
recognised only one OMP whereas other sera detected up to six OMPs. Mandrell et a/., 
(1989) also suggested the following reasons for differences in antibody responses of 
sera from different individuals; primed immune system, persistence of infection or 
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vaccine antigen, different proportions of inhibiting and non-inhibiting antibody and 
antibody affinity. 
Human antibody ELiSAs in this study have shown that circulating IgM of human sera 
are far less than IgG responses to the N. lactamica OMPs. Wedege et al., (1986) found 
the same result by western blotting with far fewer individuals mounting an IgM response 
to the OMPs than mounted an IgG response. 
3.3.6. Serum Bactericidal Activity of N. lactamica Antiserum. 
Natural protection in young children by N. lactamica carriage is suggested to result in 
the production of bactericidal antibodies. Gold et al., (1978) found that forty percent of 
carriers of N. lactamica developed bactericidal antibody titres directed towards N. 
meningitidis of serogroups A, Band C. Bactericidal activity is associated with protection 
against meningococcal disease (Goldscheider et al., 1969). Prior to disease outbreaks 
in, for example, students (Jones et al., 2000), the bactericidal titre of the population is 
low and susceptibility is high. In this study, the bactericidal activity of mouse and rabbit 
serum against serogroup Band C meningococci with human and rabbit complement, 
respectively, was assessed. The sera tested were raised against N. lactamica pooled 
proteins. 
The 'gold standard' correlate of protection against serogroup Band C meningococcal 
disease is a serum bactericidal titre of 4 or more with human complement 
(Goldschneider et al.,1969, Borrow et al., 2001). However good sources of human 
complement that lack antibodies against N. meningitidis are not readily available so 
rabbit complement has been assessed (Borrow et al., 2001). Using rabbit complement, 
a titre of 8 was suggested as a correlate of protection. Titres of less than 8 with rabbit 
complement predict susceptibility to meningococcal disease and titres of more than 128 
are highly predictive of protection. Similarly, Santos et al., (2001) suggested that a 
human bactericidal antibody titre of more than 128 is required when using rabbit 
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complement to be sufficiently confident of predicted protection. Use of rabbit 
complement elevates bactericidal antibody titres to serogroup C meningococci in 
comparison with human complement. They recommend the use of human complement 
for assays because the use of a threshold titre of 128 with rabbit complement is less 
sensitive. Milagres et al., (2000) assessed the bactericidal activity of human 
convalescent sera against serogroup B meningococci. They found that titres of more 
than 2 indicated a specific immune response. 
Serum bactericidal assays involving sera raised in mice against N. lactamica OMPs 
provided disappointing results. Sera were found to have variable and very low levels of 
bactericidal antibodies cross-reactive with N. meningitidis. Protection experiments 
carried out in this study consisted of only 2 booster vaccinations after primary 
immunisation and Cartwright et al., (1999) found that bactericidal titres to a novel 
hexavalent PorA vaccine after two booster vaccinations post primary immunisation were 
unimpressive. A third booster vaccination after primary immunisation was found to much 
improve bactericidal titres. Bactericidal titres for mouse sera raised against N. lactamica 
OMP sub-unit vaccines may be increased with a third boost. West et al., (2001) showed 
that mouse serum raised against recombinant Tbp A was not bactericidal although 
protection was conferred by this protein. They suggested that the serum bactericidal 
assay may not, therefore, be a good predictor of protection in humans either. Similary, 
Perkins et al., (1998), suggest that serum bactericidal titres may be an insensitive 
correlate for protective efficacy for some outer membrane protein vaccines. When a 
serum bactericidal titre is present it is likely to correlate to protective efficacy but lack of 
bactericidal titre does not necessarily imply that a vaccine is not protective. They 
suggest that antibodies that are not bactericidal may be protective through other 
mechanisms such as opsonophagocytosis. An alternative reason for the low bactericidal 
titres found may be the lack of a ParA protein expressed by N. lactamica (Kim et al., 
1989). Bactericidal antibodies are often directed towards PorA proteins of N. 
meningitidis. Removal of PorA from a vaccine shows a strong reduction in bactericidal 
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antibody titres but removal of PorB has little effect (Van der Ley, 1992, Saukkonen, 
1989). 
The rabbit sera tested were bactericidal; however the pre-immune serum was also 
bactericidal. Against serogroup C the sera had a titre of between 4 and 8 and against 
serogroup B meningococci titres of 128 were observed. In both cases, the bactericidal 
titres could not be used to predict protection by the vaccines. West et a/., (2001) also 
showed that when compared to mouse sera, rabbit sera were bactericidal, but similarly 
serum from unimmunised rabbits was also bactericidal. 
Granoff et al., (1998) designed an ELISA that correlated to human bactericidal antibody 
responses. It detected high avidity antibodies by addition of ammonium thiocyanate to 
the blocking buffer to selectively remove low avidity antibodies. Aase et a/., (1995) 
suggested that there was a weak correlation between serum IgG levels and serum 
bactericidal activity but that there was good correlation between opsonic activity and 
serum IgG levels. However, the correlation between bactericidal activity and opsonic 
activity was weak and they recommend the use of both bactericidal assays and opsonic 
assays in the assessment of vaccines. It would, therefore be of interest to determine 
whether the protective antibodies have opsonic activity and whether this can be used to 
explain the protection observed by the N. lactamica proteins. 
3.4. Conclusions. 
Protection by N. lactamica OMPs is not serogroup, serotype or serosubtype specific, 
suggesting that N. lactamica would provide a suitable target for vaccine development 
against meningococcal disease. Proteins of between 25 and 43 kOa provided the 
greatest protection to mice, but the protection observed may not be due to bactericidal 
activity of the antibodies raised. Thus, bactericidal antibodies may not be the best 
correlate of protection in mice and testing sera for opsonophagocytic or other funtional 
antibody activity may provide answers as to how LMW N. lactamica vaccines protect. 
113 
Chapter 3 
LOS does not appear to be involved in the protection observed by the LMW group, as 
the quantity of endotoxin was greater in a less protective vaccine formulation. However, 
the accurate determination of LOS is difficult and thus the results are not conclusive. 
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Chapter 4 
Surface Enhanced Laser Desorption Ionisation to 
Identify Neisseria meningitidis OMPs Cross-
Reactive with Neisseria lactamica Antiserum 
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4.1. Introduction. 
In chapter 3, immunisation with N. lactamica OMPs and derived fractions, was shown to 
protect mice against lethal meningococcal challenge. N. lactamica antiserum was also 
cross-reactive with detergent extracts from a variety of meningococcal strains 
suggesting that N. lactamica antiserum protects by interaction with specific 
meningococcal OMPs and that N. lactamica OMPs are homologous to meningococcal 
OMPs. However, the N. meningitidis OMPs recognised by N. lactamica antiserum are 
unknown. In this chapter, Surface Enhanced Laser Desorption Ionisation (SELDI) was 
used to identify N. meningitidis OMPs that cross-react with N. lactamica antiserum. The 
serum was bound to tosyl-activated magnetic beads and these were used as an affinity 
capture surface. Pools of N. meningitidis proteins separated by preparative 
electrophoresis were incubated with the beads, which were then placed directly onto a 
hydrophobic ProteinChip surface. The proteins bound by the fixed antibody were then 
desorbed and their molecular mass determined by the SELDI time-of-flight instrument. 
Using this method the molecular weights of proteins cross-reacting with the serum could 
be identified. The ultimate aim of this work was to identify the N. meningitidis proteins 
which the protective anti-No lactamica antibodies are directed against. 
4.1.1. Mass Spectrometry. 
Mass spectrometry (MS) can be applied to all elements and molecules with a molecular 
mass greater than 15 Da. The basis of MS is the measurement of mass. It requires only 
very small amounts of sample (analyte) due to the high sensitivity of the technique and 
several substances can be determined at one time The sample can be in gaseous, 
liquid or solid form. 
The masses of ionised molecules are measured using a mass spectrometer, which can 
separate charged atoms or molecules according to their mass to charge ratio (mlz). If 
the ions measured have one charge (Le. z=1), m/z is equivalent to the molecular mass 
(www.asms.org, www.bmss.org.uk). The sample is converted to the gaseous phase 
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either before or during the ionisation process. Once the sample has been ionised, the 
ions are propelled through an analyser. Analysers are either field instruments, e.g. 
magnetic sector, quadrupole mass filters, ion traps, or time of flight (ToF) instruments. 
ToF instruments separate ions by their different flight times over a known distance. Ions 
are accelerated and directed into a flight tube. Ions with a like charge have equal kinetic 
energy (kinetic energy is equal to 1/2mv2, where v is the velocity of the ion). Therefore, 
the lower the ion's mass, the greater its velocity and the shorter its time of flight. So like 
charged ions will have differing times of flight depending on their mass. 
A number of techniques have been used for ionisation of the sample, including electron 
ionisation (EI), fast atom bombardment (FAB), matrix assisted laser desorption 
ionisation (MALOI) and electrospray ionisation (ESI). EI involves bombarding the 
gaseous sample with a beam of electron generating ions. For FAB ionisation the sample 
is dissolved in a liquid matrix. The function of the matrix is to mediate the transfer of 
energy from the laser to the sample. The liquid surface is bombarded with a beam of 
high kinetic energy atoms or ions. ESI involves dissolving the sample in a mixture of 
water and either acetonitrile or methanol which is then pumped through a fine stainless 
steel capillary and a high electric potential creates an electrostatic spray of multiply 
charged droplets. MALOI uses a crystalline matrix and a beam of photons to ionise the 
sample. Like FAB the sample is dissolved in a matrix such as 2,5-dihydrobenzoic acid or 
sinapinic acid and allowed to crystallise on a stainless steel target. The surface is then 
bombarded with a pulsed laser beam and the sample ionised. Ion generation by MALOI 
is not clearly understood. It is thought that the matrix absorbs most of the photon energy 
and converts the mixture into vapour. Ions form in the vapour by either proton transfer 
from the matrix to the analyte forming positive ions or from the analyte to the matrix 
forming negative ions. Due to the heterogenous mixture of the analyte and matrix best 
ion formation occurs at particular spots in the preparation (Baar, 2000). The most 
effective matricies for protein ionisation are a.-cyano-4-hydroxycinnamic acid or sinapinic 
acid. 
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MALDI is successfully used to generate ions from proteins of over 100 kDa and it has 
been reported that proteins of up to 500 kDa in E. coli Iysates have also been detected 
by MALDI (Chong et al., 1997). MALDI and ESI are now the most commonly used 
techniques for analyte ionisation. 
For MALDI good sample preparation is required to provide the best results. The matrix 
and analyte may separate upon solvent evaporation. Homogeneity of the sample is 
critical and mostly depends on the properties of the matrix and the sample. Additives 
such as trifluoroacetic acid and ethanol help maintain a homogeneous mixture 
(Hillenkamp et al., 1990). Also matrix ions are often formed and these may covalently 
bond or non-covalently complex with the analyte. These are known as matrix adducts 
and they deteriorate the resolution of the mass by broadening the signal of interest 
(Saar, 2000). 
4.1.2. Surface Enhanced Laser-Desorption Ionisation. 
In 1993 Hutchens and Yip developed a new form of MALDI. Although essentially the 
same as MALDI, they redeveloped the sample application surface and called the new 
technique surface enhanced laser-desorption ionisation (SELDI). Two forms of SELDI 
were described; surface enhanced neat desorption (SEND) and surface enhanced 
affinity capture (SEAC). SEND surfaces contained the energy absorbing material so that 
application of matrix is not required after sample application. For SEAC either the 
sample application surfaces (probe surface) were used as affinity capture platforms or 
analyte capture was indirect and performed on beads which were then applied to the 
probe surface and analysed (Hutchens and Yip, 1993). For both of these techniques 
matrix was applied as for conventional MALDI. Using SEND peaks on the mass 
spectrum were symmetrical and there was no evidence of matrix adducts. SEAC also 
produced good quality results. Using beads they found that the quality of the signal was 
not compromised by presentation of the analyte on a surface that was not flush with the 
probe surface. They suggested SEAC as a method for the selective capture of specific 
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analytes by altering the affinity capture reagents as required. Merchant et a/., (2000) 
reviewed SELDI and suggested that SEAC was the SELDI application showing most 
promise as the probe surface has a role in sample extraction, presentation and 
amplification. Molecules bind to the surfaces via hydrophobic, electrostatic covalent 
bonding and other interactions. Sequential washing steps with the appropriate buffer 
can isolate molecules with a strong affinity for the chemically active surface. 
Compounds with shared chemical properties are retained. 
Ciphergen (USA) have designed an assortment of chemically-defined surfaces. These 
are in the form of chips containing 8 or 24 spots with affinity capture surfaces and are 
called ProteinChip Arrays (www.ciphergen.com). ProteinChip Arrays contain chemically· 
(cationic, anionic, hydrophobic or hydrophilic) or biochemically (antibody, receptor or 
DNA) defined surfaces. Samples are specifically captured by the surface and can be 
analysed directly to determine their mass or enzymically digested on the chip to 
determine their peptide composition. Once the sample has been purified on the chip it is 
analysed by ToF (Figure 4.1). A matrix is applied and promotes laser based desorption 
ionisation. Detected analyte is displayed as for MS. 
SELDI has been used by Hutchens' group to detect and characterise lactoferricin and 
lactoferrin (Kuwata et a/., 1998a, 1998b, 1998c). Lactoferricin was initially captured 
specifically using molecules with terminal n-butyl groups. Lactoferricin and lactoferrin 
fragments in human gastric contents were quantified. 
4.1.3. Beads as an Affinity Capture Surface. 
MagnetiC beads can be used for purifications linked to ToF. Beads are particularly 
important because minute quantities of proteins can be characterised and the surface 
area for analyte binding is increased intensifying the signal. Beads can be placed 
directly on to the probe or ProteinChip and the laser causes the analyte to dissociate 
from the beads. Although Hutchens and Yip found that there were no problems with the 
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resolution of the signal associated with using beads (Hutchens and Yip, 1993) Merchant 
et al., (2000) suggest that particulates on the probe surface compromise resolution and 
mass accuracy. Solvents or acid can be used to elute bound sample from the beads 
immediately prior to analysis. This may enhance the signal produced. They also suggest 
that introduction of beads to the spectrometer may in fact contaminate the instrument. 
4.2. Results. 
4.2.1. Separation of N. meningitidis OMPs. 
To reduce the complexity of the proteins analysed by SELDI, proteins were separated 
into small groups. Complex mixtures of proteins can result in only the most concentrated 
proteins being observed on a SELDI mass spectrum, with far fewer proteins than are 
actually present in the mixture being detected. Using preparative electrophoresis, only 
proteins from a detergent extract of an unencapsulated meningococcal strain could be 
separated. The DE of N. meningitidis, strain Me58 cap-, a meningococcal strain similar 
to the challenge strain K454 (B 15 P1.7, 16) used in chapter 3, was fractionated by size 
into small pools of OMPs (Figure 4.2). Preparative electrophoresis worked well in 
separating the OMPs from the unencapsulated strain. Proteins of >45 kDa were 
undetectable by coomassie stain but upon concentration these proteins were detectable 
as shown by SELDI (section 4.2.4). The proteins were pooled into five groups based on 
size, and concentrated. 
4.2.2. Purification of IgG from N. lactamica Rabbit Antiserum. 
Purified IgG from sera was used for SELDI analysis so that the mass spectrum of 
meningococcal protein binding was not contaminated by the presence of other serum 
components. Sera were raised in rabbits against N. lactamica LMW, MMW, HMW, L2 
and L3 protein pools, the preps used in mouse protection studies (chapter 3) as 
described in section 2.7.5. IgG was purified from these sera using a 5ml protein G 
column. IgG was eluted from the column with 0.1 M glycine, pH2. Purified IgG was 
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Figure 4.2 Separation of N. meningitidis strain MCS8 cap' by preparative 
electrophoresis. The molecular weight markers are shown in lane A. Increasing sized 
OMP fractions are shown in lanes 8-J . 
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analysed on a Paragon gel (Beckman-Coulter) and no contamination of the IgG was 
observed (Figure 4.3). The Paragon gel consists of 1 % agarose and is used for 
electrophoretic separation of proteins in serum. The remaining serum eluted from the 
column prior to IgG elution was shown to consist of albumin, alpha1, haptoglobin, 
transferrin and complement. 
4.2.3. SELDI of N. lactamica IgG. 
Affinity capture of purified IgG using the H4 ProteinChip was carried out to assess 
whether the sera were contaminated with albumin. H4 chips are used for capturing 
proteins through hydrophobic interactions and can be used for ascertaining the purity of 
protein preparation (www.ciphergen.com). Serum albumin competes with IgG for 
binding sites on the ProteinChip, therefore reduced quantities of IgG implies reduced 
sensitivity of the system. Also, albumin is easily ionised and detected, producing a large 
peak on the spectrum, thus reducing the comparative intensity of other peaks (Paul 
Langford, personal communication). This is a more sensitive method for assessing 
contamination than the paragon gel system, as it can be used to detect proteins to the 
fM level. Peaks that might be expected to be seen on the mass spectra of sera would be 
of 22 kOa, 48 kOa, 74 kOa, 148 kOa or 66 kOa corresponding to the light chain, the 
heavy chain, the half antibody, intact antibody or serum albumin respectively. Half 
antibody (72 kDa) and intact IgG (145 kOa) could clearly be seen on the spectra of the 
purified IgG but a peak corresponding to serum albumin was not observed (Figure 4.4). 
4.2.4. Contents of Meningococcal Protein Pools. 
The molecular weights of the proteins present in each of the meningococcal OMP pools 
were assessed. Again H4 chips were used for affinity capture of the proteins. From the 
spectra, it can be seen that the pools consisted of proteins of gradually increasing mass 
(Figure 4.5). Pool 1 consisted of a few proteins with a maximum molecular weight of 
11.2 kOa. Pool 2 consisted of proteins with masses up to 33.6 kDa. It also contained 
proteins over-lapping to a certain extent with those in pool 1. Pool 3 had a similar profile 
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Figure 4.3 Paragon Gel showning purified IgG from N. lactamica antisera on lanes B, D, 
F and H. Lanes C, E, G and I show serum components after removal of IgG including 
albumin , haptoglobin, transferrin and complement. ControllgG is shown on lane A. 
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Figure 4.4 Mass spectra of rabbit sera raised against N. lactamica LMW, MMW, 
HMW, L2 and L3 outer membrane protein pools . Half antibody and intact IgG can be 
seen as peaks of 72 kOa and 145 kOa respectively. 
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Figure 4.5 Mass spectra of meningococcal protein pools separated by preparative 
electrophoresis in the 5-45 kOa molecular weight range. Protein pools were bound to 
H4 chips and analysed. 
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to pool 2 but the intensities of the peaks at 26.8 kDa, 29.5 kDa and especially at 33.6 
kDa were greater. Pools 4 and 5 consisted of few small proteins and as well as having 
peaks on their spectra at 28.1 kDa and 33.6 kDa, an additional peak was observed at 
66.7 kDa (Figure 4.6). 
The mass spectra of the N. lactamica protein pools against which the rabbit sera were 
raised are shown on Figure 4.7. L2 and L3 consist of proteins of similar molecular mass 
range but no proteins of more than 33 kDa were observed. As expected however, MMW 
and HMW consisted of proteins of >33 kDa. 
4.2.5. Affinity Capture and Analysis of Meningococcal OMPs by N. lactamica 
Antiserum. 
Beads coated with normal rabbit serum and N. lactamica LMW, MMW, L2 and L3 
antisera were used as affinity capture surfaces. The beads were incubated with each of 
the meningococcal pools described (Section 4.2.4) for 4-5 h. Beads were initially 
washed with water to remove unbound protein and analysed. The washing stringency 
was increased using PBS containing 0.5% (v/v) Triton X100 and the beads were again 
analysed. All of the assays were carried out in duplicate. Beads coated with normal 
rabbit serum were incubated with meningococcal protein pools 1, 2, 3, 4, 5, and the 
complete detergent extract of OMPs. Analysis of protein binding by this serum showed 
that it did not have an affinity for any of the proteins after either of the washing steps 
(Figures 4.8 and 4.9). 
LMW antiserum bound a number of the proteins from each of the pools (Figure 4.10). 
The serum bound proteins with molecular weights of approximately 11.2, 13.7,26.9, 
28.1 and 33.7 kDa from more than one protein pool when washed with water. After 
washing with the more stringent buffer the 11.2, 13.7 and 33.7 kDa proteins remained 
bound by the serum (Figure 4.11). However, the intensity of the peaks appeared to be 
Slightly reduced. Duplicate analyses confirmed these results. 
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Figure 4.6 Mass spectra of N. meningitdis pool 4 and pool 5 in the 10-90 kOa molecular 
weight range . 
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Figure 4.7 Mass spectra of N. lactamica protein pools against which rabbit sera were 
raised. LMW, L2 and L3 did not consist of proteins >33.5 kOa. MMW and HMW protein 
pools additionally consisted of a 66.6 kDa protein. 
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Figure 4.8 Cross-reactivity of meningococcal protein pools with normal rabbit serum 
after washing with water. Normal rabbit IgG was covalently bound to Dynabeads and 
used as control sera. Meningococcal proteins were not bound by this serum. 
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Figure 4.9 Cross-reactivity of meningococcal protein pools with normal rabbit serum 
after washing with PBS containing 0.5% Triton X-100. 
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Figure 4.10 Cross-reactivity of meningococcal protein pools with LMW antiserum serum 
after washing with water. Anti-LMW IgG was covalently bound to Dynabeads and 
incubated with MC58 cap· protein pools 1-5. After washing with water, a number of 
proteins were bound by the serum. 
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Figure 4.11 Cross-reactivity of meningococcal protein pools with LMW antiserum serum 
after washing with PBS containing 0.5% Triton X-100. A number of proteins remained 
bound by anti-LMW IgG after further washing including the 11 .2, 13.7 and 33.7 kDa 
proteins. 
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L2 antiserum bound the same proteins as LMW antiserum. The protein of 28.1 kDa was 
only bound from protein pools 4 and 5 (Figure 4.12). Additionally, it bound a protein of 
approximately 17.4 kDa. Washing with Triton X100 stripped L2 antiserum incubated with 
pools 4 and 5 of any proteins above 17.4 kDa (Figure 4.13). Proteins of 28.1 and 33.7 
kDa remained bound when beads incubated with protein pools 1 and 2 were washed 
with this buffer. 
After washing with water, similar binding patterns were obtained using L3 antiserum with 
each of the N. meningitidis protein pools was observed as for LMW and L2 antisera 
(Figure 4.14). Proteins of the same molecular weights were bound by each of the sera, 
indicating that these proteins are particularly cross reactive with the N. lactamica 
antisera. However, it also implied that there was no difference between the specificity of 
LMW, L2 and L3 antisera. This reflects the level of resolution of preparative 
electrophoresis. Duplication of washing with Triton X100 provided conflicting results 
regarding the avidity of protein binding by L3 antiserum. Initially there was no effect on 
the proteins bound by L3 antiserum after washing with Triton X100 (Figure 4.15). 
However, after duplication of the assay, no proteins remained bound by the serum 
(Figure 4.16). 
N. lactamica MMW antiserum binding was assessed with pools 2, 3, 4 and 5 as pool 1 
only consisted of proteins <12 kDa and MMW serum was raised against proteins of 43-
65 kDa. Similarly to the results obtained with L2, L3 and LMW antisera, MMW 
antiserum bound proteins of 11.2, 13.7, 17.4, 26.9, 28.1 and 33.7 kOa (Figure 4.17). 
Additionally, a protein of approximately 53.2 kOa from pools 2 and 4 was bound by the 
serum. Pools 3, 4 and 5 contained a protein of approximately 66.7 kDa which was 
bound by the MMW antiserum. LMW, L2 or L3 sera did not bind either the 53.2 kDa 
protein or the 66.7 kDa protein. Stringent washing removed any trace of the 53.2 kDa 
protein and often removed the 66.7 kOa protein (Figure 4.18). 
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Figure 4.12 Cross-reactivity of meningococcal protein pools with L2 antiserum serum 
after washing with water. Anti-L2 IgG was covalently bound to Oynabeads and incubated 
with MCS8 cap- protein pools 1-5. After washing with water a similar pattern of cross-
reactivity as with anti-LMW IgG was observed. A protein of 17.4 kOa was additionally 
bound by this serum. 
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Figure 4.13 Cross-reactivity of meningococcal protein pools with L2 antiserum serum 
after washing with PBS containing 0.5% Triton X-100. A number of proteins remained 
bound by anti-LMW IgG after further washing including the 11 .2, 13.7 and 33.7 kDa 
proteins. However, proteins of >17.4 kDa were stripped from beads incubated with MC58 
cap' protein pools 4 and 5. 
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Figure 4.14 Cross-reactivity of meningococcal protein pools with L3 antiserum serum 
after washing with water. A similar pattern of cross-reactivity of MC58 cap- protein pools 
was observed with Oynabeads coated with anti-L3 IgG as with beads coated with anti-
LMW IgG and anti-L2 IgG. 
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Figure 4.15 Cross-reactivity of meningococcal protein pools with L3 antiserum serum 
after washing with PBS containing 0.5% Triton X-100. A number of proteins remained 
bound by anti-LMW IgG after further washing and bound proteins were observed from 
MC58 cap· poolS after this washing step. 
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Figure 4.16 Duplicate assay showing cross-reactivity of meningococcal protein pools with 
L3 antiserum serum after washing with Triton X-100. No proteins from the meningococcal 
protein pools 4 or S remain bound by L3 antiserum after washing with Triton X-100. 
Proteins with a molecular mass greater than 17.4 kOa are also removed after this wash 
step from protein pools 1, 2 and 3. 
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Figure 4.17 Cross-reactivity of meningococcal protein pools with MMW antiserum serum 
after washing with water. Anti-MMW IgG was covalently bound to Dynabeads and 
incubated with MC58 cap· protein pools 2-5. This serum bound similar proteins to anti-
LMW IgG, anti-L2 IgG and anti-L3 IgG and additionally bound a protein of 53.2 kDa from 
pools 2 and 4 and a protein of 66.7 kDa fro pools 3,4 and 5 and the DE of Me58 cap·. 
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Figure 4.18 Cross-reactivity of meningococcal protein pools with MMW antiserum serum 
after washing with PBS containing 0.5% Triton X-100. Many proteins remained bound by 
anti-MMW IgG however, the 53.2 and 66.7 kOa proteins we removed from the serum after 
this washing step. 
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The proteins bound by HMW antiserum were inconsistent with the previous results. This 
is unsurprising, as this protein pool was least protective in the mouse protection model 
(Section 3.2.2). Proteins of 11.2, 17.4, 26.9 and 33.7 kDa from the meningococcal 
protein pool 3 were bound by HMW antiserum but higher molecular weight proteins 
bound by MMW antiserum were not cross-reactive with this serum. Stringent washing 
removed all proteins bound by this serum, except for the 33.7 kDa protein from pool 3, 
indicating that HMW antiserum has a low affinity for the meningococcal proteins 
(Figures 4.19 and 4.20). 
4.2.6. Putative Identification of Cross-Reacting OMPs using ExPasy. 
ExPasy Tagldent is a tool that allows the identification of proteins by their mass, if this 
mass has been determined by mass spectrometric techniques (www.expasy.org).1t 
searches sequence databases of particular organisms provided they are completely 
sequenced and the data is published, using Swiss Prot. Many different proteins from the 
N. meningitidis genome database have molecular weights similar to those of each of the 
peaks. Proteins with molecular weights within +/-5% and +/-2% of the molecular weights 
of the peaks are shown on table 4.1. Due to the accuracy of SELOI analysis proteins 
within +/-2% of the peak should provide the better indication of the protein identity. A 
definitive identity of the proteins corresponding to each peak cannot be made. However, 
of the list of proteins within +/-2% of the peaks, the meningococcal protein with 
molecular weight closest to the 11.2 kDa peak was aspartate 1-decarboxylase (11.1 
kOa). 50S ribosomal protein L20 (13.7 kDa) was most similar in molecular weight to the 
13.7 kDa peak. Superoxide dismutase has a molecular weight of 17.36 kDa and was 
most similar to the molecular weight of the peak at 17.3 kOa. Hypothetical 
methyltransferase (27.0 kDa) was most similar in molecular weight to the 26.9 kDa 
peak. The molecular weight of Acyl-[acyl-carrier protein]-UOP-N-acetylglucosamine 0-
acetyltransferase (28.2 kDa) was most similar to the 28.2 kOa peak. The molecular 
weight of the meningococcal class 3 protein (33.8 kOa) was most similar to the 33.7 kOa 
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Figure 4.19 Cross-reactivity of meningococcal protein pools with HMW antiserum serum 
after washing with water. Anti-HMW IgG was covalently bound to Oynabeads and 
incubated with MCS8 cap- protein pools 3-5. Only proteins from pool 3 were bound by this 
serum and proteins of 53.2 and 66.7 kOa were not bound from this pool. 
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Figure 4.20 Cross-reactivity of meningococcal protein pools with HMW antiserum serum 
after washing with PBS containing 0.5% Triton X-100. This washing step removed all 
bound proteins from MC58 cap· protein pool 3 except for the 33.7 kOa protein. Anti HMW 
IgG had low affinity for the MC58 OMPs. 
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Table 4.1 Putative meningococcal proteins cross-reacting with N. lactamica antisera as 
identified using ExPasy Tagldent. All proteins listed have molecular weight within 5% of 
the molecular weight of the peak. Highlighted proteins have molecular weights within 
2% of the molecular weight of the peak. 
Peak Putative protein Locus 
11226.00a FK506 Binding Protein NMB0027 
Glutamyl T-RNA amidotransferase subunit C NMB1355 
Aspartate 1-decarboxylase NMB1282 
Hypothetical protein NMB0837 
13712.80a Probable glycine cleavage system H protein 13643.07 NMB0575 
50S ribosomal protein L 19 13767.95 NMB0589 
50S ribosomal protein L20 13710.15 NMB0723 
Ribonuclease P protein component 14211 .41 NMB1905 
30S ribosomal protein S6 13949.02 NMB1323 
17378.90a Bacterioferritin A 17961 .25 NMB1207 
Disulphide bond formation protein B 17701.21 NMB1649 
Dihydrofolate reductase 17751 .52 NMB0308 
(3R)-hydroxymyristoyl-[acyle carrier protein] dehydratase 16626.53 NMB0179 
Fimbral Protein Precursor (pilin) 17298.65 NMB0018 
H8 Outer Membrane Protein 16885.79 NMB1533 
2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase 17019.54 NMB1512 
Superoxide Dismutase [Cn-Zn] 17360.36 NMB1398 
Hypothetical protein 17284.82 NMB1816 
26868.00a 3-dehydroquinate dehydratase 27186.21 NMB1446 
Acyl-[acyl-carrier protein]-UDP-N-acetylglucosamine 0-
acetyltransferase 28154.91 NMB0178 
Probable septum site-determining protein 26221 .11 NMB0170 
Hypothetical methyltransferase 27037.62 NMB1328 
Na-translocating NADH-quinone reductase subunit C 27606.57 NMB0567 
3-methyl-2-oxobutanoate hydroxymethyltransferase 27739.25 NMB0870 
Pyridoxal phosphate biosynthetic protein 26565.58 NMB0448 
1-acyl-sn-glycerol-3-phosphate acetyltransferase 27943.25 NMB1294 
Thiazole biosynthesis protein 28067.06 NMB2071 
3-dimethylubiquinone-9 3-methyltransferase 26529.48 NMB2030 
Hypothetical protein 27417.04 NMB2054 
28173.60a 3-dehydroquinate dehydratase 27186.21 NMB1446 
Shikimate 5-dehydrogenase 28564.71 NMB0358 
Competence lipoprotein comL 29274.90 NMB0703 
Dihydrolipocolinate reductase 28328.10 NMB0203 
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(Table 4.1 continued) 
Peak Putative Protien Locus 
Acyl-[acyl-carrier protein]-UDP-N-acetylglucosamine 0-
acetyltransferase 28154.91 NMB0178 
Hypothetical methyltransferase 27037.62 NMB1328 
Na-translocating NADH-quinone reductase subunit C 27606.57 NMB0567 
3-methyl-2-oxobutanoate hydroxymethyltransferase 27739.25 NMB0870 
1-acyl-sn-glycerol-3-phosphate acetyltransferase 27943.25 NMB1294 
Thiazole biosynthesis protein 28067.06 NMB2071 
TonS protein 29198.89 NMB1730 
Hypothetical protein 27417.04 NMB2054 
33719.30a GTP binding protein 34617.03 NMB0678 
Glycerol-3-phosphate dehydrogenase 35337.90 NMB2060 
Porphobilinogen deaminase 33478.47 NMB0539 
33kDa chaperonin 33204.66 NMB2000 
Lacto-N-neotetraose biosynthesis glycosyl transferase 32790.00 NMB1926 
UDP-3-0-[3-hydroxymyristoyl] N-acetylglucosamine 
deacetylase 33986.69 NMB0017 
T -RNA delta(2)-isopentenylpyrophosphate transferase 34870.26 NMB0935 
Class 3 protein , p~rin 33845.23 PorS 
Proline iminopeptidase 34956.75 NMB0927 
Recombination associated protein 33263.72 NMB0851 
Glucose-1-phosphate thymidylyltransferase 32161.71 NMB0062 
Transposase for insertion sequence element 181106 32758.54 NMB1539 
T-RNA psuedouridine synthase B 33632.50 NMB1374 
Hypothetical adenine-specific methylase 33955.36 NMB1655 
66656.40a Chaperone protein DNA K (heat shock protein 70) 68791.66 NMB0554 
1-deoxy-D-xylulose 5-phosphate synthetase 68749.57 NMB1876 
DNA primase 65915.11 NMB1537 
Glutaminyl-T-RNA synthetase 64649.85 NMB1560 
Transferrin binding protein B 63343.98 TbpB 
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peak and DNA primase (65.9 kDa) was most similar in molecular weight to the 66.7 kOa 
peak. 
4.2.7. Further Identification ofthe 17.3 and 66.7 kDa Proteins Peaks. 
To reduce the list of putative proteins bound to the sera at the different molecular 
weights, mutant strains missing a protein listed or having an alteration to the protein 
listed rendering it unrecognisable to the serum can be used. From the list of putative 
proteins only superoxide dismutase C- (SodC-) and transferrin binding protein B- (TbpB-) 
mutant strains were available for this study. SodC, with a molecular weight of 17.36 
kOa, was identified as a possible protein from the list of putative proteins as it has a 
molecular weight similar to the peak on the spectra at 17.3 kOa. TbpB, with a molecular 
weight of 63.34 kOa, is similar to the peak at 66.7 kOa, although its molecular mass is 
not within 2% of the peak. Comparison of binding spectra obtained with detergent 
extracts of wild type and mutant strains to N. lactamica antisera will determine whether 
differences can be suggested which are due to the mutation. For example, using the 
TbpB- mutant, the absence of a peak at 66.3 kOa, when bound by N. lactamica serum 
but the presence of the peak in the wild type strain, would indicate that this peak 
corresponds to TbpB. Therefore the serum may originally have been raised against N. 
lactamica TbpB, amongst other proteins, from N. Lactamica and it may be involved in 
the protection by N. lactamica against N. meningitidis. 
The mutant strains used for this work were prepared by other laboratories. The TbpB-
mutant of N. meningitidis, strain B16B6, was prepared as described by Irwin et al., 
(1993) and the SodC- mutant of MC58 was prepared by Wilks et al., (1998). The 
mutants were insertional, obtained by in vitro cassette mutagenesis. 
Figure 4.21 shows the reactivity of N. lactamica antiserum with the strain against which 
the serum was raised, N. lactamica, strain Y92-1009, and compares the reactivity of the 
mutant strains with the wild type strains by western blotting. Using this method no 
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C o E F 
Figure 4.21 Western blot comparing cross-reactivity of N. lactamica LMW antiserum 
with Tbp8- and SodC- mutant strains and their wild type parent strains. Molecular 
weight markers are shown on lane A. Cross-reactivity of LMW antiserum with; N. 
lactamica, strain Y92-1009, is shown on lane 8 ; N. meningitidis, 81686 wt on lane C; 
N. meningitdis, 81686 Tbp8- on lane 0; N. meningitidis, MCS8 wt on lane E; N. 
meningtidis, MC58 SodC- on lane F. 
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difference can be seen between the TbpB- strain and the wild type strain. However, 
fewer high molecular weight proteins were observed in the SodC- strain than the wild 
type strain. 
Using SELDI analysis of OMPs from TbpB- and wt strains, the 66.7 kDa protein was 
identified as TbpB. Figure 4.22 shows that a protein of approximately 66 kDa was bound 
by N. lactamica LMW antiserum from the B16B6 wt detergent extracted OMPs but 
nothing was bound with the corresponding molecular weight form the TbpB- mutant 
strain. Therefore, the N. lactamica antiserum consisted, in part, of antibodies directed 
towards TbpB, suggesting that TbpB from N. lactamica is immunogenic. 
No such observations were made using the SodC- mutant strain (Figure 4.22). Although 
a peak of 17.3 kDa was observed when pools of MC58 OMPs were incubated with N. 
lactamica antiserum, the corresponding peak was not observed using the wild type or 
mutant strains to attempt to identify this peak. Therefore no conclusions can be made 
about the identity of the 17.3 kDa peak. 
4.3. Discussion. 
SELDI has been used by a number of authors as a tool for protein identification and 
characterisation. Hinshelwood et al., (1999) used SELDI to identify the complement C3b 
binding site of complement factor B. Boyle et 81., (2001) used SELDI to analyse 
streptococcal virulence factor, SpeB, and its production by S. pyogenes. They showed 
that SpeB secretion was a function of cell growth and that SELDI could be used to 
rapidly distinguish SpeB negative and positive isogenic variants and also show the 
intermediates associated with SpeB production. Davies et al., (1999) used SELDI to 
assess variants of amyloid 13 peptide, the component of senile plaques associated with 
Alzheimer's disease. A further use of MALDI which is facilitated by SELDI has been the 
identification of biomarkers for diagnosis of disease. For example, Johnston-Wilson et 
81., (2001) looked for differences between samples from individuals with psychiatric 
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Figure 4.22 Comparison of cross-reactivity with LMW antiserum of Tbp 8· and Sod C· 
meningococcal strains and their parent wild-type strains. A proteins of approximately 66 
kDa from the 81686 wt DE was bound by N. lactamica anti-LMW IgG but the 
corresponding protein in the mutant strain was not observed implying that this protein 
peak corresponds to Tbp8. Results using MCS8 wt and SodC· strains were inconclusive. 
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disease and controls. SELDI has also been used by Kuwata et al., (2001) to observe the 
products of digestion of lactoferrin. However, no work prior to this study has used SELDI 
as a tool for observing the cross reactivity of complex mixtures of proteins with serum 
raised against complex mixtures of proteins from another species and to identify these 
proteins. 
In this study. sera were raised in rabbits against OMPs from N. lactamica that were 
previously shown to be protective in mice (chapter 3, section 3.2.2). The cross-reactivity 
of these sera with OMPs from N. meningitidis was assessed using SELD/. Proteins with 
molecular weights of approximately 11.2. 13.7. 17.4,26.9. 28.1. 33.7. 53.2 and 66.7kDa 
were most cross-reactive with the range of antisera tested, suggesting that proteins 
homologous to these from N. lactamica are important in mounting a cross-reactive 
immune response against N. meningitidis. Putative identifications of these proteins were 
made by comparing the molecular masses of the proteins with the published proteome 
of N. meningtidis. strain Me58. 
4.3.1. SELOI as a Tool for Protein Identification. 
The molecular masses of the proteins bound by N. lactamica sera were compared to the 
masses of proteins from the proteome of N. meningitidis using ExPasy Tagldent and 
searching the SwissProt database. A number of putative proteins were identified. 
corresponding to each of the bound proteins. However, the data was ambiguous; there 
were no putative proteins with molecular weights exactly matching the mass of the 
bound protein. As a best guess of identity, the putative protein closest in molecular 
weight to the bound protein could provide the best identity. Alternatively. as sera were 
raised against N. lactamica OMPs and the meningococcal protein pools consisted of 
OMPs, some proteins may have a slightly different mass between N. meningtidis and N. 
lactamica homologues. We could also assume that the putative proteins should be 
transmembrane. Transmembrane prediction packages, such as TMpred, proteins can 
predict that proteins have a transmembrane location. However. it uses a set of rules 
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based on naturally occurring transmembrane proteins to predict this, which may not 
necessarily apply to the protein of interest. For this study, transmembrane proteins 
among the putative proteins identified were predicted (Table 4.2). This still left a long list 
of putative proteins for each of the bound proteins except for the proteins of 11.2 and 
13.7 kDa, where none of the putative proteins were predicted to be transmembrane. 
Predicting transmembrane proteins among the putative proteins did not provide enough 
information to aid identification of the cross-reactive proteins. Also transmembrane 
prediction does not automatically imply the protein is an OMP as the proteins may be 
bound to an intracellular membrane. Finally, to identify the cross-reactive proteins, 
mutant strains missing the protein of interest were used. Serum binding of OMPs from 
the mutant strain and the wt strain were compared using SELDI. Using this method we 
were able to show that the 66.7 kDa protein was probably TbpB. However, to predict 
with certainty the identity of the 66.7 kDa protein, other strains with mutations in the 
remaining proteins from the list corresponding to the protein of 66.7 are required. Using 
the SodC mutant strain to identify the 17.4 kDa protein produced ambiguous results. 
The use of mutant strains is limited unless the strains used to prepare the mutant are 
the same as the wt strain being tested for binding. In this case the TbpB- strain was 
81686, but initial assessment of binding to N. lactamica antisera was carried out with 
pools of N. menigntidis, strain MCS8, OMPs. Better identification of meningococcal 
proteins bound by N. lactamica antisera would have been made if the meningococcal 
proteins could have been purified and binding of individual proteins assessed. Individual 
cross-reactive proteins could have been cleaved into peptide fragments and the true 
identity of the protein found. 
MS facilitates the identification of proteins and a number of authors discuss the use of 2-
dimensional (2D) electrophoresis and cleavage of individual proteins of interest to obtain 
a set of peptides corresponding to the protein as a preliminary step to protein 
identification prior to MS. Peptide mass fingerprinting is the most commonly used 
method for identification of proteins using MS. The protein of interest is enzymically or 
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Table 4.2 TMpred Transmembrane Prediction of Putative Proteins Identified using 
ExPasy. Transmembrane prediction does not automatically imply that the protein is an 
outer membrane protein. X means that the protein is not predicted to be 
transmembrane . ./ means that the protein is predicted to be transmembrane. 
Peak Putative rotein TIM (XI.r) 
11226.00a FK506 Binding Protein X 
Glutamyl T-RNA amidotransferase subunit C X 
Aspartate 1-decarboxylase X 
Hypothatical protein X 
13712.80a Probable glycine cleavage system H protein X 
50S ribosomal protein L 19 X 
50S ribosomal protein L20 X 
Ribonuclease P protein component X 
30S ribosomal protein S6 X 
17378.90a Bacterioferritin A X 
Disulphide bond formation protein B .r 
Dihydrofolate reductase ./ 
(3R)-hydroxymyristoyl-[acyle carrier protein] 
.r dehydratase 
Fimbral Protein Precursor (Pilin) .r 
H8 Outer Membrane Protein .r 
2C-methyl-D-erythritol 2,4-cyclodiphosohate synthase .r 
Superoxide Dismutase [Cn-Zn] .r 
Hypothetical protein X 
26868.00a 3-dehydroquinate dehydratase ./ 
Acyl-[acyl-carrier protein]-UDP-N-acetylglucosamine 0-
.r acetyltransferase 
Probable septum site-determining protein X 
Hypothetica I methyltransferase X 
Na-translocating NADH-quinone reductase subunit C ./ 
3-methyl-2-oxobutanoate hydroxymethyletransferase X 
Pyridoxal phosphate biosynthetic protein X 
1-acyl-sn-glycerol-3-phosphate acetyltransferase ./ 
Thiazole biosynthesis protein ./ 
3-demethylubiquinone-9 3-metyltransferase X 
Hypothetical protein X 
28173.60a 3-dehydroquinate dehydratase .r 
Shikimate 5-Dehydrogenase .r 
Competence lipoprotein comL .r 
Dihydrolipocolinate reductase .r 
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(Table 4.2 continued) 
Peak Putative Protien TIM (X/'/) 
Acyl-[acyl-carrier protein]-UDP-N-acetylglucosamine 0-
acetyltransferase ,/ 
Hypothetical methyltransferase X 
Na-translocating NADH-quinone reductase subunit C ,/ 
3-methyl-2-oxobutanoate hydroxymethyletransferase ,/ 
1-acyl-sn-glycerol-3-phosphate acetyltransferase ,/ 
Thiazole biosynthesis protein ,/ 
TonB protein ,/ 
Hypothetical protein X 
33719.30a GTP binding protein X 
Glycerol-3-phosphate dehydrogenase ,/ 
Porphobilinogen deaminase X 
33kDa chaperonin X 
Lacto-N-neotetraose biosynthesis glycosyl transferase X 
UDP-3-0-[3-hydroxymyristoyl] N-acetylglucosamine 
deacetylase X 
T-RNA delta(2)-isopentenylpyrophosphate transferase ,/ 
Class 3 protein, p~rin ,/ 
Proline iminopeptidase ,/ 
Recombination associated protein X 
Glucose-1-phosphate thymidylyltransferase ,/ 
Transposase for insertion sequence element 181106 X 
T -RNA psuedouridine synthase B X 
Hypothetical adenine-specific methylase ,/ 
66656.40a Chaperone protein DNA K (heat shock protein 70) X 
1-deoxy-D-xylulose 5-phosphate synthetase ,/ 
DNAprimase ,/ 
Glutaminyl-T-RNA synthetase X 
Transferrin binding protein B ,/ 
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chemically cleaved and the peptide mixture produced by cleavage is analysed by MS. 
The peptide mass spectrum is compared to spectra obtained by theoretical cleavage of 
proteins sequences stored in databases. Only a small number of accurately measured 
peptide masses are required for protein identification and proteins in fM concentrations 
can be identified from 20 gels (Gevaert et al., 2000). Peptide analysis was carried out 
after 20 electrophoresis of Escherichia coli OMPs (Molloy et al., 2000). 20 
electrophoresis gave information regarding the pi of the proteins prior to cleavage, 
which was used reduce the number of outcomes when searching for the peptide 
identity. 
However, 2D-electrophoresis is a labour-intensive and time-consuming process. Many 
large or hydrophobic proteins do not enter the gel so a complete picture of the proteins 
that constitute the entire proteome of an organism is not obtained (Graves and 
Haystead, 2002). Low copy proteins are also problematic to detect and the gel cannot 
be overloaded because the resolution of the gel will decrease and co-migration of 
proteins will increase. Therefore, less complex mixtures of proteins are best for analysis 
by 20-electrophoresis. However a protein mixture of reduced complexity was used in 
this chapter therefore 20 separation of these proteins may have proved useful. A further 
problem with the use of 2D-electrophoresis prior to MS is that proteins cannot be 
extracted efficiently from gels. However, the protein of interest can be digested whilst in 
the gel and peptides extracted more efficiently. Analysis of the peptide profile of a 
protein by MS provides more information about the protein than can be obtained from 
the mass of the whole protein. Using MALOI or SELDI the peptide mixture can be 
analysed directly, without purification. The main problem with peptide analysis is that 
although the mass measured by MS is accurate there is ambiguity in peptide 
identification as a peptide can be of the same mass, independent of the order of its 
constituent amino acids. The masses of a large number of the peptides of a cleaved 
protein must be obtained to achieve the correct identity of the protein. Also, this 
technique is not suitable for mixtures of even 2 proteins, as the peptide mixture of the 
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proteins would be very complex (Graves and Haystead, 2002), therefore the constituent 
proteins of the protein pools used in this study would have to be purified, probably by 20 
electrophoresis. However, Park and Russell (2001) have recently used MS to identify 
protein constituents from complex mixtures. Synthetic protein mixtures were prepared 
and the mixture was subjected to thermal denaturation and then tryptic digestion. The 
peptides were analysed by MALDI and the digest fragments identified. 
4.3.2. Benefits of SELDI Compared with Western Blotting. 
Western blotting provided little information about the identity of the meningococcal 
proteins from the wt and mutant strains cross-reactive with N. lactamica antiserum. The 
molecular weights of the cross-reactive proteins were approximate, unlike SELDI where 
the accuracy is 0.1 %. Molecular weights are determined after separation by comparison 
of the migration of the proteins to a set of protein standards. The accuracy of protein 
molecular weight determination by SDS-PAGE, and therefore western blotting, ranges 
from between a few percent up to 30% (Jardine, 1990). Burnette (1981) first described 
Western blotting as a technique for immunological detection. The molecular weight of 
the protein affects the rate of transfer of the protein. Higher molecular weight proteins 
are transferred less quickly than low molecular weight proteins. Therefore, the accuracy 
of western blotting is further reduced when compared to SELDI as not all proteins may 
have been transferred at the point of incubation with sera and the capacity for error is 
much greater. Boyle at al., (2001) demonstrated that 0.75 ng of protein were detectable 
using SELDI compared to 5 Jig of protein by western blotting. The sensitivity of SELDI 
allows detection of protein samples without pre-concentration, which decreases the time 
spent on an assay. They suggest SELDI is more sensitive, more rapid and more 
economic than methods involving SDS-PAGE and western blotting. 
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4.3.3. Proteins Identified by SELDI. 
A number of the proteins putatively identified by corresponding in molecular weight to 
the proteins cross-reactive with N. lactamica antiserum, have been discussed by other 
authors. including pathogenicity proteins discussed by Tettelin et al., (2000). Prior to 
publication of the complete genome sequence of N. meningitidis, TbpB, bacterioferritin 
B, pilin, UgR, PorB. SodC and LtgE were known pathogenicity proteins, however, LpxA 
and FabZ have subsequently been added to the list. 
Pilin, H8 and SodC, with molecular weights of 17.298 16.885 and 17.360 kDa 
respectively, were suggestions for the 17.378 kDa protein cross-reacting with N. 
lactamica antiserum. Neisserial pili aid adherence of meningococci (and gonococci) to 
human endothelia (Dunn et a/., 1995). Non-piliated strains do not adhere to the cells 
and cellular damage, caused by LOS, correlates to the level of pilus-facilitated 
adherance. Pili bind to CD40 receptors on human cells and contact between this 
receptor and pili cause internalisation of the bacterium (Kallstrom et a/., 1997). Perrin et 
al., (1999) suggested that N. lactamica do not possess the genes for pilin homologous 
to meningococcal pilin genes. However, pili have been observed on commensal 
Neisseria by electron microscopy (Wistreich et a/., 1971). Additionally, Aho et al., (2000) 
showed that all commensal and pathogenic Neisseriae that colonise humans posses 
homologous pilin genes by PCR using primers directed at the conserved regions of 
meningococcal and gonococcal pilin genes. 
The H8 antigen is common to pathogenic Neisseria. Black et a/., (1985) showed that it 
was immunogenic and detected antibody responses to it in human meningococcal 
disease sera. Woods et a/ .• (1987) showed that the monoclonal antibody to H8 did not 
confer passive protection to mice against meningococcal challenge. However they 
suggested that active immunisation may be a better method for analysiS of H8 as a 
vaccine antigen. Cannon et a/., (1984) found that H8 was present only in pathogenic 
157 
Chapter 4 
Neisseria species. However Aho et a/., (1987) showed that as well as having the gene 
for H8, shown by DNA hybridisation assays, commensal strains also expressed H8. 
Meningococcal SodC catalyses the conversion of the superoxide radical anion to 
hydrogen peroxide preventing production of free radicals which are toxic to the 
bacterium. Wilks et aJ., (1998) showed by Southern blotting that commensal Neisseria 
strains, including N. lactamica, do not possess SodC. 
H8 is not within 2% of the molecular weight of the protein bound by N. lactamica 
antiserum and is a less likely candidate putative protein than the membrane bound 
proteins which are within 2% of the molecular weight. Therefore, it seems most likely 
that the protein bound by the N. lactamica antiserum is either disulphide bond formation 
protein a, Pilin or SodC. However, SodC is not present in commensal Neisseria (Wilks 
et aI., 1998) so it is unlikely that the protein bound to N. lactamica antiserum is SodC. 
TonS was listed as one of the putative proteins with a molecular weight within 5% of the 
molecular weight of the 28.173 kDa protein cross-reactive with the N. lactamica 
antiserum. TonS is involved in iron acquisition by N. meningitidis and thought to be an 
energy transducing protein, spanning the inner membrane and periplasm. It may 
facilitate uptake of ligands by the TonS-dependent outer membrane porin family of 
proteins. TonS mutant strains are unable to use haemoglobin, transferrin or lactoferrin 
as iron sources in culture (Stojiljkovic et a/., 1997). However, Desai et al., (2000) 
showed that pathogenic Neisseria can grow, albeit at a low frequency, and therefore 
utilise exogenous iron without TonS in culture. Recently, Larson et a/., (2002) showed 
that TonS mutant strains were unable to grow within an intracellular location without iron 
supplementation and they suggested that TonS is required for acquisition of intracellular 
iron. 
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PorS has a molecular weight of 33.786 kDa and its molecular weight is within 2% of the 
molecular weight of the 33.719 kDa protein cross-reactive with N. lactamica antiserum. 
N. lactamica do not possess OMPs that are antigenically similar to meningococcal class 
2 or 3 proteins when tested for using subtyping antibodes (Kim et al., 1989). However, 
N. lactamica does posses a porin that is more similar to the meningococcal PorS than 
PorA (Perrin et al., 1999). Of the putative proteins listed, PorS is the only 
transmembrane protein within 2% of the molecular weight of the bound protein so it is 
likely that the cross-reactive protein is PorS and that N. lactamica posesses a protein 
antigenically similar to PorB. Although subtyping antibodies are not cross-reactive with 
the N. lactamica porin, these antibodies are raised against the variable regions of the 
meningococcal PorS proteins suggesting that the N. lactamica porin may be 
antigenically similar in the non-variable regions of the meningococcal PorB. However, 
human T-cell responses towards the PorS component of the Norwegian OMV vaccine 
are low in comparison to the responses to the PorA protein (Meyer Naess et al., 1998). 
Saukkonen et al., (1989) also found that monoclonal antibodies against PorS were not 
protective against meningococcal infection in rats. Nevertheless, patients surviving 
systemic meningococcal disease have higher levels of anti-PorS IgG than anti-PorA 
IgG. PorS conjugate vaccines have also been shown to elicit high levels of bactericidal 
antibodies. 
TbpS was listed as a putative protein with a molecular weight similar to the 66.665 kDa 
protein cross-reactive with N. lactamica antiserum. It has been suggested by a number 
of authors as a meningococcal vaccine candidate (Ala'Aldeen et al., 1994, Lehmann et 
al., 1999). Using a mutant strain of N. meningifidis, it was shown that the 66.665 kDa 
cross-reactive protein was TbpS, as a protein of this molecular weight was bound by the 
serum from the wt strain but not form the mutant strain. 
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4.4. Conclusions. 
Using SELDI to identify the constituent proteins from complex mixtures that cross-react 
with N. lactamica antisera. it has been shown that meningococcal proteins do cross-
react with sera raised against protective protein pools of N. lactamica and that proteins 
with homologous immunogenic epitopes to these exist in N lactamica. However. using 
this technique. only information relating to the molecular mass of the cross-reacting 
proteins could be obtained. The identity of the proteins could be confirmed using further 
purification steps such as 20 electrophoresis and tryptic digestion of isolated proteins 
followed by mass spectrometry and molecular weight comparison to predicted peptides. 
However. this procedure is complicated. labour intensive and time consuming. The 
method described in this chapter could be used as a rapid method to provide 
preliminary identification of cross-reactive proteins by mass and proteins of interest 
could be investigated in further detail. 
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Construction and Screening of a Neisseria 
lactamica Genomic Library 
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5.1. Introduction. 
This study has demonstrated that N. lactamica OMPs protect mice against lethal 
meningococcal challenge (Chapter 3). In chapter 4, meningococcal OMPs recognised 
by antibodies in sera raised against protective N. lactamica OMP pools were analysed 
by SELD/. In this chapter, an alternative approach was used to identify immunogenic N. 
lactamica OMPs using the same sera raised against N. lactamica OMPs. An N. 
lactamica genomic expression library was prepared in phage A, screened for antigen 
expression with N. lactamica antiserum and positive genomic inserts were sequenced. 
The sequences identified were al/ homologous to published meningococcal DNA 
sequences of N. meningitidis serogroup B, strain Me58, and serogroup A, strain Z2491. 
The N. lactamica genome has not yet been sequenced. The sequences described in 
this chapter demonstrate the level of conservation between Neisseriae and the cross-
reactivity between species. 
5.1.1. Genomic Libraries. 
A genomic library is a set of clones that are used to represent the entire genome of an 
organism. Ideally it should comprise of the entire genome of the organism as a set of 
overlapping cloned fragments of DNA with no misrepresentation of sequences (Nicholl, 
2000). The cloned DNA fragments should be large enough to contain whole genes and 
their flanking sequences (Kaiser and Murray, 1985). Phage A. and cosmid vectors are 
the best and most commonly used vectors for genomiC library production. The size of 
the genome and the insert size of a library influence the number of clones required to 
ensure coverage of the genome at 99% confidence (P). The number of clones required 
(N) can be calculated as follows: 
N = In(1-P) Iln[1-(X/y)] 
Where x is the average size of the DNA fragment in base pairs (b.p) and y is the size of 
the target genome (Ausubel et al., 1995). Sufficiently random cleavage can be obtained 
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using partial digestions with restriction enzymes. However fragments larger than the 
capacity of the vector are excluded from the library so enzymes that cut the DNA of 
interest frequently and without bias are used. Mbol is a commonly used restriction 
enzyme with a four nucleotide restriction site and cuts on average one every 256 b.p; 
thus a collection of fragments that are essentially random and follow a normalised 
distribution are produced (Nicholl, 2000). 
5.1.2. The A. ZAP Vector. 
In this study, the A ZAP vector (Stratagene) was used to create a N. lactamica genomic 
library. It can accommodate DNA inserts of up to 12 kb in length. The pBK-CMV plasmid 
vector containing inserted DNA can be excised from the A ZAP vector allowing 
characterisation of the insert in a plasmid system. Cells containing A ZAP can express 
the insert as a fusion protein and can be screened for expression using antibody 
probes. Expression of the insert is driven by the lacZ promotor and induced by IPTG 
and cells containing phage with inserted DNA are selected for by blue/white colour 
screening. T3 and T7 promotors flank the multiple cloning site of the plasmid vector and 
contain common primer sites for DNA sequencing. These promotors are also 
recognised by DNA dependent RNA polymerase, which initiate the synthesis of RNA 
from double stranded DNA templates. Vectors carrying the bacteriophage T3 and T7 
promotors can be used to express cloned genes in vivo. The plasmid contains the f1 
origin of replication from the M13 bacteriophage and this is used for excision of the 
cloned DNA in plasmid form (Figure 5.1). When cells containing A ZAP are co-infected 
with helper phage (M13), single stranded DNA copies of the cloned DNA and pBK-CMV 
DNA are produced. This is circularised by the gene II product of the helper phage and 
secreted from the host into the medium. Treatment of the cells and A ZAP at 70°C 
causes cell and phage lysis but the single stranded copy of the pBK-CMV plasmid 
containing cloned DNA is not affected. E. coli cells are then infected with the single 
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stranded plasmid which is converted to a double stranded plasmid and maintained 
within the cells (www.stratgene.com, www.csun.edu). 
5.1.3. Immunological Screening of a Genomic Library. 
The N. lactamica genomic library was screened with N. lactamica antiserum to identify 
fusion proteins expressed by A ZAP that were recognised by antibodies in the serum. 
Once identified, these inserts were excised from A ZAP and maintained as inserts in 
pBK-CMV as described in the previous section. Immunological screening of A ZAP is in 
principle similar to western blotting. Due to the lytic capabilities of the A ZAP vector, E. 
coli cells infected with the phage are lysed and plaque formation is observed on a lawn 
of cells. Plaques are transferred to nitrocellulose membranes and these are screened 
using serum and cross-reactive plaques identified and isolated. These plaques are then 
used to infect fresh cells and pBK-CMV plasm ids containing cross-reactive inserts are 
produced. Sequencing of the inserts can be carried out using the T3 and T7 sequencing 
primers from the sites flanking the inserted DNA. 
5.1.4. DNA Sequencing. 
Sequencing a gene provides useful information about coding regions of genes, 
homology of the genes and non-coding regulatory regions of the gene. Sequencing 
techniques are based on electrophoretic techniques and were developed by Allan 
Maxam and Walter Gilbert (Maxam et a/., 1977) and Fred Sanger and Alan Coulson 
(Sanger et a/., 1977) respectively. The Maxam-Gilbert method uses chemicals to cleave 
radiolabelled DNA and generate a set of oligonucleotides differing by one nucleotide 
(Nicholl, 1994). The Sanger-Coulson method utilises E. coli DNA polymerase large 
fragment (Klenow fragment) to synthesize a complementary copy of a single stranded 
DNA template from a primer. DNA polymerase is capable of using dideoxynucleoside 
triphosphates (ddNTP) as substrates. When a ddNTP is incorporated to the 3' end of 
the growing DNA strand, elongation is terminated, generating set of fragments 
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terminating in one of four dNTPs corresponding to guanine (G), cytosone (C), adenine 
(A) and tymine (T). 
Sequencing was carried out by Cytomyx (Cambridge) using the Mega8ace 1000 
capillary DNA sequencer in combination with dye termination cycle sequencing. The 
ddNTPs carry four distinct fluorescent dyes and the sequence is read as a colour code 
using a fluorescence detection system (Graham et al., 2001) 
5.1.5. Sequencing Primer Design. 
Clones were sequenced by primer walking. A primer is a short synthetic oligonucleotide 
complementary to a section of the template DNA for sequencing. Primers for 
sequencing template DNA inserted into p8K-CMV were designed using Primer Select 
(DNAStar) and the following rules. Primers should be 17-2B bases in length. The G and 
C base content of the primer should be 50-60%. The 3' end of the primer should consist 
of either G or C, or CG or GC to allow strong annealing of the primer to the template for 
binding of the DNA polymerase and it increases efficiency of priming. The melting 
temperature of the primer and the template DNA (Tm) should be between 55-BO°C. 3'-
ends of primers should not be complementary as primer dimers will be synthesised 
preferentially to any other product. Primer self-complementarity i.e. the ability to form 
secondary structures such as hairpins, should be avoided. Runs of three or more Cs or 
Gs in primers should also be avoided as they may promote mispriming with G or C-rich 
sequences because of stability of annealing between Gs and Cs (www.bioquest.org). 
5.1.6. Sequence Homology Searching. 
Homology of sequenced DNA or an amino acid sequence with DNA or protein 
sequences listed in a database can provide information about the function of the protein 
coded for by the sequence. DNA homology searches shown in this chapter were carried 
out using the Institute for Genomic Research (TIGR) comprehensive microbial resource 
blast searches (www.tigrblasUigr.org). 
166 
Chapter 5 
5.1.7. N. meningitidis Genome Sequences. 
The complete genome sequence of N. meningitidis, serogroup B, strain MC58 has been 
determined by Chiron and of serogroup A, strain Z2491 by the Sanger Center (Tettelin 
et al., 2000, Parkhill et al., 2000). Sequencing of a serogroup C meningococcal strain 
(FAM18) by the Sanger Center is in progress (www.sanger.ac.uk). N. meningitidis, 
strain MC58 has a genome of 2,272,351 bp and an average G and C content of 51.5%. 
The 2158 open reading frames (ORF) were identified coding for 678 proteins. Of the 
2158 ORFs, 91.2% have homology to ORFs in Z2491 and the ORFs without similarity 
are hypothetical proteins. The genome of Z2491 is 2,184,406 bp in length with a G and 
C content of 51.8% and it contains 2121 ORFs. Both the genome of MC58 and Z2491 
contain a number of repetitive elements providing the ability of the genes to undergo 
phase variation and contributing to the ability of N. meningitidis to evade the immune 
system. These could encourage sequence variation by acting as the target sites for 
recombination and the production of new alleles of the gene. 
5.2. Results. 
5.2.1. N. lactamica Genomic Library. 
Genomic DNA from N. lactamica strain Y92-1009, was prepared using a CsCI gradient 
and partially digested with Mbol. Digested DNA of between 1 and 4 kb was gel purified 
and used to produce the genomic library. Digested DNA was ligated and packaged in to 
the 'A ZAP vector according to the manufacturer's instructions. The number of 
recombinant phage required to cover the entire genome of N. lactamica was determined 
to be 4050 clones (P=0.01). This was calculated on the assumption that the genome of 
N. lactamica is similar in length to that of N. meningitidis and based on a working 
dilution of 250 phage per plate. Approximately this number of recombinant phage were 
used to transfect E. coli, strain XL 1-Blue MRF', and the phage from the plaques 
produced were recovered in SM buffer to form the genomic library. The library was 
screened for recombinant phage that cross-reacted with serum raised in rabbits against 
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N. lactamica OMPs. Initially, the screening was with serum raised against N. lactamica 
low molecular weight (LMW) OMPs (43 kDa), but no cross-reactivity at all was 
observed. However, cross-reactivity of the phage library was observed on screening 
with serum raised against N. lactamica detergent extract (DE) OMPs. Cross-reactive 
phage were identified and re-screened to eliminate false positive reactions. The pBK-
CMV vector was excised from the rescreened cross-reactive phage with the help of 
ExAssist helper phage and the plasmids were able to replicate in the E. coli, strain 
XLOLR. Recombinant plasm ids were sequenced with the T3 and T7 primers whose 
annealing sites flank the insert (Figure 5.2). As sequencing only yields approximately 
500 bases of reliable sequence and the N. lactamica inserts were all between 1 and 4 
kb in length, further sequencing was required. This was carried out by primer walking 
Le. primers were designed to anneal to the ends of the previous sequences and 
sequencing of the inserts was complete when sequence data from the T3 end of the 
insert overlapped with sequence data from the T7 end of the insert. Table 5.1 shows a 
list of the clones sequenced and the meningococcal proteins to which they show 
homology using the TIGR website to carry out 'Blast' searches (www.tigr.org/cmr-blast/). 
Although a number of different primers were designed, the sequence of clone 4 remains 
incomplete due to inability to obtain overlapping sequence data. Homology of the N. 
lactamica sequences with meningococcal genes is high and each of the inserts shows 
homology to more. than one gene which it overlaps. Complete sequence data for each of 
the N. lactamica inserts is shown on appendix A3. Overlap with the vector is highlighted. 
5.2.2. Alignment of N. lactamica DNA Sequences with Homologous 
Meningococcal Genes. 
The sequences of meningococcal proteins with homology to the N. lactamica 
sequences were obtained from the NCBI database and searching GenBank 
(www.ncbLnlm.nih.gov). Homology of the N. lactamica sequences with these genes is 
shown in appendix A4. 
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Table 5.1 Putative Identification of N. lactamica sequenced inserts and their Homology 
to meningococcal sequences. (* proteins whose coding region was also found with 
translation of the DNA and are in the same orientation as the promotor) 
Clone Putative protein Locus 8erogroup 
Homology 
3 Putative integral membrane protein* NMA0174 A 
89% 
(496/552) 
Hypothetical protein NMB0102 B 
89% 
(466/518) 
4 Carbamoyl phosphate synthase large NMA0602 A 
97% 
subunit* 
(340/347) 
Carbamoyl phosphate synthase large NMB1855 B 94% 
subunit 
(330/348) 
NADH Dehydrogenase I, chain K* NMAOO05 A 95% (291/304) 
NADH Dehydrogenase I, chain K NMB0254 B 95% (290/304) 
Pyruvate dehydrogenase, E1 component NMA1554 A 93% (653/696) 
Pyruvate dehydrogenase, E1 component* NMB1341 B 93% (653/696) 
8 Putative inosine-5-monophosphate 
guaB A 96% 
dehydrogenase 
(667/691) 
Inosine-5-monophosphate dehydrogenase NMB1201 B 
95% 
(657/691 ) 
Putative ribonuclease* NMA1371 A 
85% 
(722/847) 
Ribonuclease II family protein NMB1200 B 
85% 
(720/847) 
9 Pyruvate dehydrogenase, E1 component* 
NMA1554 A 94% (646/684) 
pyruvate dehydrogenase, E1 component NMB1341 B 
94% 
(646/684) 
Dihydrolipoamide acetyltransferase 
component of pyruvate dehygrogenase NMA1555 A 
84% 
(909/1074) 
complex* 
Pyruvate dehydrogenase, E2 component NMB1342 B 
85% 
(903/1060) 
10 308 ribosomal protein 81 
hip A 90% (1114/1233) 
308 ribosomal protein 81* NMB1301 
B 90% 
(1114/1233) 
19 Hypothetical protein* 
NMA0037 A 90% (429/475) 
Hypothetical protein* NMB0222 
B 90% 
(429/475) 
Hypothetical protein* NMA0038 
A 90% 
(176/195) 
Hypothetical protein* 
NMA0036 A 94% (270/285) 
20 Putative integral membrane protein 
NMA1899 A 83% (780/936) 
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(Table 5.1 continued) 
Clone Putative protein Locus Serogroup Homology 
Hypothetical protein* NMB1645 B 84% 
(786/936) 
Putative integral membrane protein* NMA1898 A 83% 
(698/834) 
Hypothetical protein NMB1644 B 83% 
(702/834) 
23 Dihydrolipoamide acetyltransferase 
component of pyruvate dehygrogenase NMA1555 A 89% 
complex* ( 1152/1292) 
Pyruvate dehydrogenase, E2 component NMB1342 B 89% 
(1153/1291) 
Pyruvate dehydrogenase, E 1 component* NMA1554 A 91% 
(632/693) 
Pyruvate dehydrogenase, E1 component NMB1341 B 91% 
(632/693) 
25 Alanyl-tRNA synthetase alaS A 94% 
(2277/2420) 
Alanyl-tRNA synthetase* NMB1595 B 93% 
(2270/2420) 
Lactoferrin binding protein B IbpB A 86% 
(543/626t 
Lactoferrin binding protein B NMB1541 B 85% 
(469/546) 
26 Putative hydrolase* NMA0387 A 90% 
(276/304) 
Glyoxylase II family protein NMB2049 B 91% 
(277/304) 
putative Na(+)-translocating NADH- NMA0750 A 93% 
ubiquinone reductase subunit C (669/716) 
putative Na(+)-translocating NADH- NMB0567 B 92% 
ubiquinone reductase subunit C (6601716) 
putative Na(+)-translocating NADH- nqrD A 97% 
ubiquinone reductase subunit 0* (400/411 ) 
putative Na( + )-translocating NADH- NMB0566 B 88% 
ubiquinone reductase subunit 0 (445/501) 
Putative peri plasmic protein A 85% 
(207/243) 
Conserved hypothetical protein NMB2050 B 81% 
(187/229) 
34 Putative thiamine biosynthesis protein* NMA0746 A 94% 
(616/651 ) 
Thiamine biosynthesis lipoprotein NMB0563 B 91% 
(657/717) 
Na(+ )-translocating NADH-ubiquinone A 91% 
reductase subunit E (545/598) 
Na(+ )-translocating NADH-ubiquinone NMB0565 B 91% 
reductase subunit E* (547/598) 
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(Table 5.1 continued) 
Clone Putative protein Locus Serogroup 
Homology 
36 Haemagglutinin 1 haemolysin-related NMB1768 B 
89% 
protein* 
(1705/1909) 
42 DprA homologue dprA A 
91% 
(1084/1182) 
DNA processing chain A* NMB0116 B 
90% 
(1090/1204) 
Nitrogen assimilation regulatory protein* NMB0115 B 84% (827/982) 
Putative two-component transcriptional A 
84% 
reQulator 
(825/982) 
Hypothetical protein* NMA0157 A 
84% 
(381/453) 
Putative smg protein NMB0117 B 
83% 
(378/453) 
53 BirA bifunctional protein birA 
A 85% 
(879/1027) 
BirA protein 1 Bvg accessory factor* NMB2075 B 
85% 
(880/1028) 
Putative peri plasmic protein 
A 91% 
(390/425) 
Hypothetical protein NMB2074 
B 90% 
(243/270) 
59 Pyruvate dehydrogenase, E2 component 
NMB1342 B 83% (637/765) 
Dihydrolipoamide acetyltransferase 
component of pyruvate dehygrogenase NMA1555 
A 83% 
(637/765) 
complex* 
pyruvate dehydrogenase, E 1 component NMB1341 B 
94% 
(643/681 ) 
Pyruvate dehydrogenase, E 1 component* NMA1554 A 
94% 
(643/681 ) 
63 Putative peri plasmic protein 
NMA0386 A 89% (370/412) 
Conserved hypothetical protein* NMB2050 
B 90% 
(373/410) 
Ubiquinol cytochrome c reductase, NMB2051 
B 86% 
(302/348) 
cytochrome c1 
Cytochrome c1 * NMB0385 
A 86% 
(302/348) 
73 HemK protein* 
NMA0369 A 93% (663/706) 
HemK protein 
NMB2065 B 91% (700/761) 
Putative amino acid permease ATP-binding 
A 64% 
(477/735) 
protein 
Amino acid permease ATP-binding protein NMB0696 
B 64% 
(481/743) 
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(Table 5.1 continued) 
Clone Putative protein Locus Serogroup Homology 
75 Probable ATP-dependent DNA helicase dinG A 90% 
(1031/1139) 
Probable ATP-dependent DNA helicase* NMB0287 B 90% 
(1040/1149) 
Hypothetical inner membrane protein A 96% 
(2251234) 
Hypothetical protein NMB0288 B 96% 
(217/225) 
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5.2.3. Translation and Alignment of N. lactamica Sequences with Meningococcal 
Protein Sequences. 
N. lactamica sequences were then translated into their amino acid sequences in all six 
reading frames, three forward and three reverse, using Expasy-Translate tool 
(www.expasy.ch/tools/dna.html). Each of the translated amino acid sequences were 
compared to the amino acid sequences of the meningococcal proteins with which the 
DNA sequences had homology and the DNA coding regions found. The putative 
proteins coded for by the N. laciamica inserts are indicated by a star on Table 5.1 and 
the proteins coding region of the sequenced inserts are indicated on appendix A3. Each 
of the N. lactamica inserts codes for at least one protein but often the sequence for each 
protein is incomplete. The coding regions are in the same reading frame as the 
promotor. 
5.2.4. Specificity of the Immunological Recognition of Phage Proteins. 
ELISA was used to assess the cross-reactivity of recombinant phage with a variety of 
human and animal meningococcal and N. lactamica antisera. Antisera against anthrax, 
pneumococcal and TB cell Iysates were also used as negative control sera. Empty 
phage were used as a control for cross-reactivity of the sera with phage rather than the 
inserts. The negative control sera showed no cross-reactivity with the recombinant 
phage and the meningococcal sera only showed reactivity with recombinant phage. 
However, the sera were broadly cross-reactive with each of the recombinant phage 
(Table 5.2). The reactivity of human convalescent sera with the recombinant phage was 
also assessed (Table 5.3) and the results were variable with some patient sera being 
broadly cross-reactive with the recombinant phage and others being reactive with only a 
few recombinant phage. 
5.3. Discussion. 
A number of authors have described the use of genomic libraries prepared from N. 
meningitidis to identify genes of interest. Frosch et al., (1989) isolated the genes 
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Antiserum 
TB Anthrax S.pn NIDE N.cOMV K4540MV MC58wt MC58 cap- N.I LMW N.I MMW N.I HMW N.I L1 N.I L2 N.I L3 
Clone OMV OMV 
3 <100 <100 <100 1924 917 1806 231 457 1469 1227 500 6786 789 1207 
4 <100 <100 <100 3542 785 5135 608 501 595 302 509 1245 564 691 
8 <100 <100 <100 753 486 388 166 296 161 236 653 <100 396 432 
9 <100 <100 <100 191 341 487 432 230 1809 <100 695 <100 430 339 
10 <100 <100 <100 8068 584 604 4939 261 810 1432 1403 1882 932 1341 
19 <100 <100 <100 454 419 614 381 300 441 172 485 168 950 381 
20 <100 <100 <100 2147 625 572 326 446 689 206 702 532 609 449 
23 <100 <100 <100 234 420 343 <100 805 367 <100 178 <100 440 <100 
25 <100 <100 <100 1385 631 408 142 283 1189 890 723 1086 621 533 
26 <100 <100 <100 249 271 273 <100 386 128 <100 <100 <100 455 286 
34 <100 <100 <100 1456 474 582 424 453 195 981 1425 1373 833 953 
36 <100 <100 <100 3362 501 578 298 371 1538 2098 2227 2322 1109 1249 
42 <100 <100 <100 1092 443 518 227 243 3514 1875 662 672 645 733 
53 <100 <100 <100 4398 592 660 393 378 3339 1018 880 1733 530 883 
59 <100 <100 <100 344 321 652 661 557 131 <100 <100 <100 357 239 
63 <100 <100 <100 3921 758 648 482 1003 2260 2175 1991 2735 1085 1656 
73 <100 <100 <100 476 332 380 498 144 508 447 2102 <100 781 521 
75 <100 <10 o <100 295 377 464 304 358 6738 196 1578 <100 917 478 
empty <100 <10 o <100 <100 <100 <100 <100 <100 <100 L_<1QO 
'---
<100 <100 ,<100 <100 
Table 5.2 Raw titres for cross-reactivity of animal sera with recombinant phage. Anthrax, TB and pneumococcal antisera were used as negative 
control sera and empty phage particles as negative control phage. 
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Clone 26 2 7PV TE 251618 252322 
3 1116 1255 5970 515 <100 2563 
4 1179 1082 1492 <100 <100 323 
8 333 819 1087 <100 186 648 
9 776 510 528 <100 <100 <100 
10 750 1218 1530 <100 <100 370 
19 972 1262 938 <100 <100 362 
20 494 1184 1310 287 277 559 
23 182 667 244 232 <100 246 
25 230 651 455 144 <100 425 
26 <100 635 141 <100 <100 358 
34 263 774 430 168 <100 388 
36 130 717 956 <100 378 776 
42 197 618 383 195 <100 549 
53 222 691 812 <100 289 702 
59 260 344 129 142 <100 <100 
63 557 808 1896 <100 226 612 
73 469 653 926 <100 <100 505 
75 660 772 1680 <100 <100 434 
empty <100 <100 <100 <100 <100 <100 
Table 5.3 Raw titres for cross-reactivity of human convalescent sera with recombinant 
phage. Human sera shows variable reactivity with the inserts and inconsistency 
between sera. 
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responsible for capsule production in N. meningitidis serogroup B. A cosmid library in E. 
coli was screened with a monoclonal antibody specific for capsular polysaccharide of 
group B meningococci. A 24 kb genomic fragment elicited detectable capsular 
polysaccharide in E. coli and was made up of five regions all necessary for capsule 
synthesis. A genomic library of N. meningitidis in ').. ZAP II was screened for DNA 
encoding TbpA (Palmer et a/., 1993). USing this library, tbpA was isolated with a DNA 
probe and shown to be highly homologous to that of N. gonorrhoea. Using a similar 
method, Ait-Tahar et a/., (2000) screened a meningococcal genomic library for cross-
reaction with human convalescent sera. The most promising positive clone, autA, was 
characterised. It encoded the putative autotransporter A protein of N. meningitidis, 
having a peptide sequence sharing molecular characteristics of the autotransporter 
family of proteins, and is highly conserved among meningococci and for this reason they 
suggested it as a potential vaccine candidate due to being highly conserved. 
Zysk et a/., (2000) described the use of a pneumococcal genomiC plasmid expression 
library to identify unknown immunogenic proteins. Recombinants were screened with a 
convalescent phase serum and 78 cross-reactive proteins were identified and 
sequenced. With a similar aim and methodology, the N. lactamica genomic library 
described in this chapter was used to identify immunogenic N. lactamica proteins. 
A plasmid-based genomic library of N. lactamica has been previously prepared (Morgan 
et a/., 1996) to clone the Niall! restriction modification system and express it in E. coli. 
NIall! is a type " restriction endonuclease. However, to my knowledge, a N. lactamica 
genomic expression library has not been screened to assess the presence of 
immunogenic sequences. 
For this study, a ').. ZAP phage display library was prepared from N. lactamica genomic 
DNA and various N. lactamica genes were identified as coding for proteins that were 
immunogenic and could be involved in protection. These proteins have been shown by 
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ELISA to cross-react with a variety of animal and human sera raised against 
meningococci. 
5.3.1. Immunogenic N. lactamica Proteins. 
A variety of N. lactamica proteins were immunogenic as detected by cross-reactivity 
with N. lactamica antiserum and recombinant phage ELISA. Eighteen recombinant 
phage were cross-reactive and these were sequenced to identify the encoded genes. 
Sequencing showed that 7 clones were identical and one insert could not be completely 
sequenced. The remaining clones showed a high degree of homology to a variety of 
meningococcal serogroup A and B genes. These sequences coded completely or 
partially for a total of 23 proteins. 
The putative proteins identified by sequence comparison with N. meningitidis are 
described on Table 5.1 of this study. Of these, lactoferrin binding protein B (LbpB), 
encoded for by clone 25, and haemagglutinin/haemolysin-related protein, encoded for 
by clone 8, are putative pathogenicity proteins (Tettelin et al., 2000). Lbp8 has been 
discussed by a number of authors as a potential vaccine candidate. It binds lactoferrin, 
an alternative iron source, and is expressed in conjunction with LbpA under conditions 
of iron stress. Meningococcal LbpB shows homology to meningococcal TbpB, and the 
gene encodes a protein of 77.5 kDa, with 33% identity to TbpB. This homology consists 
of two stretches of negatively charged residues which might be involved in lactoferrin 
binding. Mutants lacking LbpB exhibit a reduced ability to bind lactoferrin (Petterson et 
al., 1998). Petterson et al., (1999) examined sequence conservation of LbpB in a variety 
of meningococcal strains. Sequence variability was high, especially among the 
negatively charged residues, so only the charge of these residues is probably important 
for lactoferrin binding. The variability of the sequences was suggested to be a drawback 
for vaccine development purposes. Translation of clone 25 showed that the section of 
the sequence with homology to LbpB was in the opposite direction to the promotor and 
it could not therefore be expressed. 
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A genomic library prepared from N. meningitidis in M 13 phage was used by Newcombe 
et al., (2000) and screened for proteins present in convalescent sera but not in acute 
sera. Using this method they identified a number of outer membrane proteins, virulence 
proteins and regulatory proteins. The proteins identified are listed on Table 5.4 (Dr J. 
Newcombe, personal communication). Alanyl tRNA synthetase, encoded for by clone 
25, was identified both by this work and the method described in this chapter. A 
haemagglutinin precursor and a haemolysin activator protein were also identified and a 
haemagglutinin/haemolysin related protein, coded for by clone 36, was identified using 
the N. lactamica genomic library. The M13 phage display library was also screened with 
the same N. lactamica antiserum used for screening in this chapter. The only protein 
identified was NusG. This protein was not identified by screening the N. lactamica 
genomic library in this chapter. 
The remaining sequences identified, are not described as encoding for putative 
pathogenicity proteins (Tettelin et al., 2000). However, CarB, encoded for by clone 4, 
and dihydrolipoamyl transferase, coded for by clones 59, 23 and 9, have been 
mentioned by other authors (Lawson et al., 1995, Ala Aldeen et al., 1996). The 
carbamoyl phosphate synthase enzyme is coded for by the genes carB and carA which 
catalyses the formation of carbamoyl-phosphate from carbon-dioxide, adenosine-
triphosphate and glutamine and is the first step in the arginine and pyrimidine 
biosynthetic pathways. It has primarily been investigated in N. gonorrhoea because 20-
30% of naturally occurring clinical isolates have absence of in the carbamoyl phosphate 
synthase enzyme (Lawson et al., 1995). The genes are co-transcribed in the order carA-
carB and they are separated by a large intervening sequence ranging in size from 
approximately 2.2 to 3.7 kb. If the absence of carbamoyl phosphate synthase, observed 
in gonococci, is also observed in meningococcal clinical isolates, this protein is probably 
not suitable as a vaccine candidate. 
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Putative protein 
Porin 
Solvent tolerance protein 
Virulence associated protein 
Pilin 
Sensor histidine kinase 
Dihydro-deoxyphosphooctonate aldolase 
Shikimate dehydrogenase 
Haemagglutinin precursor 
Haemolysin activator precursor 
Transmembrane transport protein 
ATP-dependent helicase 
Thiamine biosynthesis protein 
Thiol-disulphide interchange protein 
MSc methyltransferase 
Alanyl t-RNA sythetase 
IPP transferase 
Proylyl endopeptidase 
Hypothetical proteins 
Chapter 5 
Table 5.4 Proteins identified by screening a N. meningitidis genomic library with human 
conavlescent serum. (Infomation supplied by J. Newcombe) 
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Ala'Aldeen et al., (1996) screened a A ZAP " expression library with rabbit serum raised 
against 70 kOa proteins purified from OMVs of N. meningitidis and identified 
dihydrolipoamide acetyltransferase, encoded for by the gene aeeF, as one of the 
reactive clones. It is a component of the pyruvate dehydrogenase complex. It is highly 
conserved across both prokaryotic and eukaryotic species and is immunogenic in 
animals when used as purified protein or as a component of live meningococci. 
Convalescent patient sera are also cross-reactive with dihydrolipoamide 
acetyltransferase. However, it is unknown whether the reactivity of human sera is with 
conserved epitopes of the proteins and shared with man and therefore whether use of 
this protein as a vaccine antigen would risk tolerance or autoimmunity. Normal human 
sera were also cross-reactive with the protein but meningococci are commensals of the 
nasopharynx and this carriage may elicit antibody responses to bacterial 
dihydrolipoamide acetyltransferase. 
All of the N. lactamiea sequences identified in this chapter consisted of genes encoding 
proteins that are cross-reactive with sera raised against N. lactamica OMPs as shown 
by ELISA. Therefore all of the proteins, either individually or pooled may be involved in 
the protection elicited by N. laetamiea shown in chapter 3. Most of the N. laetamiea 
sequences from cross-reactive recombinant phage consisted of more than one gene 
and encoded for more than one protein. It is possible that all or some of the proteins 
encoded for are immunogenic or protective if expressed and in the correct orientation. 
Production of recombinant proteins would provide further information about which are 
the immunogenic proteins and their protective efficacies. Time did not allow for 
continuation of this study. It would have been interesting to compare the results of 
screening the library with both N. lactamica and human N. meningitidis antiserum. 
Proteins identified by both screening conditions may be the most promising vaccine 
candidates. However, at the time of screening, the quantities of human meningococcal 
antiserum required were not available. The ELISA data shown in this chapter suggests 
that the selected recombinant phage are cross-reactive with meningococcal antiserum. 
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Screening with meningococcal antiserum could also be carried out once recombinant 
proteins have been produced and purified. Screening with sera only identifies 
immunogenic proteins, indicating that these proteins may be involved in protection, but 
protective efficacy can only be assessed in an animal model. 
5.3.2. Problems Sequencing Clone 4. 
Clone 4 proved difficult to completely sequence. Sequence data was obtained from 
each end of the insert. Homology of each of these with N. meningitidis suggests that 
clone 4 consists of two fragments of DNA from different parts of the N. lactamica 
genome. These have probably become ligated into the same vector at the point of 
preparation of the genomic library and a 2.5 kb region covering the join between the two 
sections was impossible to sequence. Sequencing difficulties are often encountered and 
there are a number of different causes. The quality of the DNA template is very 
important for sequencing. Contaminants such as salt, carbohydrate, protein, excessive 
dNTPs or primers can effect the data (www.le.ac.uk). Mixed sequence data can be 
obtained as a result of two templates being present in the sequencing reaction. 
However, this was probably not the problem encountered here as the template was 
used to obtain part of the sequence data. DNA that contains repeat sequence regions is 
often very difficult to sequence. For example, if a homopolymeric region is encountered, 
the rate at which the relevant nucleotide is used is greater than the other nucleotides, 
and the sequencing reaction may stop prematurely. The worst repeat regions tend to be 
G C based as there is difficulty incorporating the bases or the template DNA can form 
secondary structures in these regions. The N. meningitidis genome contains a number 
of repetitive elements which are associated with phase variation, more than any other 
bacterial genome sequenced to date (Tettelin et al., 2000, Parkhill at al., 2000). In 
Neisseria these repeat regions generally consist of G or C repeats and may contribute 
difficulty in sequencing (Snyder at al., 2001). CarB, encoded for by the partly sequenced 
clone 4, contains a number of repetitive sequences and these may be responsible for 
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the problems encountered here and in total CarB has a GC content of 57% (Lawson et 
al.,1995). 
5.4. Conclusions. 
Using a A ZAP Express library, 15 different fragments of N. lactamica DNA were shown 
to cross-react with serum raised against protective N. lactamica OMPs. One fragment 
was not completely sequenced, probably due to secondary structure of the DNA caused 
by repetitive elements, but the remainder were completely sequenced and contained 
either partial or complete genes encoding for 23 separate proteins. The genes and 
encoded proteins showed high homology to equivalent meningococcal proteins. The 
clones are broadly cross-reactive with animal and human sera against meningococci 
implying that the proteins are immunogenic and that they may be possible vaccine 
candidates. Further investigations need to be carried out to identify the important 
proteins for immunogenicity or protective efficacy. This comprises of preparation of 
recombinant proteins and efficacy trials in animal models. However, the method used in 
this study has proved effective for the identification of novel vaccine candidates. It may 
be interesting to re-screen the library for further cross-reactive antigens with either the 
same serum or variety of meningococcal antiserum. It would also be interesting to 
discover the homology of the immunogenic proteins identified in this study with other 
meningococcal strains whose genomes are not yet sequenced using, for example, 
Southern blotting. 
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General Discussion 
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6.1. Overview. 
This study presents the important observation that vaccines based on N. lactamica 
protect mice against lethal meningococcal challenge. To identify the components 
responsible for this protection, N. lactamica detergent extracted OMPs were separated 
by preparative electrophoresis, into three pools of proteins consisting of LMW, MMW 
and HMW proteins. The LMW protein pool was shown to be the most protective of 
these. Further separation of this pool indicated that proteins of 25-43 kOa provided 
protection and those N. lactamica proteins with a molecular weight of greater than 43 
kOa were unprotective at meningococcal challenge doses higher than 1 x 108 CFU. This 
differs from with data reported by Sierra et al., (1990) who supplemented an OMV 
vaccine with HMW proteins to increase the protective efficacy of the vaccine. N. 
lactamica OMPs were shown to elicit antibodies that were cross-reactive by ELISA with 
a broad range of meningococci of different serogroups, serotypes and serosubtypes and 
these cross-reacting antibodies were of isotypes IgG1 and IgG2b. Using western 
blotting, N. lactamica OMP antiserum was most cross-reactive with meningococcal 
proteins of 30 kOa and 67 kOa. In a western blotting study with human meningococcal 
disease sera, Wedege et al., (1998) identified a N. meningitidis, 30 kOa protein as PorB. 
In this study, mouse N. lactamica OMP antisera were not bactericidal and although 
rabbit antisera showed some bactericidal activity, pre-immune rabbit serum was also 
bactericidal to the target strains thus, the titres did not correlated with protection. 
Bactericidal antibodies are directed towards PorA in OMV vaccines (Van der Ley, 1992, 
Saukkonen, 1998). N. lactamica, unlike meningococci, do not posess a PorA protein 
(Derrick et al., 1999) which may be responsible for the lack of bactericidal activity of N. 
lactamica anitserum. West et al., (2001) have also shown that a protein antigen can be 
protective in a mouse disease model without inducing bactericidal antibodies. 
SELDI and N. lactamica genomiC library screening were used to identify immunogenic 
N. lactamica proteins. Meningococcal OMPs cross-reactive with N. lactamica antiserum 
were identified by SELDI. Using the molecular weight of the cross-reacting proteins and 
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comparisons with the meningococcal protein data base (www.expasy.co.uk).alist of 
putative proteins cross-reactive with N. lactamica antiserum was generated and it was 
shown that proteins with epitopes homologous to the cross-reacting meningococcal 
proteins were present in N. lactamica. These may provide the protection observed 
against lethal meningococcal challenge following vaccination with N. lactamica OMPs. 
However, this technique only provided conclusive identification of one protein, the 66.7 
kDa cross-reactive meningococcal protein, TbpB. Further conclusive results could have 
been provided if the meningococcal proteins were further separated into individual 
proteins by preparative 2D electrophoresis for example, and the proteins cleaved to 
obtain a set of peptides corresponding to each protein. Comparison of the peptide mass 
spectra with those of theoretically cleaved proteins can provide the identity of a protein, 
though there was not sufficient time within this study. This is the first study that has 
assessed cross-reactivity of complex mixtures of proteins with serum raised against 
complex mixtures of proteins using SELD!. The majority of meningococcal proteins 
cross-reacting with N. lactamica serum had molecular weights below 43 kDa and N. 
lactamica OMPs less than 43 kDa provided protection to mice against lethal 
meningococcal challenge. 
Using a N. lactamica genomic library, the DNA sequences of recombinant N. lactamica 
proteins cross-reactive with N. lactamica antiserum were obtained. Comparison with the 
complete genome sequences of N. meningitidis serogroup A (Parkhill et al., 2000) and 
N. meningitidis serogroup 8 (Tettelin et al., 2000) using TIGR to carry out blast searches 
(www.tigr.org) provided a list of meningococcal proteins with homology to the N. 
lactamica sequences. After translation of the DNA sequences into their amino acid 
sequences, the coding regions of the DNA were obtained and therefore the proteins 
most likely to be expressed by the N. lactamica sequences. Fifteen cross-reactive 
sequences coded either partially or completely for 23 different proteins. 
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The lists of proteins identified by SELDI and the genomic library did not overlap. 
However, these techniques do have the potential to identify corresponding proteins if 
SELDI had been used to analyse and characterise individual proteins rather than 
complex mixtures. The genomic library approach is more accurate for identifying cross-
reacting proteins and potential vaccine candidates as sequence data was obtained. In 
this study, SELDI provided information regarding the molecular weight of cross-reacting 
proteins only, and therefore did not have the sensitivity to provide definitive identification 
of meningococcal proteins cross-reacting with N. lactamica antiserum. 
Alternatively, western blotting of 10 and 20 polyacrylamide gels of N. meningitidis 
OMPs could have been used as a method for identification of immunogenic proteins that 
cross-react with N. lactamica antisera. However,this approach is limiting as the sample 
is not in its native form so not all immunogenic proteins will be identified. Sanchez et al., 
(2001) used western blotting to identify bactericidal antibodies towards antigens that are 
common to commensal and pathogeniC neisseriae. They suggested analysis of cross-
reactive antigens by western blotting precludes detection of antibodies that react with 
epitopes that are conformational. 
Apart from the OMPs identified and discussed in chapters 4 and 5, a number of other 
proteins have been described by other authors and identification of these may also have 
been expected by either or both of the methods used in these chapters. For example 
Cann and Rogers (1989) identified antigens of 70 kOa, 65 kOa and 15-20 kOa common 
to meningococci and N. lactamica that were recognised by antibodies in convalescent 
sera from children. Troncoso et al., (2000) discussed 32 kDa and 55 kOa proteins 
common to N. lactamica and N. meningitidis. However, none of these proteins were 
identified and their molecular weights were obtained by western blotting, so it cannot be 
deduced whether some of these proteins were in fact identified by SELD!. For example, 
the 65 kOa protein identified by Cann and Rogers could be the same as the 66.7 kOa 
protein identified by SELDI. Also the proteins identified by Troncoso et al., may 
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correspond to the 33.7 kDa and 53.2 kDa proteins identified as putative proteins by 
SELDI. Various proteins were identified by Wedege et a/., (1998) as immunogenic by 
western blotting of human post vaccination sera with N. meningitidis OMVs. Again, a 
protein of 65 kDa was identified along with a protein of approximately 30 kDa, identifed 
as the Opa protein, which may be homologous to the 28.1 kOa protein identified by 
SELD!. However, this protein was not listed as a putative protein cross-reactive with N. 
lactamica antisera in chapter 4. High antibody titres have been observed directed 
towards class 5 proteins (25-30 kOa) in human convalescent sera (pool man et al., 
1983). However, sequences of the Opa proteins vary among meningococcal strains and 
expression of the proteins is hypervariable. Therefore the use of these proteins as 
vaccine candidates is limited (Wiertz et al., 1996). 
A protein which may have been expected but was not identified as immunogenic by 
SELDI or the N. lactamica genomic library screen is the class 4 protein, RmpM. The 
function of RmpM is unknown, but the gene is conserved between serogroup A and 
serogroup B meningococci, with 99.2% identity (Troncoso et al., 2001) and this protein 
is present in commensal Neisseriae. Antibodies directed towards RmpM, purified from 
human sera from individuals vaccinated with the Norwegian OMV vaccine reacted 
strongly with the purified protein but weakly with whole bacterial cells (Rosenqvist et al., 
1999). This suggests that antibodies raised towards the vaccine RmpM component are 
not directed towards surface-exposed regions of RmpM. Therefore any protection 
elicited by the OMV vaccine may not be due to antibodies directed towards RmpM. 
6.2. Neisseria lactamica as a Vaccine against Meningococcal Disease. 
N. lactamica is involved in natural immunity to meningococcal disease. Gold et al., 
(1978) examined the correlation between acquisition of N. lactamica and the 
development of cross-reacting antibodies directed towards N. meningitidis. Cross-
reactive and bactericidal antibodies developed in children who were asymptomatic 
carriers of N. lactamica. Sixty-six percent of children showed an increase in cross-
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reactive anitbody titres and 40% showed an increase in bactericidal antibody titres 
towards meningococci of serogroups A, Band C. They suggested that due to the 
bactericidal activity of carrier sera some of the cross-reacting antibodies might be 
involved in protection. However, the results obtained in chapter 3 of this study showed 
that N. lactamica OMPs do not lead to the formation of bactericidal antibodies in mice 
even though protection was observed. It may be that formation of bactericidal antibodies 
as a correlate of protection is only reliable for human disease. Therefore the efficacy of 
N. lactamica as a vaccine needs to be assessed in man. It has been shown in this study 
that as well as protecting mice against lethal meningococcal challenge, antibodies 
raised against N. lactamica are cross-reactive with a broad range of meningococcal 
isolates. Although many authors have discussed the involvement of N. lactamica in 
protecting naturally against meningococcal disease and the cross-reactivity of antigens 
between N. lactamica and N. meningitidis, none have assessed the protective efficacy 
of N. /actamica-based vaccines in any form (Gold et al., 1978, Olsen et al., 1991, 
Adrade et al., 1986, Kim et al., 1989, Troncoso et al., 2000, Cartwright et al., 1987). The 
results obtained in this study suggest that N. lactamica may provide a suitable vaccine 
against serogroup B meningococcal disease which is effective independent of serotype 
and serosubtype. 
A N. lactamica OMV vaccine may have greater potential as a vaccine against 
meningococcal disease than a N. meningitidis OMV vaccine due to the lack of PorA. 
PorA in N. meningitidis OMV vaccines is immunodominant, implying that responses to 
other protein components of the vaccine may be poor. For example, although the porin 
proteins are the most abundant neisserial outer membrane proteins and are present in 
equal amounts (Blake et al., 1986), vaccination with N. meningitidis OMVs in adult 
volunteers elicits strong T-cell responses to PorA and responses to PorB are 
significantly lower. Due to the enormous heterogeneity of PorA amongst N. meningitidis, 
meningococcal OMV vaccines can only really be effective if they contain various PorA 
representing the circulating serosubtypes. PorA would not comprise part of a N. 
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lactamica OMV vaccine, so this vaccine may induce an immune response which is not 
directed towards an individual protein, but towards a variety of proteins and would be 
independent of serosubtype. Another advantage of N. lactamica as a vaccine against 
meningococcal disease is that because N. lactamica is a commensal organism, its 
antigens are not under the same selective pressure as its pathogenic relative, N. 
meningitidis. A vaccine produced from meningococcal proteins may require modification 
over time with the changing antigens of circulating N. meningitidis strains in the same 
way that flu vaccines are updated. For example, TbpB displays extensive sequence 
divergence throughout the gene, which are likely to have resulted from selective 
pressure exerted by the immune system (Legrain et al., 1996). A vaccine may target a 
subset of polymorphic antigens and the efficacy of vaccination with these is determined 
by the degree of cross-protection afforded by the vaccine (Gupta et al., 1999). 
Ala'Aldeen et al., (2000) studied long-term carriage of N. meningitidis among university 
students and development of meningococcal disease. It was found that a student who 
had carried N. lactamica followed by N. meningitidis developed meningococcal disease 
caused by the homologous meningococcal strain. They suggested that carriage of N. 
meningitidis or N. lactamica will not necessarily protect against disease development 
and that the use of N. lactamica or attenuated N. meningitidis as vaccines should be 
given cautious consideration. No data was supplied regarding antibody titres, serum 
bactericidal activity or the health of the patient. Therefore, it is unknown whether this 
patient ever mounted an immune response prior to disease. N. lactamica carriage is 
common in the meningitis belt of Africa, but it is unclear why the incidence of serogroup 
A meningococcal disease is so high and carriers of N. lactamica in this area do not 
develop long lasting immunity (Blakebrough et al., 1982). 
There has been a great deal of interest in meningococcal OMPs as vaccine candidates 
either in OMV vaccines or as individual antigens (Sections1.8.4. and 1.8.5.). Of these, 
only OMVs are licensed as vaccines and the major OMPs show a great deal of 
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heterogeneity. This study has shown that a number of N. lactamica outer membrane 
components may be useful vaccine candidates due to their homology with 
meningococcal OMPs and the cross-reactivity of sera raised against them. Whether 
useful individually or as constituents of a live or OMV vaccine, it is important to 
characterise the protective components of a N. lactamica-based vaccine. Sanchez et al., 
(2001) suggest however, that use of an OMP-based vaccine may reduce carriage and 
colonisation by commensal species including N. lactamica. This may harm natural 
immunity and this is only acceptable if vaccine-induced protection is adequate. 
6.3. Future Work and Improvements to this Study. 
There are a number of ways in which this project can be furthered and improved. Firstly, 
as bactericidal activity of mouse and rabbit sera raised against N. lactamica does not 
correlate to protection, some other method of protection must be active. It would be of 
interest therefore to assess the opsonophagocytic activity of these sera as it could 
provide a better correlate of protection. Clinical trials in man with N. lactamica vaccines 
would provide the most information regarding the protective efficacy of N. lactamica. In 
addition because, the formation of bactericidal antibodies generated by N. lactamica 
carriage has in the past been observed in man, it would be expected that vaccination 
with N. lactamica would induce bactericidal antibodies. 
Use of 2D preparative electrophoresis, rather than 1 D preparative electrophoresis used 
in this study, would have provided better information regarding the protective 
components of N. lactamica. However 2D electrophoresis is best for analysis of small 
groups of proteins rather than the entire proteome of an organism (Graves and 
Haystead, 2002), so a combination of the two methods would provide most information. 
Further separation of the LMW protective N. lactamica vaccine by 2D-electrophoresis 
and immunisation of mice with individual proteins from this group could be used to 
assess immune responses of mice to these proteins. However, the value of this is likely 
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to be limited due to proteins not being in their native form. This process would also be 
extremely time consuming, labour intensive and expensive in terms of the animals used. 
Chapter 4 showed the use of SELDI to identify meningococcal proteins cross-reactive 
with N. lactamica antisera. 2D-electrophoresis of meningococcal proteins followed by 
enzymic digestion and then SELDI would provide more useful information regarding the 
proteins of N. meningitidis that cross-react with sera raised against N. lactamica OMPs. 
This is the most important change that could be made and potentially the most fruitful in 
terms of results that could be made to this project and is discussed in more detail in 
section 4.3.1. 
A N. lactamica genomic library was used as an alternative approach to identify the 
protective components of N. lactamica. A more useful approach may have been to 
screen the library with a variety of different sera against N. meningitidis. N. lactamica 
proteins with epitope homology to meningococcal proteins, against which an immune 
response had been raised, could have been identified directly. However, from the 
results obtained in chapter 5, it is obvious that the proteins of interest when expressed 
in recombinant phage are cross-reactive with a variety of human and animal sera. 
It would be useful to know the presence and conservation of the proteins identified by 
screening the N. lactamica genomic library in a variety of meningococcal strains i.e. are 
the proteins and genes identified present and expressed in different serogroups, 
serotypes and serosubtypes of N. meningitidis and are the sequences conserved? 
Finally, it would be useful to produce recombinant forms of these proteins in large 
enough quantities to assess their protective efficacy and immunogenicity in animal 
models and human clinical trials. 
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6.4. Concluding Remarks. 
N. lactamica OMPs of less than 43 kDa have been shown to provide protection to mice 
against lethal meningococcal challenge. Sera raised against N. lactamica OMPs have 
been used to identify putative N. lactamica proteins involved in protection by SELDI and 
through screening a genomic expression library. SELDI did not identify individual 
proteins and the proteins putatively identified using this technique did not overlap with 
those identified using the genomic library screen. However, proteins identified as 
potential vaccine antigens by other authors were putative proteins identified by SELDI. 
Using a N. lactamica genomic expression library, 23 proteins were identifed as potential 
vaccine candidates with homology to meningococcal proteins. The aim of this project, to 
identify the protective components of N. lactamica has been fulfilled; potential vaccine 
candidates have been identified. Further work to assess the protective efficacy of these 
proteins is required and would provide additional evidence to show how N. lactamica 
protects against meningococcal disease. 
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